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Hereditary hearing impairment 
Hearing impairment is the most common birth defect and the most prevalent 
sensorineural disorder in developed countries.1 Hearing impairment forms a major 
social and economic burden. Approximately one in every 1000 newborns is deaf and 
one in 300 newborns has congenital hearing impairment of a lesser degree. 
Furthermore, an additional one in 1000 children becomes profoundly hearing 
impaired before adulthood.2 In the general population, the prevalence of hearing 
impairment increases with age. Ten percent of the Western population has hearing 
impairment severe enough to impair communication.2-4 Age-related hearing 
impairment (ARHI) or presbycusis is the most common sensory deficit in the 
elderly. Approximately 35% of individuals between 60 and 70 years demonstrate a 
pure-tone average threshold (PTA, average of the thresholds at 0.5, 1, 2 and 4 kHz) 
of 25 dB or more. In the age group between 70 and 80 years, as much as 50% of the 
individuals has a PTA threshold of 25 dB or more.5 This increasing prevalence 
reflects the impact of genetic and environmental factors on the development of 
hearing impairment.4 
Hearing impairment can be classified as genetic or nongenetic (acquired), prelingual 
or postlingual, and syndromic or nonsyndromic. The characteristics for an adequate 
clinical description of genetic hearing impairment are shown in table 1.6-8 Hearing 
impairment is classified by type, onset, severity and frequency. Hereditary hearing 
impairment can be caused by a mutation in a single gene (monogenetic disorder, e.g. 
most forms of syndromic and early onset nonsyndromic hearing impairment) or can 
be a complex trait, influenced by an interplay between genetics and environment 
(e.g. otosclerosis and presbycusis).6, 9, 10 
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Clinical 
manifestation 
Characterization Explanation 
Type of HI Conductive Results from abnormalities of the external/outer ear 
and/or middle ear. Normal BC thresholds (<20 dB HL) 
and ABG >15 dB averaged over 0.5, 1 and 2 kHz. 
Sensorineural Cochlear Results from malfunction of inner ear 
structures (i.e. cochlea). BC thresholds 
>20 dB HL and ABG <15 dB HL 
averaged over 0.5, 1 and 2 kHz. 
Auditory 
neuropathy 
Results from damage or dysfunction at 
the level of the 8th cranial nerve, 
auditory brain stem or cerebral cortex. 
Mixed Combination of conductive and sensorineural HI. BC 
thresholds >20 dB and ABG >15 dB averaged over 0.5, 
1 and 2 kHz. 
Severity of HI Mild 20-40 dB HL 
Moderate 41-70 dB HL 
Severe 71-95 dB HL 
Profound >95 dB HL 
Audiometric 
configuration 
Low frequency 
ascending 
>15 dB HL difference between the worst low 
frequency thresholds and the better high frequency 
thresholds. 
Mid frequency  
U-shaped 
>15 dB HL difference between the worst mid 
frequency thresholds and the better low and high 
frequency thresholds. 
High frequency Gently sloping: 15-29 dB HL difference between the 
mean of 0.5 and 1 kHz, and the mean of 4 and 8 kHz. 
Steeply sloping: >30 dB HL difference between the 
above frequencies. 
Flat <15 dB HL difference between the mean of 0.25 and 1 
kHz, the mean of 1 and 2 kHz, and the mean of 4 and 8 
kHz. 
Frequency 
ranges 
Low frequencies ≤0.5 kHz 
Mid frequencies >0.5 kHz and ≤2 kHz 
High frequencies >2 kHz and ≤8 kHz 
Extended high 
frequencies 
>8 kHz 
Symmetry of 
HI 
Bilateral <10 dB HL difference between the ears in at least two 
frequencies. Average over 0.5, 1 and 2 kHz of both ears 
>20 dB. 
Unilateral >10 dB HL difference between the ears in at least two 
frequencies.  
<20 dB HL average over 0.5, 1 and 2 kHz of the better 
ear. 
Asymmetrical > 10 dB HL difference between the ears in at least two 
frequencies.  
>20 dB HL average over 0.5, 1 and 2 kHz of the better 
ear. 
Age of onset Prelingual HI present before speech develops. 
Postlingual HI after the development of normal speech. 
Table 1. Characteristics for an adequate clinical description of hearing impairment.8 ABG: 
air-bone gap; BC: bone-conduction; HI: hearing impairment; HL: hearing level.  
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1 
Acquired hearing impairment  
Approximately 25% of childhood hearing impairment is caused by environmental 
factors and commonly results from prenatal infections (TORCH; toxoplasmosis, 
other infections (e.g. syphilis), rubella, cytomegalic virus and herpes) or postnatal 
infections, particularly bacterial meningitis. Congenital cytomegalovirus infection is 
the most common cause of congenital acquired hearing impairment in developed 
countries.4, 11 In the Netherlands, approximately 1000 children per year are born 
with congenital cytomegalovirus infection. Of these children approximately 180 
children (0.1% of all newborns) will exhibit hearing impairment. In one of five 
children with bilateral profound hearing impairment, the cause of hearing 
impairment can be attributed to congenital cytomegalovirus infection.12   
Acquired hearing impairment in adults is often multifactorial caused by both genetic 
and environmental factors (e.g. infections, acoustic or cerebral trauma, ototoxic 
drugs). Noise exposure is the most common environmental factor to attribute to 
acquired hearing impairment in adults. An individual’s susceptibility to hearing 
impairment most likely reflect the environmental-genetic interaction.4 
Prelingual and postlingual hearing impairment 
Hearing impairment may begin before the development of speech (prelingual) or 
thereafter (postlingual). Prelingual hearing impairment is most frequently present 
at birth (congenital), but may start in early infancy before the acquisition of 
language. Often, prelingual hearing impairment is severe and stable. More than 50% 
of prelingual hearing impairment is genetic, most often autosomal recessive and 
nonsyndromic. The inheritance of prelingual nonsyndromic hearing impairment is 
estimated to be autosomal recessive in 75-85% of the cases, autosomal dominant in 
20-25% of the cases and X-linked in 1-1.5% of the cases. (Figure 1) Mitochondrial 
inheritance is less than 1%.6 
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Figure 1. Causes of prelingual hearing impairment ≥ 40 dB in children. The percentages 
between parenthesis are the percentages in relation with congenital hearing impairment in 
general.  
Postlingual hearing impairment is much more frequent than prelingual hearing 
impairment. Although postlingual hearing impairment has mostly a multifactorial 
inheritance, monogenetic forms exists with mainly autosomal dominant 
inheritance.4 
Knowledge of the cause of hearing impairment can provide information on 
prognosis. Also, genetic counseling and risk assessment are dependent on the 
accurate determination of the specific genetic diagnosis. Furthermore, early 
identification of hearing impairment and timely intervention are essential for 
optimal cognitive development in children with prelingual hearing impairment. All 
children with a risk for hereditary hearing impairment should receive screening 
audiometry. Therefore, correct diagnosing of the specific cause of hearing 
impairment is essential. 
Monogenic hearing impairment 
Syndromic hearing impairment 
Syndromic hearing impairment is characterized by hearing impairment in 
combination with other abnormalities. Important syndromic features are branchial 
cleft pits, cysts or fistulae, preauricular pits, telecanthus, heterochromia iridis, white 
forelock, pigmentary anomalies, high myopia, pigmentary retinopathy, goiter and 
Congenital hearing 
impairment 
Idiopathic 
25% 
Nongenetic 
25% 
Genetic   
50% 
Syndromic 
30% (15%) 
Nonsyndromic 
70% (35%) 
Autosomal dominant  
15-24% (7%) 
Autosomal recessive 
75-85% (28%) 
X-linked       
1-2% (<1%) 
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1 
craniofacial anomalies. Most cases of monogenetic hearing impairment are 
nonsyndromic. Nevertheless, over 400 genetic syndromes with hearing impairment 
have been described. Syndromic hearing impairment accounts for up to 30% of 
prelingual hearing impairment.6 However, the relative contribution of syndromic 
hearing impairment to all forms of hearing impairment is much smaller because of 
the impact of postlingual hearing impairment. Waardenburg syndrome is the most 
common type of autosomal dominant syndromic hearing impairment, followed by 
branchio-otorenal syndrome (BOR) and Stickler syndrome. Usher syndrome is the 
most common type of autosomal recessive syndromic hearing impairment, followed 
by Pendred syndrome, and Jervell and Lange-Nielsen syndrome. Alport syndrome 
and Mohr-Tranebjaerg syndrome demonstrate an X-linked pattern of inheritance. 
Mitochondrial mutations can also cause syndromic hearing impairment.4 
Non-syndromic hearing impairment 
More than 70% of prelingual hereditary hearing impairment is nonsyndromic.13 The 
different loci for nonsyndromic hearing impairment are designated DFN (DeaFNess) 
and named after the mode of inheritance: DFNA (autosomal dominant), DFNB 
(autosomal recessive), DFNX (X-linked) and DFNY (Y-linked). Additionally, two 
modifier loci (DFNM) and one locus for auditory neuropathy (AUNA) have been 
documented. Otosclerosis loci are designated OTSC. The number following the 
designations reflects the order of mapping.7  
The clinical manifestations and molecular genetics of autosomal dominant, 
autosomal recessive and sex-linked nonsyndromic hearing impairment are shown in 
table 2, table 3 and table 4, respectively.7 Not all the causative genes of these loci are 
identified. Different mutations in the same gene can cause hearing impairment with 
distinctive modes of inheritance, for example DFNB1 and DFNA3 are caused by 
mutations in GJB2 and GJB6, and DFNB21 and DFNA8/12 by mutations in TECTA. 
Furthermore, nonsyndromic and syndromic hearing impairment can be caused by 
different mutations in the same gene, for example DFNB18 and Usher syndrome 1C 
may be caused by mutations in USH1C gene, DFNB12 and Usher syndrome 1D by 
mutations in CDH23 gene, DFNB4 and Pendred syndrome by mutations in SLC26A4 
gene, and DFNA6/14/38 and Wolfram syndrome by mutations in WFS1 gene. 
Moreover, mutations in MYO7A can cause DFNB2, DFNA11 and Usher syndrome 1B.4  
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Table 2. Clinical manifestations and molecular genetics of autosomal dominant 
nonsyndromic hearing impairment. No clinical data are available for DFNA29, DFNA32, 
DFNA34, DFNA35, DFNA37, DFNA40, DFNA42, DFNA45, DFNA46, DFNA55, DFNA56, 
DFNA61, DFNA62 and DFNA63. The data are derived from OMIM46 (see OMIM numbers in 
table). The genes marked with * are also involved in syndromic hearing impairment: 1. 
Wolfram syndrome, 2. Usher syndrome, 3. Stickler syndrome, 4. Epstein, Fletcher and 
Sebastian syndrome, 5. Branchio-oto-renal syndrome, 6. Dentinogenesis imperfecta. HI: 
hearing impairment. 
Table 3. Clinical manifestations and molecular genetics of autosomal recessive 
nonsyndromic hearing impairment. No clinical data available for DFN19, DFNB34, DFNB41, 
DFNB43, DFNB50, DFNB52, DFNB54, DFNB56, DFNB57, DFNB58, DFNB60, DFNB64, 
DFNB69, DFNB70, DFNB75, DFNB76, DFNB78, DFNB80, DFNB86, DFNB87, DFNB88, 
DFNB90, DFNB92 and DFNB94. The data are derived from OMIM46 (see OMIM numbers in 
table). The genes marked with * are also involved in syndromic hearing impairment: 1. 
Usher syndrome, 2. Pendred syndrome, 3. Stickler syndrome. HI: hearing impairment. 
Table 4. Clinical manifestations and molecular genetics of sex-linked nonsyndromic hearing 
impairment. The data are derived from OMIM46 (see OMIM numbers in table). The gene 
marked with * is also involved in syndromic hearing impairment: 1. Charcot-Marie-Tooth 
disease. HI: hearing impairment. 
 
Autosomal dominant nonsyndromic hearing impairment 
Autosomal dominant hearing impairment is frequently postlingual. The 
characteristic phenotype of a person with autosomal dominant nonsyndromic 
hearing impairment is progressive postlingual hearing impairment that begins in the 
second or third decade of life. However, stable congenital hearing impairment or an 
onset in the fourth decade of life or later can also be seen. (Table 2) The 
heterogeneity in autosomal dominant nonsyndromic hearing impairment is high 
with multiple genes implicated in the pathogenesis. However, the audioprofile can 
be distinctive and therefore useful in genetic testing of specific candidate genes. 
Furthermore, audioprofiling can be helpful in predicting the progression of hearing 
impairment in an individual with autosomal dominant nonsyndromic hearing 
impairment of known cause.4, 14-19 An Age Related Typical Audiograms (ARTA) gives 
a comprehensive phenotype presentation and is therefore extremely useful in 
characterization of progressive DFNA types. Huygen et al. described the 
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construction of an ARTA from regression analysis (threshold on age) of age-related 
threshold data.20 Unfortunately, mutations in different genes can lead to very similar 
phenotypes and therefore a similar ARTA. Additional distinguishing phenotypic 
features are then very important, for example speech recognition and vestibular 
function. Nevertheless, an ARTA can be used to compare the type of hearing 
impairment, the age of onset and the progression of hearing impairment in relation 
to the genotypes. An ARTA does not only help in selecting potentially interesting loci 
for linkage analysis or genes for mutation analysis, but it is also valuable for genetic 
and individual counseling.20, 21 In addition, the program AudioGene22 can perform 
automatic audioprofile analysis of the audiometrical data of an individual or a 
family. 
Mutations in the same gene can cause very distinct phenotypes. One of these genes is 
TECTA. The encoded protein, α-tectorin, is one of the main noncollagenous proteins 
of the tectorial membrane, a ribbon-like strip of extracellular matrix that lies over 
the stereocilia of the hair cells and is critical for the mechanical transmission and 
amplification of sound. Missense mutations of TECTA cause autosomal dominant 
non-syndromic hearing impairment (DFNA8/12), whereas nonsense mutations 
cause autosomal recessive non-syndromic hearing impairment (DFNB21). (Table 2) 
The phenotype of DFNA8/12 depends on the domain and residue affected. The 
established genotype–phenotype correlations indicate that missense mutations in 
the zona pellucida domain and in the N-terminal region lead to mid-frequency 
sensorineural hearing impairment, whereas missense mutations in the zonadhesin 
region cause high-frequency sensorineural hearing impairment. If cysteine residues 
are affected hearing impairment is progressive; if other residues are affected 
hearing impairment is stable. The accurate genotype-phenotype correlations will 
lead to better diagnostic and prognostic information for patients with hereditary 
hearing impairment.23-25  
Autosomal recessive nonsyndromic hearing impairment 
Most cases of autosomal recessive inherited hearing impairment show prelingual 
severe to profound hearing impairment. (Table 3) Approximately 50% of autosomal 
recessive nonsyndromic hearing impairment in Mediterranean populations can be 
attributed to DFNB1, caused by mutations in GJB2 (encoding connexin 26) and/or 
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GJB6 (encoding connexin 30). The remaining 50% of cases are attributed to 
mutations in numerous other genes, many of which have been found to cause 
hearing impairment in only one or two families.4, 26-29 The prevalence of GJB2 and 
GJB6 mutations in the Netherlands is lower. The carrier frequency rate for GJB2 
mutations in the general United States population of northern European descent is 
approximately 1 in 33.26 From the Dutch patients with recessive hearing impairment 
reported by Kemperman et al. 15,8% of the cases had mutations in the GJB2 or GJB6 
gene.30 
Sex-linked nonsyndromic hearing impairment 
Sex-linked nonsyndromic hearing impairment is not very common, but can exhibit a 
wide range of clinical manifestations.4 The clinical manifestations and molecular 
genetics of sex-linked nonsyndromic hearing impairment  are shown in table 4.7 
Mitochondrial nonsyndromic hearing impairment 
The majority of mutations in mitochondrial genes cause a broad spectrum of 
maternally inherited multisystem disorders. However, specific mutations in           
MT-RNR1 and MT-TS1 can cause nonsyndromic hearing impairment by currently 
unknown mechanisms.31 The phenotypic variation of these mutations is great with a 
highly variable penetrance of hearing impairment. Heteroplasmy is the main source 
of variation in severity of the hearing impairment. Unidentified genetic or 
environmental factors play also a role in the progression of the hearing 
impairment.31 Furthermore, hearing impairment can be induced by administration 
of aminoglycosides in some individuals with specific mutations in MT-RNR1.32 
Auditory neuropathy 
Auditory neuropathy is a disorder in which the transmission of the auditory signals 
from the inner ear to the auditory nerve and auditory brainstem is distorted. 
Auditory neuropathy is characterized by normal outer hair cell function and 
disrupted inner hair cell function and/or auditory nerve function. The pure-tone 
levels of patients with auditory neuropathy can vary from normal to severely 
impaired. These patients also experience great difficulty in understanding speech, 
particularly in the presence of background noise. Auditory neuropathy can be 
congenital or acquired. Congenital auditory neuropathy is mostly genetic and may 
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occur either isolated or in association with a syndrome. Approximately 40% of 
auditory neuropathy cases may have a genetic cause.33 Autosomal dominant 
nonsyndromic auditory neuropathy can be caused by mutations in DIAPH3. The 
phenotype is variable with most frequently postlingual (1st decade) progressive 
profound hearing impairment.34 Mutations in OTOF35-37 and PJVK38 can cause 
recessive nonsyndromic auditory neuropathy with prelingual onset and usually 
severe to profound hearing impairment. DFNX5 causes also auditory neuropathy 
with variable hearing impairment.39 
Modifier genes 
Modifier genes can act either as an enhancer or as a suppressor of hearing 
impairment. A dominant deafness modifier, designated DFNM1, has been 
demonstrated to cause nonpenetrance in family members who were homozygous 
for the DFNB26 haplotype. The location of DFNM1 is within the DFNA7 interval, 
suggesting that the DFNM1 suppressor phenotype and DFNA7 hearing impairment 
may be phenotypic variants of the same gene.40  
Gene expression in the cochlea and gene function in the inner ear 
Figure 2 shows the important structures of the cochlea.48 The pathogenic 
mechanism of hearing impairment dependents on the involved gene. For example, 
DFNA8/12 (TECTA gene) and DFNA13 (COL11A2 gene) related hearing impairment, 
originating from tectorial membrane abnormalities, exhibit intra-cochlear 
‘conductive’ hearing impairment. Defects in the tectorial membrane result primarily 
in an attenuation of sound, whereas suprathreshold measures, such as otoacoustic 
emissions and speech perception in noise, are preserved rather well. The results of 
additional audiologic testing in DFNA8/12 and DFNA13 patients resembled the 
results found in patients with middle-ear conductive hearing impairment.49, 50 
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1. Inner hair cells  6. Spiral ganglion  10. Basilar membrane 
2. Outer hair cells  7. Auditory nerve  11. Scale vestibuli  
3. Supporting cells  8. Reissner’s membrane 12. Scale media 
4. Spiral ligament  9. Tectorial membrane 13. Scale tympani 
5. Stria vascularis 
Figure 2. Transverse section of the cochlea (available at hereditary hearing loss homepage; 
http://hereditaryhearingloss.org/main.aspx?c=.HHH&n=87131) 
 
Most of the genes involved in nonsyndromic hereditary hearing impairment can be 
divided in different categories based on their function in the inner ear. One category 
of genes is involved in maintaining ion homeostasis in the inner ear. These genes 
mainly encode channels or ion pumps (e.g. GJB2, GJB3, GJB6, GJA1, KCNQ4, SLC26A4, 
SLC26A5 and WFS1). Another category of genes encodes cytoskeletal components 
(e.g. ACTG1, CCDC50, DIAPH1, DSPP, ESPN, RDX and TRIOBP), adhesion proteins (e.g. 
CHD23, PCDH15 and TMHS), motor proteins (e.g. MYH9, MYH14, MYO1A, MYO3A, 
MYO6, MYO7A and MYO15A) and scaffolding proteins (e.g. WHRN and USH1C). A 
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further group of genes encodes protein components of the extracellular matrix and 
the tectorial membrane (e.g. COCH, COL11A2, OTOA, STRC and TECTA). An additional 
category contains transcription factors involved in cochlear development (e.g. 
ESRRB, EYA4, GRHL2, POU3F4 and POU4F3). MicroRNAs, such as MIR96, are 
noncoding regulatory RNAs that influence translation and stability of target mRNAs 
and form a separate group. Nevertheless, there are still numerous genes with 
unknown function.48 
Treatment 
In many types of hearing impairment, including hereditary forms, apoptosis of 
sensory hair cells is involved. In humans there is still no prove that damaged hair 
cells can regenerate spontaneously. Therefore it is likely that damaged hair cells 
cause permanent hearing deficits.51 Specific inhibitors of apoptosis can prevent hair 
cell degeneration and are targets for therapies to preserve hearing.52  
Reactive oxygen species, or free radicals, are released by damaged hair cells after a 
traumatic event and can initiate apoptosis of hair cells. Free radical scavengers can 
bind these free radicals and prevent or inhibit hair cell apoptosis. Thus, future 
therapies for preventing hearing impairment may include systemic or localized 
application of free radical scavengers.52 
Replacement of hair cells, which are damaged by sound or ototoxic drugs has been 
demonstrated in birds. Supporting cell proliferation or transdifferentiation can 
replace the lost hair cells. Furthermore, hair cells of rats can be replaced after injury 
during neonatal development if epidermal (EGF) and/or transforming growth factor 
alfa (TGF-α) supplements were administered during the recovery process.52  
Kawamoto used gene therapy to generate new hair cells in guinea pigs.53 Some non-
sensory cells in the immature inner ear of mice can differentiate into hair cells when 
the Math1 gene (Atoh1 gene in human) was introduced into these cells.52, 54 In 
addition to hair cell development, substantial improvement in hearing thresholds in 
deaf mice was also demonstrated.55 Furthermore, the lack of Math1 in a knockout 
mouse resulted in no hair cell development.56 Atoh1 is a potent transcription factor 
that induces the non-sensory cochlear cells to develop into new hair cells. However, 
plasticity and repair of damage during development do not usually persist into 
adulthood. Nevertheless, in vivo data indicate that non-sensory cochlear cells 
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maintain their competence to become new hair cells in mature animals. The ability 
to generate hair cells in the mammalian organ of Corti may lead to treatments for 
sensorineural hearing impairment caused by apoptosis of sensory hair cells.52 
Regeneration of hair cells does not address the often ongoing hair cell loss caused by 
a genetic mutation in hereditary hearing impairment. Thus, the optimal solution for 
hereditary hearing impairment may be defective gene replacement. However, gene 
replacement therapy poses far greater challengers than other forms of cochlear gene 
therapy. To date, restoring hearing in hereditary hearing impairment with gene 
replacement therapy is not possible yet.54   
Complex hearing impairment 
Age related hearing impairment 
Age related hearing impairment (ARHI), or presbycusis, is a complex trait, caused by 
an interplay between genetics and environment. The variation in ARHI is large, but 
little is known about the factors influencing the severity of hearing impairment. Part 
of this variation can be explained by medical conditions and by a different exposure 
to environmental factors, for example occupational noise. The importance of other 
environmental risk factors is less clear and often controversial. Some environmental 
factors are well-documented and clearly have an influence on hearing thresholds, 
but it is unclear to what extent they influence hearing at a later age.5 Smoking can 
cause a significant dose-dependent increase in high-frequency hearing impairment. 
High body mass index (BMI) was also correlated with hearing impairment. Moderate 
alcohol consumption has probably a protective effect on hearing. These results 
suggest that a healthy lifestyle can protect against age-related hearing impairment.57 
Approximately half of the variance in ARHI is probably due to genetic factors, 
however, little is known about the precise genetic determinants.5 Several genome-
wide linkage studies and association studies on candidate genes for ARHI were 
performed to identify some of the genetic factors involved in ARHI.10 The first locus 
on chromosome 8q24.13-q24.22 for ARHI was reported by Huyghe et al.58 Two 
other studies identified the first susceptibility genes, NAT2 and KCNQ4, for ARHI.59, 60 
Moreover, Van Eyken et al.10 found an association between ARHI and GSTT1 and 
GSTM1 in the Finnish population and confirmed the previously reported correlation 
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with NAT2 in the general European population. Furthermore, a strong association 
between ARHI and GRHL2 was demonstrated and replicated by Van Laer et al.61 
Further research will be necessary to identify the causative variant(s) in these 
candidate genes.  
Otosclerosis 
Otosclerosis is also a complex disease caused by an interaction between 
environmental and genetic factors. In the following paragraphs, a detailed 
description of otosclerosis is given.   
Epidemiology 
Otosclerosis is one of the most common causes of adult-onset hearing impairment in 
the Caucasian population with a prevalence of 0.3-0.4%. The prevalence in blacks, 
Asians and Native Americans is much lower. The difference in occurrence of 
otosclerosis between races might be a reflection of differences in both genetic and 
environmental factors.9, 62-64  
The histological form of otosclerosis is defined as an asymptomatic disease that can 
be identified only by morphological examination. Histological otosclerosis is far 
more common than clinical otosclerosis and is found in 10% of the Caucasian 
population.64-66  
Several studies reported a higher prevalence of clinical otosclerosis in women with a 
female to male ratio of approximately 2:1. Histological studies of the temporal bone 
do not demonstrate a difference in sex ratio for histological otosclerosis.64, 67 Besides 
a sex difference in prevalence, there is also a sex difference in the severity of hearing 
impairment caused by otosclerosis. Females had worse bone-conduction thresholds 
and developed more frequently sensorineural hearing impairment than males.63, 68 
It has been demonstrated that during periods of endocrine change (e.g. pregnancy 
and puberty) otosclerosis may be initiated or progress in women, particularly with 
subsequent pregnancies. Recently, however, authors found no adverse effect of 
having children on hearing in otosclerotic women, not even with increasing 
numbers of pregnancies. Neither did breastfeeding affect the degree of hearing 
impairment.69 Furthermore, no adverse effect of oral contraception use on 
otosclerosis could be demonstrated.70 Nevertheless, it is well established that 
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oestrogens are critical regulators of the skeleton. Oestrogens are stimulators of 
osteocytic activity and may contribute to the ossification of otosclerotic foci.71 
Furthermore, estrogen possibly has a protective effect on hearing.72 Despite the 
established participation of estrogens in osteocytic and osteoblastic function, their 
role in the pathogenesis of otosclerosis remains unsettled.64 Otosclerosis is more 
likely to occur during childbearing ages and pregnancy could just be an incidental 
event. 
Pathogenesis 
Otosclerosis is characterized by abnormal bone remodeling at specific sites of 
predilection confined to the endochondral layer of the otic capsule. The otic capsule 
is formed by three layers of bone, namely the endosteal layer next to the 
perilymphatic space, the intermediate endochondral layer with remnants of 
cartilage tissue, which are known as the ‘globuli interossei’, and the outer periosteal 
layer.65, 67 The otic capsule is a unique structure and has almost completely absent 
growth and plasticity.73  
Three types of otosclerotic lesions can be identified, namely cellular (spongiotic), 
fibrotic and sclerotic lesions. The early spongiotic phase may convert into the 
fibrotic phase and finally into the mature and inactive sclerotic phase.74 The first 
histological sign of otosclerosis is resorption of bone around blood vessels by 
osteoclasts with secondary enlargement of perivascular spaces and intensive 
neovascularization.67, 75 The hyperemic blood vessels of the adjacent promontory 
can be observed through the tympanic membrane as a red blush known as the 
‘Schwartze sign’.64, 76 The Schwartze sign is closely associated with otosclerotic 
lesions extending to the promontory and is occasionally observed in cochlear 
otosclerosis. An objective increase in the blood flow to the promontory in patients 
demonstrating the Schwartze sign has been demonstrated using laser Doppler 
flowmetry.77 As the otosclerotic focus expands, a central resorption space is formed 
containing a rich cellular content of monocytes, macrophages, multinucleated 
osteoclasts and osteoblasts (cellular spongiotic phase). Subsequently, new bone is 
formed characterized by dysplastic immature basophilic bone. In this fibrotic phase, 
osteoblastic activity leads to formation of new spongiotic trabecular bone, 
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distinctive from the surrounding normal lamellar bone. The extracellular matrix of 
the new spongiotic trabecular bone contains disoriented collagen fibrils and 
undergoes progressive fibrosis and calcification in the sclerotic phase. This 
reorganization of spongiotic trabecular bone leads to formation of relatively 
avascular and acellular dense sclerotic bone with a woven pattern.67, 78 The different 
phases (otospongiosis and otosclerosis) can occur simultaneously and one does not 
necessarily precede the other.76 
The activity of the otosclerotic foci can be classified from Grade I (most active) to 
Grade IV (inactive or healed) on the basis of cellularity, presence of osteoclasts and 
osteoblasts, degree of vascularization and the amount of extracellular collagen 
matrix.65 
Etiology 
Otosclerosis is a heterogeneous disease possibly with multiple etiologies. Several 
theories have been postulated, including collagen disorders65, 79 (e.g. osteogenesis 
imperfecta80, 81 and osteoporosis82), hormonal disorders (e.g. estrogen-induced 
hyperprolactinemia83), autoimmune diseases (e.g. antibodies to type II and IX 
collagen79, 84, human leukocyte antigen (HLA) genotypes65), enzymatic disorders 
(e.g. increased diastrophic dysplasia sulfate transporter (DDST) activity85) and 
inflammatory disorders (e.g. persistent measles virus86-88 and osteoprotegerin 
deficiency89, 90). Disturbances of various homeostatic functions have been associated 
with otosclerosis, for example prostaglandin overproduction, abnormal response to 
parathyroid hormone and therefore overproduction of alkaline phosphatase, and 
insufficient production of osteoprotegerin mediated through RANK and RANKL 
(receptor activator of nuclear factor κB and its ligament).91, 92 Moreover, several 
genetic variations have been related to an increased risk for otosclerosis, for 
example certain bone morphogenetic proteins (BMPs) polymorphisms that result in 
an increased chondrogenesis.67, 93, 94 Also, specific polymorphisms in angiotensin 
converting enzyme (ACE) and angiotensin (AGT) demonstrate an increased bone 
remodeling.95-97 Transforming growth factor-β1 (TGF-β1) variants contribute to 
susceptibility to otosclerosis by modulating extracellular matrix production67, 98, 99 
and genetic variants of COL1A1 cause disoriented collagen structures99, 100. However, 
despite the intensive research and the identification of a variety of factors involved 
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in the development of the disease, the etiology of otosclerosis is still not fully 
understood.65, 97 
Otosclerosis is considered a heterogenetic disease. The heterogenetic heredity could 
explain the variable manifestations of the disease, that does not appear at the same 
age with the same progression and intensity in all patients. The role of heredity has 
originally been implied from demographic and epidemiologic observations and 
more recently from DNA analysis techniques. Epidemiological studies suggested an 
autosomal dominant inheritance with incomplete penetrance of approximately 40% 
and variable expression.63, 64 Although a strong familial component exists, several 
studies have reported that sporadic otosclerosis represents 40-50% of all clinical 
cases.63, 64, 76 Variable phenotypic expression within the same otosclerosis family and 
a high proportion of sporadic cases suggest the contribution of environmental 
factors in the etiology of otosclerosis.64 
Genetic analysis 
There are different methods to identify the genes involved in otosclerosis. In the 
past, otosclerosis genes were addressed by examining an association with a known 
gene complex or with a specific clinical factor, like eyes or hair color or blood group. 
All these studies failed to demonstrate evidence of linkage or cosegregation.  
Candidate gene analysis is also one of the methods. These population-based studies 
investigate associations between genes and a disease, and require some 
understanding or hypothesis of the disease process to select possible candidate 
genes.64, 67  
Linkage analysis focuses on large families segregating a disease to identify the 
causative gene. The location on a chromosome involved in the disease is identified 
by demonstrating a co-segregation between phenotype and genotype by analyzing 
several hundred to several thousand of genetic markers. The identification of the 
locus is the first step towards the identification of the gene itself. Large families with 
affected and unaffected individuals are needed for conclusive results. However, 
families large enough for genetic linkage study are rare, and in these families, factors 
like reduced penetrance and phenocopies complicate linkage analyse.9, 63, 64, 67, 101 
Another method is a genome-wide association study. This approach does not 
depend on the selection of candidate genes that presume an understanding of 
  INTRODUCTION 
39 
 
1 
otosclerosis at the molecular level and does not need large families. It holds the 
promise of identifying genes and pathways that are causally related to otosclerosis 
but are not intuitively obvious at this time.67, 101  
Otosclerosis loci and candidate genes 
Genetic linkage studies have demonstrated the involvement of ten loci.102-109 (Table 
5) Details of OTSC6 and OTSC9 have not been published yet. Although these loci have 
been mapped, no causative genes have been identified. The identified loci include 
genes involved in collagen biosynthesis and metabolism, in the immune system, in 
cartilage and bone homeostasis, in growth suppression and in intercellular 
communication. To identify specific disease-causing genes, refinement of the 
candidate regions and mutation analysis of candidate genes is required. 
Identification and functional analysis of the causative genes and corresponding 
proteins may provide new insights into the molecular mechanisms of otosclerosis 
and may reveal targets for prevention and treatment of the disease.64 
The OTSC2 locus contains the T-cell receptor beta locus (TRB locus) and Schrauwen 
et al. implicated this as the causative gene in the OTSC2 region. The human T-cell 
receptor (TCR) complex comprises integral membrane proteins with a fundamental 
role in the adaptive immune system. These proteins activate T cells in response to 
antigens presented by HLA molecules on antigen-presenting cells. A significant 
lower T-cell receptor-β (TCR-β) mRNA expression, a significant lower percentage of 
blood circulating TCR-αβ+ T-cells and a significantly increased CD28null population 
were detected in OTSC2 patients compared with controls and patients with the 
complex form of the disease. These data suggest a disturbed T-cell development and 
ageing in OTSC2 patients. Moreover, expanded populations of CD28null T cells are 
related to autoimmune diseases. The cytotoxic capacities and the decreased 
susceptibility to immunoregulation of these T cells might facilitate or sustain chronic 
autoreactive immune responses. In otosclerosis, viral infections could activate the 
immune response. In conclusion, a genetic defect in the TRB locus causes disturbed 
T cell development and ageing, and potentially influences T cell reactivity toward 
unique structures within the otic capsule, leading to otosclerosis in OTSC2 
patients.110   
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Locus Location Candidate genes and functions 
OTSC1 
102 
15q25-
26 
Aggrecan; non-collagenous component of extracellular matrix of 
cartilage. 
OTSC2 
103, 111 
7q34-36 TIF1a; growth suppressor required for the growth-inhibitory activity of 
retinoic acid in bone remodeling. 
PLOD3; involved in collagen biosynthesis and metabolism by 
interfering with chondrocytic responses to TNFα-mediated stimuli. 
TRB locus; prominent role in immune system (recognition of antigens 
and subsequent activation of T cells). 
OTSC3 
104, 112  
6q21.3-
22.3 
HLA locus; major histocompatibility complex (MHC) plays an important 
role in the immune system by presenting antigens to T cells. 
COL1A1; type I collagen, the major collagen component of bone. Also 
involved in osteogenesis imperfecta. 
COL11A2; type XI collagen, found in cartilage extracullar matrix and is 
important for the integrity and development of the skeleton. Also 
involved in DFNA13. 
CDKN1A; critical role in cellular response to DNA damage. 
OTSC4 
105 
16q21-
23.2 
Cadherin 1 and 3; transmembrane proteins that mediate cell 
recognition and adhesion. Expressed in connective tissues, bone and 
cochlea. 
COG4 and 8; multiprotein complexes involved in Golgi structure and 
intracellular membrane trafficking. Expressed in the immune system. 
Zink finger proteins; multifunctional proteins with both transcriptional 
and posttranscriptional functions. Broad expression pattern including 
the inner ear, immune system and fibrous tissue. 
DEAD family; implicated in many cellular processes involving RNA, 
including cellular growth and division. Expressed in the immune 
system, cartilage and fibrous tissue. 
OTSC5 
106, 113 
3q22-
q24 
PCOLCE2; involved in cartilage homeostasis and extracellular matrix 
function. 
CHST2; involved in cartilage homeostasis and extracellular matrix 
function. 
ATP1B3; Na,K-ATPase enzyme responsible for transport of sodium and 
potassium ions in most cells. 
OTSC7 
107, 114, 
115 
6q13-
16.1 
COL12A1; type XII collagen of the fibril-associated collagens with 
interrupted triple helices. 
COL9A1; type IX collagen of the fibril-associated collagens with 
interrupted triple helices. 
TGF-β1; involved in the chondrogenesis and bone remodeling of the 
otic capsule. 
OTSC8 
108, 112 
9q13.1-
21.11 
TJP2; tight junction protein of the membrane-associated guanylate 
kinase (MAGUK) family that are involved in the organization of 
epithelial and endothelial intracellular function. 
TRMP3; cation-selective channel important for cellular calcium 
signaling, homeostasis and osteoclast activity. 
KLF9; regulation of cranial facial development. 
OTSC10 
109, 116 
1q41-44 TGF-β2; important in bone formation and remodeling. 
AGT; angiotensinogen, which is involved in the renin-angiotensin-
aldosterone-system (RAAS). RAAS is important in regulation of blood 
pressure and body-fluid homeostasis. AGT II also influences bone 
remodeling. During pregnancy, RAAS is activated and levels of AGT rise. 
Table 5: Loci for otosclerosis derived from the Hereditary Hearing Loss Homepage. OTSC6 
and OTSC9 are reserved. 
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Furthermore, a genome-wide association study suggested a strong association of 
otosclerosis and chromosome 7q22.1.117 The Reelin gene (RELN) is located in this 
region. RELN encodes a secretory glycoprotein, which has a crucial role in the 
regulation of neuronal migration and positioning and in synaptic plasticity in brain 
development. Its known functions are difficult to relate to otosclerosis, making it 
unclear how this gene could be involved in the disease. However, two causative 
variants of RELN are suggested to be involved in otosclerosis.118, 119 Furthermore, 
expression of RELN mRNA is found in human stapes footplates samples and in both 
mouse and human inner ear structures. RELN is expressed to a higher degree in 
osteocytes than osteoblasts. Although, the function of RELN is difficult to reconcile 
with our understanding of the pathogenesis of otosclerosis, it can help to reevaluate 
the molecular mechanisms that lead to this disease.101, 117, 118 
Clinical symptoms 
The characteristic clinical symptom of otosclerosis is progressive unilateral or 
bilateral conductive hearing impairment. The disease is bilateral in 70-80% of the 
patients and usually there is a symmetrical extension and distribution of otosclerotic 
foci, although, hearing impairment can be asymmetrical. The symptoms depend on 
the site of the otosclerotic foci.64, 71, 76 The most common site is anterior to the oval 
window, followed by the round window niche, and the apical and medial cochlear 
wall, respectively. Other sites of predilection are posterior to the oval window, the 
posterior and anterior wall of the internal auditory canal, around the cochlear 
aqueduct and semicircular canals, and within the footplate.73 The expansion of 
otosclerotic foci from the fissula ante fenestrum posteriorly towards the stapedial 
footplate causes gradual immobilization of the stapediovestibular joint and results 
in conductive hearing impairment, ranging from 0 to 50 dB.120 Characteristically, 
hearing impairment is gradually progressive and first affects the low frequencies. 
The degree of conductive hearing impairment seems to be determined by the stage 
of stapedial footplate fixation.120, 121 Low frequency hearing impairment is thought 
to be caused by the presence of highly cellular fibrous tissue that characterizes the 
spongiotic phase. As the pathologic changes progress to a stage of localized bony 
fixation of the anterior part of the footplate, it is thought to result in a moderate 
conductive hearing impairment spanning all frequencies with a gradual widening of 
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the air-bone gap. The hearing impairment increases to moderately severe when the 
diffuse bony ankylosis involves the entire circumference of the annular ligament, 
completely preventing the motion of the stapes.121-123 
This progressive fixation in stapedial ankylosis is responsible for the decreased or 
absent reflexes seen on impedance testing.124 The air-bone gap seems to be 
determined by narrowing and loss of the annular ligament. Bone-conduction 
thresholds and air-bone gaps are worse in cases with sclerotic lesions.67, 76, 125  
A characteristic phenomenon in the audiogram of a patient with otosclerosis is the 
peak in the bone-conduction threshold at 2000 Hz. Carhart was the first to notice a 
notch in the audiometric curve with the largest depression at 2.000 Hz and this 
notch is named after him. The Carhart notch does not refer to a worse cochlear 
function at this frequency, but reflects the lacking mechanisms that are responsible 
for the transmission of vibrations of the surrounding bone to the middle ear. This 
transmission is still largely unclear, especially because the mechanisms influence 
each other. By one of these mechanisms, the vibrations of the surrounding bone are 
transferred to the ossicles. This mechanism is not present in otosclerosis because of 
the fixation of the ossicles. The direct transmission of the vibrations of the 
surrounding bone to the liquid in the cochlea is also limited because the fixated 
stapes suppresses these liquid movements. Thus, there is a weakening of the sound 
transmitted by the bone conductor, especially at frequencies of 2000 Hz for 
unknown reasons.  
Anterior spread of fenestral otosclerotic foci leads to invasion of the cochlear 
endosteum and involvement of the stria vascularis, subsequently contributing to 
sensorineural hearing impairment.126, 127 Although the cause of sensorineural 
hearing impairment is unknown, it may be related to the release of enzymes by 
remodeling of the bony labyrinth immediately surrounding the cochlea. Various 
enzymes have been found in the perilymph of otosclerosis patients.76 These toxic 
enzymes interfere with the mobility of outer hair cells and can result in 
sensorineural hearing impairment.128, 129 The literature provides conflicting 
information regarding the prevalence of sensorineural hearing impairment in 
patients with otosclerosis, but long-term follow-up studies suggest that about 10% 
of the patients with conductive hearing impairment develop sensorineural hearing 
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impairment. Cochlear otosclerosis can exists in the absence of conductive hearing 
impairment and is recognized as a separate entity, although isolated cochlear 
otosclerosis is a rare event.9, 63, 125, 130 
The mean age of onset of clinical otosclerosis is in de third decade of life, but an age 
shift toward an older onset age has been reported. Some patients with otosclerosis 
exhibit hearing impairment in childhood whereas other patients as late as 60 years 
of age.63, 101, 131, 132 Moreover, there is an increase in the prevalence of otosclerosis 
with age.76 Approximately 90% of the patients are younger than 50 years at the time 
of diagnosis.67 
Other clinical features besides hearing impairment are tinnitus and/or vertigo.71 
Tinnitus is a frequent symptom of otosclerosis, especially in patients with 
considerable sensorineural hearing impairment combined with stapedial footplate 
fixation. The prevalence of chronic tinnitus in otosclerosis ranges from 45% to 85%. 
Tinnitus is more frequently associated with mature (sclerotic) otosclerosis than 
with immature otosclerosis.67, 133 The exact mechanism of this symptom is yet 
unknown.120, 134, 135 
Otosclerosis has also been associated with an increased incidence of vestibular 
symptoms.136 Ten to 24% of the patients with otosclerosis suffer from vertigo. 
Advancement of the otosclerotic foci in medial direction to the basal turn of the 
cochlea, the vestibule and the underlying otolitic organs is seen, and may lead to 
vestibular symptoms due to invasion and degeneration of the vestibular nerve 
endings, probably by changes in the biochemical composition of the endolymph. 
Loss of vestibular nerve fibers in clinical otosclerosis is directly related to the size of 
the lesion.67, 137, 138 Vestibular symptoms can include transitory, recurrent, rotary, 
positional or spontaneous vertigo.137 Spontaneous episodic vertigo is the most 
frequent manifestation. However, the vestibular symptoms, the frequency of 
occurrence, the duration of the vertigo attack and the intensity of the vestibular 
symptoms vary from patient to patient but also in time in the same patient.136 A 
correlation with an increased incidence of benign paroxysmal positional vertigo 
(BPPV) has also been described. Otosclerosis is suggested to be responsible for the 
production of cupular deposits, however, an association between these deposits and 
vestibular symptoms could not be confirmed.120, 137  
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Vestibular involvement is more pronounced in patients with sensorineural hearing 
impairment and occurs more frequently in patients with sclerotic otosclerosis.76 
However, no consistent relationship could be demonstrated between the severity of 
vestibular symptoms and the results of caloric testing. Caloric and/or rotational 
hypoexcitability is most frequently seen in otosclerosis, followed by directional 
preponderance and positional nystagmus. Vestibular hyperreactivity is also possible 
and is presumably caused by labyrinth irritation.139  
Radiological examination 
In most cases of otosclerosis the diagnosis is based on clinical findings combined 
with the results of audiometry. However, the use of imaging in the detection of 
otosclerosis has increased with the development of spiral computed tomography 
(CT) scanners with high-resolution images. This type of CT scanners is at present the 
imaging modality of choice for the assessment of the osseous labyrinth, labyrinthine 
windows and cochlear capsule. In otosclerosis, high resolution CT gives the 
opportunity to assess the extent of the disease, and to confirm non-penetrance 
and/or cochlear involvement. In most cases, CT can detect the otospongiotic stage of 
the disease process, characterized by a hypodense lesion in the otic capsule. But 
large mature, sclerotic lesions of the otic capsule may go undetected by CT as they 
have the same density as normal bone tissue of the otic capsule.140 Detection rates of 
surgically confirmed otosclerosis with presurgery CT of up to 91% have been 
reported.141 The best method for the detection of otosclerotic foci on CT is to use 
sub-millimeter slice thickness and assess the images directly on a workstation. 
Although CT cannot replace histology in assessing microscopic lesions of the otic 
capsule, high-resolution CT scans are a valid tool that can be used to confirm, 
localize and determine the size of clinically suspected otosclerotic foci.142  
The radiologic classification of otosclerosis has been proposed when the high 
resolution CT of the temporal bone was incorporated into the diagnostic work-up of 
hearing impairment. (Table 6) Fenestral and cochlear types of otosclerosis have 
been described. The fenestral type refers to hypodense lesions of demineralized 
bone adjacent to the oval window area and/or impinging in the stapedial footplate. 
The cochlear type is radiologically diagnosed as the presence of hypodense areas of 
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demineralization surrounding the cochlea, often described as ‘double ring’ or ‘fourth 
turn’ sign.142  
 
 
Table 6. Classification of otospongiosis based on CT imaging.142  
 
Je Shin et al. demonstrated that patients with and without a family history of 
otosclerosis had different radiologic expression of their disease. In the familial forms 
the lesions are more often detectable, bilateral and extensive, whereas fenestral 
otosclerosis occurs more often in sporadic forms of otosclerosis.143 
The relationship between endosteal involvement and the degree of sensorineural 
hearing impairment has long been controversial, but after the use of more 
technically advanced CT scans, a positive correlation between CT findings and the 
severity of sensorineural hearing impairment could be established; the severity of 
sensorineural hearing impairment is correlated with the extension of the foci within 
the otic capsule. A pericochlear focus without extension to the endosteum is not 
sufficient to cause sensorineural hearing impairment. But when the endosteum is 
involved, sensorineural hearing impairment can be correlated with otosclerosis.141 
Treatment 
Stapes surgery 
Conductive hearing impairment can be corrected by a hearing aid as well as by a 
surgical procedure. The basic surgical steps include disarticulating the 
incudostapedial joint, removal of stapes superstructure and opening up the stapes 
footplate. The surgical management for otosclerosis has evolved from total 
extraction of the footplate, the so called stapedectomy to a small hole in the 
posterior part of the stapes footplate, the stapedotomy.144 In a stapedotomy, the 
Fenestral 
otospongiosis 
Group 1 Otospongiosis limited to the fissula ante fenestram 
Group 2 Otospongiosis extends to at least half the diameter of the oval 
window niche and/or the cochleariform process 
Group 3 Otospongiosis extending over the entire diameter of the oval 
window niche 
Cochlear 
otospongiosis 
Group 1 Otospongiosis not exceeding the diameter of one cochlear turn 
Group 2 Between group 1 and 3 
Group 3 Spongiotic involvement of the entire otic capsule 
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continuity of the ossicular chain is normally reestablished by positioning a piston, 
fixed to the long process of the incus and reaching into the vestibule through the 
footplate. The aim of stapes surgery is to restore the vibration of fluids within the 
cochlea.66, 144 
Although the sensorineural component of the hearing impairment cannot be 
corrected, stapes microsurgery has proven to be highly successful to restore the 
normal conduction mechanism and can improve hearing thresholds by as much as 
50 dB.145 In the early postoperative period, the patients show a significant 
improvement in hearing thresholds, accompanied by a significant improvement in 
speech discrimination scores. The pure-tone thresholds for air- and bone-
conduction intend to improve for approximately 2 years postoperatively and then 
deteriorate in a linear fashion. This deterioration in hearing impairment 2 years 
postoperatively is similar to the decline associated with presbycusis alone, meaning 
that stapedotomy has no demonstrable adverse effects on the cochlear function.125, 
146 
However there are complications of stapes surgery. In some instances, surgery 
results in no improvement in hearing or, even worse, in deterioration of hearing. 
Potential side effects of a stapedotomy include a change in sense of taste on the 
same side of the tongue, vertigo, perforation of the tympanic membrane and 
intolerance of very loud noises.144 Compared to stapedectomy, stapedotomy results 
in equivalent pure-tone thresholds but better high frequency hearing and speech 
discrimination. Furthermore, stapedotomy reduces many of the complications of 
stapedectomy such as postoperative vertigo and sensorineural hearing 
impairment.144, 147  
Pharmacological treatment 
Although the treatment of hearing impairment associated with otosclerosis is well 
established, there is no curative therapy for otosclerosis. Surgical correction of the 
conductive hearing impairment is highly effective, whereas nonsurgical intervention 
has not yet proven to prevent or slow down the disease. Inadequate knowledge of 
the biological mechanisms triggering the otosclerotic process, limits the effective 
prevention and treatment options of otosclerosis.148 Therapeutic strategies have 
been directed at suppression of bone remodeling. Furthermore, the candidate genes 
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of the otosclerosis loci and their pathological mechanisms provide possible 
treatment options.  
Agents that suppress osteoclast recruitment and activation, such as sodium fluoride, 
bisphosphonates, monoclonal anti-TNF-α antibodies and short-term recombinant 
osteoprotegerin (OPG-Fc), were used to treat otosclerosis. Furthermore, vitamin D 
deficiency seemed to be present in some otosclerosis patients. Thus, vitamin D 
supplementation might be beneficial in these otosclerotic patients.65 However, the 
efficacy of these therapeutic agents remains controversial.78, 149, 150  
Many researchers investigated the effect of sodium fluoride on otosclerosis. High 
doses are probably needed for a positive effect, but may have serious side effects 
including multiple organ failure, dysostosis and spinal stenosis. Sodium fluoride is 
thought to inhibit toxic proteolytic enzymes and osteoclast activation, and 
consecutively osteolysis and disease progression.65, 85 Moreover, there is conflicting 
evidence regarding the protective effect of a high fluoride concentration in drinking 
water. Epidemiological studies show that clinical otosclerosis is associated with 
areas that have low fluoride content in drinking water.9, 65, 151 Furthermore, the 
deterioration in air- and bone-conduction thresholds in otosclerosis patients 
drinking fluoride poor water was more pronounced than that in patients drinking 
fluorinated water. However, the difference was not statistically significant.152, 153  
Bisphosphonates are potent inhibitors of BMP synthesis. BMP are fundamental in 
bone remodeling; BMPs stimulate chondrogenesis, promote growth and act as 
inflammatory cytokines. There is some clinical evidence that bisphosphonates 
treatment is effective in the early stages of otosclerosis.150  
Furthermore, an increased TNF-α production is supposed to be a trigger of focal 
bone resorption.89, 154 TNF-α is a proinflammatory cytokine that plays a role in the 
osteolytic process, in the differentiation of osteocytes to osteoclasts or osteoblasts 
and in the intercellular communication between osteoclasts and osteoblasts. 
Administration of monoclonal anti-TNF-α antibodies (etanercept, infliximab, 
adalimumab) could be an option in the treatment of cochlear otosclerosis with 
sensorineural hearing impairment. However, more research is needed to be 
conclusive about the therapeutic use of TNF-α inhibitors in otosclerosis.65, 129, 155 
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OPG-Fc treatment could also have powerful anti-osteolytic effects, primarily in the 
early stages of otosclerosis, and preserve normal bone remodeling.156 OPG is an 
inhibitory glycoprotein that blocks osteoclast formation and osteolysis, and induces 
the apoptosis of activated osteoclasts. Therefore, lack of OPG leads to osteoporosis 
while overexpression causes excessive bone formation or osteopetrosis. 
Furthermore, OPG-deficient mice demonstrated abnormal otosclerosis-like bone 
remodeling in the otic capsule. These mice exhibited progressive hearing 
impairment. However, active remodeling was seen throughout the entire skeleton of 
these mice and not all authors could confirm the stapes fixation histologically.64, 67, 
156 Coexpression of TNF-α and OPG mRNA have been demonstrated in otosclerotic 
stapes footplates, indicating the involvement of activated osteoclasts and 
inflammatory pathways. Increased expression of TNF-α could inhibit the protective 
functions of OPG on normal bone turnover in de otic capsule and may lead to 
extensive osteoclast activation and bone resorption.67, 89, 156 Nevertheless, more 
research is needed to confirm these results.   
There is no cure for the sensorineural component of otosclerosis, however, 
conventional hearing aids, bone anchored hearing aids (BAHA) and cochlear 
implantation are beneficial.65, 66, 144, 148 BAHA can be an option in patients who are 
unable to benefit effectively from stapedotomy and/or conventional hearing aid 
rehabilitation. In contrast to stapedotomy, the risk of further hearing damage, 
tinnitus or vertigo is absent in BAHA surgery. Furthermore, BAHA surgery does not 
preclude patients from stapedotomy at a later stage. The advantage of the BAHA 
over conventional hearing aids is the better sound quality due to direct bone-
conduction. Furthermore, the benefits of the BAHA could also be related to cosmetic 
or comfort improvements.157 Cochlear implantation for patients with profound 
hearing impairment due to otosclerosis is also effective.66, 158 Better performance 
was related to less severe signs of otosclerosis on CT scan, full insertion of the 
electrode array, little or no facial nerve stimulation and little or no need to switch off 
electrodes.159 However, stapedotomy could also be effective in patients with 
profound hearing impairment. Stapedotomy can close the air-bone gap and improve 
the air-conduction thresholds to hearing levels that can be corrected with 
conventional hearing aid rehabilitation.160   
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Aim and outline of this thesis 
The general aim of this thesis was to provide further insight into the phenotype of 
hereditary hearing impairment. This thesis focuses on genotype-phenotype studies 
in DFNA3, DFNB8/10, DFNX4, Muckle-Wells syndrome and otosclerosis (OTSC10). 
Chapter 2 provides a detailed phenotypic description of three DFNA3 patients from 
two families. Mutation analyses revealed a p.Argl84Gln and a p.Arg75Trp mutation 
in GJB2 in the these two families. The phenotypes were compared to previously 
described DFNA3 families. 
Detailed phenotypic analyses of eight DFNB8/10 families are described in chapter 3. 
Differences in phenotypic effects of different TMPRSS3 mutations could be 
distinguished. This different phenotypic expression of TMPRSS3 mutations was also 
established for previously described TMPRSS3 mutations.  
In chapters 4.1 and 4.2, the clinical and genetic characteristics of a large Dutch 
DFNX4 family with a mutation in the SMPX gene are presented. The variable 
expression of hearing impairment in affected men and women was analyzed. The 
phenotype of the present family was compared to previously described DFNX4 
families. 
The phenotype of a Dutch family with Muckle-Wells syndrome (MWS) is described 
in chapter 5. Additional audiological testing has been performed to understand the 
pathogenesis of hearing impairment in MWS.  
Otosclerosis is subject of chapter 6. Detailed analysis of audiometric data from a 
Dutch otosclerosis family, in which the disease is linked to OTSC10, are presented in 
chapter 6.1. The genetic analysis of this family is provided in chapter 6.2. 
Chapter 7 provides the general discussion and conclusion. A summary of this thesis 
is described in chapter 8.       
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Abstract 
In this paper we describe the phenotype of two Dutch DFNA3 families with 
mutations in the GJB2 gene. 
Two patients from family 1 and one isolated patient from family 2 were studied. The 
audiometric examination consisted of pure-tone and speech audiometry. Two 
patients underwent vestibular testing and high-resolution computed tomographic 
scanning of the temporal bone. Mutation analysis of GJB2 and GJB6 was performed. 
All three patients had severe to profound sensorineural hearing impairment. 
Cochlear implantation was performed in two patients, and their phoneme 
recognition scores were good. Mutation analyses revealed a p.Argl84Gln mutation in 
GJB2 in family 1 and a p.Arg75Trp mutation in GJB2 in family 2. No mutations in GJB6 
were identified. Vestibular function tests and computed tomographic scans yielded 
normal findings in the examined subjects. 
Severe to profound sensorineural hearing impairment was found in these DFNA3 
patients and was well rehabilitated with cochlear implantation. A thorough 
genotype-phenotype correlation is difficult because of the small number of affected 
patients and the limited clinical data of these patients. More clinical data of DFNA3 
families need to be published in order to create a reliable and precise phenotype 
characterization. 
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Introduction 
Nonsyndromic autosomal dominant sensorineural hearing impairment, DFNA3, is 
caused by mutations in the GJB2 (gap junction protein beta 2) gene or the GJB6 (gap 
junction protein beta 6) gene, altering either connexin 26 or connexin 30, 
respectively. DFNA3 is characterized by childhood onset (prelingual or postlingual), 
progressive, moderate to severe high-frequency sensorineural hearing impairment. 
In addition, the hearing impairment in DFNA3 shows a variable severity and 
evolution in patients. The variability in phenotype can be explained by variable 
expression of the disease and can be related to genetic and/or environmental 
factors.1 Furthermore, mutations in GJB2 are also responsible for autosomal 
dominant syndromic hearing impairment with dermatologic features such as 
keratitis-ichthyosis-deafness, hystrix-like ichthyosis-deafness, Vohwinkel's 
syndrome and Bart-Pumphrey syndrome.2, 3 So far, 12 mutations in GJB2 
(p.Trp44Cys, p.Trp44Ser, p.Thr55Asp, p.Pro58Ala, p.Arg75Gln, p.Arg75Trp, 
p.Argl43Gln, p.Metl63Leu, p.Alal71Thr, p.Aspl79Asn, p.Argl84Gln and p.Cys202Phe) 
have been reported in individuals with DFNA3.1,3 The majority of these mutations 
have been shown to segregate in families and demonstrate ethnic predilections.3 
Connexin 26 (Cx26) and connexin 30 (Cx30) are related transmembrane proteins 
that form gap-junctions (connexons). Serially arranged connexons of epithelial and 
connective tissue cells of the cochlea are important for recycling potassium ions that 
pass through sensory cells during auditory transduction. Connexin mutations may 
cause hearing impairment by several mechanisms, including interference with the 
proper oligomerization or intracellular transport of connexons, impairment of 
interactions between connexons in opposing cells and the formation of channels 
with altered permeation or gating properties.4 In mice, these mechanisms disturb 
the homeostasis of cortilymph, because of impaired potassium transport by 
supporting cells, resulting in degradation of the organ of Corti.5 In the inner ear, 
Cx26 is commonly coexpressed with Cx30. Mutations in the complex locus of DFNA3, 
which contains 2 genes (GJB2 and GJB6), can result in a digenic pattern of 
inheritance of sensorineural hearing impairment.6 Furthermore, certain mutant 
proteins can have dominant negative effects on Cx26 and Cx30 that are due to 
disrupted transfer of molecules.7 
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In the present article, we report the clinical characteristics of two Dutch DFNA3 
families with a mutation in GJB2. The phenotype is compared with those previously 
published for other DFNA3 families. 
Patients and methods 
Patients 
The study was approved by the local medical ethics committee of the Radboud 
University Nijmegen Medical Centre. The six patients included in this study signed 
an informed consent form. After informed consent, medical records and previous 
audiograms were traced. 
The first family consisted of an affected mother and daughter (proband), and the 
second family of an affected son (proband). (Figure 1) Examination of the probands 
and their parents consisted of medical history, otoscopy, pure-tone audiometry and 
blood samples for linkage analysis. Clinically affected family members also 
underwent speech audiometry. The probands of both families underwent vestibulo-
ocular examination and high-resolution spiral computed tomographic (CT) imaging 
of the temporal bones. In general, attention was paid to the presence of syndromic 
features such as skin disorders. 
 
                    
 
 
 
                                        Family I                     Family II 
 
Figure 1. Pedigrees of families 1 and 2. Square: male; circle: female; open symbol: 
unaffected; solid symbol: affected. 
 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a sound-
treated room according to common clinical standards. Air conduction thresholds 
were measured in decibels hearing level (HL) at 0.25, 0.5, 1, 2, 4 and 8 kHz, and bone 
I:1 I:2
II:1 II:2
I:1 I:2
II:1 II:2
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conduction thresholds were measured in decibels HL at 0.5, 1, 2, 4 and 8 kHz. The 
individual 95th percentile threshold values of presbycusis in relation to the patient's 
sex and age were derived for each frequency with ISO 7029.8 Individuals were 
considered affected if the better-hearing ear showed all thresholds higher than the 
95th percentile threshold values for presbycusis. 
Individual longitudinal linear regression analysis of binaural mean air conduction 
threshold values on age was only performed in clinically affected persons with three 
or more consecutive measurements and an overall follow-up period of at least three 
years. The annual threshold deterioration (ATD) was calculated and the progression 
was considered significant if the 95% confidence interval did not include zero. The 
level of significance used in all tests was a p value of less than 0.05. 
Speech audiometry was performed under the above-mentioned conditions by use of 
standard Dutch consonant-vocal-consonant word lists. The maximum phoneme 
recognition score (mean of both ears) was obtained from monaural performance-
versus-intensity curves. After cochlear implantation, the words were presented 
through a loudspeaker at a fixed distance of 1 m from the patient at a normal 
conversational level of 70 dB sound pressure level (SPL). The subject responses 
were scored as the percentage of phonemes correct. 
One family member underwent the Ewing distraction test for screening of his 
hearing. This test is based on expected responses; between 9 and 13 months, the 
infant will be able to localize sounds.9 These tests were used at a time in which 
otoacoustic emissions (OAE) were not yet used in neonatal hearing screening. 
Vestibulo-ocular examination 
Two affected family members underwent vestibular and oculomotor tests. The test 
included evaluation of the vestibulo-ocular reflex using electronystagmography with 
computer analysis and saccadic smooth pursuit and optokinetic nystagmus 
responses. Vestibular stimulation comprised rotatory and caloric tests. The details 
and normal values have been described previously.10 
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Results 
In both families, DNA sequencing of the coding region and splice sites of the GJB2 
gene identified two different pathogenic mutations. Genebank accession number 
NM_004004 is used as a reference sequence. 
Family 1  
In the proband of the first family, direct DNA sequencing identified a heterozygous 
change G→A at nucleotide 551, resulting in an arginine-to-glycine substitution at 
codon 184 (p.Arg184Gln). The chromatogram is shown in Figure 2a. The mother of 
the proband carried the same mutation. No pathogenic deletion in the GJB6 gene was 
found on allele-specific polymerase chain reaction testing, so digenic inheritance of 
sensorineural hearing impairment is unlikely. A detailed family history did not 
reveal any other affected family members. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Chromatogram of the index patient of family 1. For comparison, wild-type 
sequence is added underneath. 
 
The proband of the first family is a 6-year-old girl. When the child was 9 months of 
age, her mother first had doubts about her daughter's hearing. Audiometric 
evaluation at the age of 10 months showed bilateral sensorineural hearing 
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impairment. Reproducible responses were only seen at low frequencies with 80 to 
90 dB stimulation. Furthermore, brainstem evoked response audiometry showed no 
reproducible responses for both ears with maximum stimulation (90 dB HL), 
indicating bilateral profound hearing impairment. At the age of 1 year hearing aids 
were adjusted and 1 year later the patient underwent cochlear implantation with a 
Nucleus device (Cochlear Ltd, Sydney, Australia). The implantation was uneventful 
and the implant was fully inserted. Three years after activation of the speech 
processor, the patient had a 70% phoneme score at 70 dB SPL. Unfortunately, 
compared to her peers, she is still far behind in speech and language development. 
Figure 3 shows the only available audiogram of the left (unimplanted) ear at the age 
of 5 years. The audiogram shows profound sensorineural hearing impairment. No 
skin disease or other clinical features were seen. No balance problems were 
described and vestibulo-ocular examination before cochlear implantation showed 
normal vestibular function. A CT scan of the temporal bone appeared normal. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Audiogram of the left ear of the proband of family 1 at age of 5.23 years. 
 
The mother of the proband also had profound sensorineural hearing impairment 
since the age of 3 years. Figure 4 shows the available audiograms of this individual; 
no remarkable deterioration of her hearing between the ages of 19 and 42 years was 
seen. Longitudinal regression analysis was performed and revealed only moderate 
significant progression at 1 and 2 kHz with ATD values of 0.4 and 0.3, respectively 
(data not shown). Unfortunately, no audiograms before the age of 19 years were 
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available, so possible progression of hearing impairment before this age cannot be 
ruled out. The maximum mean phoneme recognition scores at the ages of 19 and 37 
years were 30%, and no deterioration of speech reception was noticed. This 
individual reported no vestibular symptoms and vestibulo-ocular examination was 
not performed. Furthermore, there was no evidence of skin disease. 
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Figure 4. Audiograms of the mother of the proband of family 1 show air conduction 
thresholds at different ages for A) right ear and B) left ear. 
 
Family 2  
Direct sequencing of the DNA of the proband of the second family, a 6-year-old boy, 
showed a heterozygous C→T change at nucleotide 223, resulting in an arginine-to-
tryptophan substitution at codon 75 (p.Arg75Trp). The chromatogram is shown in 
Figure 2B. Allele-specific polymerase chain reaction revealed no pathogenic deletion 
in the GJB6 gene. Neither parent had this mutation in GJB2, so a de novo mutation is 
likely. 
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Figure 5. Chromatogram of the index patient of family 2. For comparison, wild-type 
sequence is added underneath. 
 
The parents of the proband first noticed progressive hearing impairment at the age 
of 6 months. The results of the Ewing hearing test at 9 months of age were reported 
as normal. Audiometry evaluation at 17 months of age, however, showed no 
reproducible auditory responses and undetectable otoacoustic emissions. Brainstem 
evoked response audiometry (BERA) showed no responses at maximum stimulation 
(90 dB HL) and confirmed the presence of profound bilateral sensorineural hearing 
impairment. The patient's hearing aids were adjusted at the age of 2 years. Six 
months later a cochlear implant was implanted on the left side and at the age of 3,5 
years the patient received a second cochlear implant on the right side (Nucleus, 
Cochlear). Both implantations were uneventful and complete insertion was 
obtained. The patient was tested 12 months after insertion of the second cochlear 
implant and showed speech reception scores of sound presented at 70 dB SPL of 
76% on the left side, 90% on the right side and 85% for both cochlear implants 
together. The phoneme scores 24 months after insertion of the second cochlear 
implant were 93% on the left side, 87% on the right side, and 96% for both cochlear 
implants together. These results show that the patient's speech reception is still 
improving 24 months after insertion of the second cochlear implant. At 1 year after 
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bilateral cochlear implantation, his word usage was comparable to that of his peers; 
however, his sentence structure is not as good as that of his peers. Except for 
dryness, no skin abnormalities were noticed. No balance problems were reported 
and vestibulo-ocular examination at the ages of 3 and 4 years showed normal 
vestibular function. Hyporeflexia of the velocity-step responses on the left side was 
seen at 5 years of age (initial velocity of 24°/s and 50°/s for left and right directions, 
respectively). However, this was after cochlear implantation, so the value of this 
finding is probably limited. A CT scan of the temporal bone showed no 
abnormalities. No relatives exhibited sensorineural hearing impairment. 
Discussion 
This report presents the audiometry features of two small Dutch DFNA3 families 
with profound sensorineural hearing impairment. Mutation analysis revealed in the 
first family a p.Argl84Gln mutation and in the second family a p.Arg75Trp mutation 
in GJB2. 
Family 1  
The p.Arg184Gln mutation in GJB2 has previously been described in a family from 
Ghana. Heterozygosity for p.Arg184Gln co-segregated with autosomal dominant 
profound sensorineural hearing impairment. None of the five affected family 
members showed skin alterations such as keratoderma.11 Unfortunately, the 
audiometry data were limited, but seem to be in line with the audiometry data of the 
Dutch girl and her mother presented here. 
Family 2 
Janecke et al.12 reported in 2001 the first p.Arg75Trp de novo mutation of the 
connexin 26 gene in a sporadic case of isolated profound hearing impairment. A      
7-year-old Austrian boy with congenital profound sensorineural hearing 
impairment (mean: 105 dB HL for both ears) was assessed for cochlear 
implantation. CT findings of the temporal bone were normal. He had no skin disease 
or other clinical features.12 Allowing for the limited information, the clinical data of 
the 7-year-old Austrian boy seem comparable with those of the 6-year-old Dutch 
boy presented here. Both had profound sensorineural hearing impairment with an 
indication for cochlear implantation. 
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The patients with the p.Arg75Trp mutation reported by Piazza et al.13 were said to 
have profound hearing impairment. Remarkably, the patients with the same 
mutation reported by Feldmann et al.14 had hearing impairment varying from 
moderate to severe.  
The p.Arg75Trp mutation was previously observed in association with dominant 
hearing impairment and palmoplantar keratoderma in an Egyptian family. The 
affected father and daughter presented with congenital prelingual hearing 
impairment and diffuse thickening of the skin of the palms and soles. Audiometry 
confirmed bilateral profound sensorineural hearing impairment with no speech 
discrimination. The palmoplantar keratoderma developed during infancy and was 
characterized by diffuse hyperkeratosis with underlying erythema, peeling and deep 
fissures. The restricted audiological data of the affected Egyptian family members 
and of the present Dutch boy seem to be comparable. However, the Dutch boy has no 
skin lesions, except for dryness, but it is possible that the skin disease has not yet 
developed because of his young age. The exact onset age of palmoplantar 
keratoderma in the Egyptian family was not mentioned. The same report also 
described the p.Arg75Trp mutation in a control individual with no skin disease and 
unknown hearing status, suggesting that the p.Arg75Trp mutation may not be 
causative. However, in silico analysis with several prediction programs (SIFT: 
http://sift.jcvi.org/vvww/SIFT/; Polyphen: http://genetics.bwh.harvard.edu/pph/; 
AGVGD: http://agvgd.iarc.fr/agvgd) indicates the p.Arg75Trp mutation to be 
pathogenic. Even more convincing, the deleterious dominant negative effect of 
p.Arg75Trp on the function of gap junctions was demonstrated in the paired oocyte 
expression system,15 as well as in communication-incompetent Hela cells.16 
In 2009, Yuan et al.17 described a p.Arg75Trp de novo mutation in a 15-year-old 
Chinese girl with sensorineural hearing impairment and palmoplantar keratoderma. 
Audiometric evaluation at the age of 15 years showed residual hearing levels. She 
developed thickening and peeling of the skin at the medial and lateral sides of her 
feet during infancy.17 The audiometric configurations of this Chinese girl and of our 
Dutch boy were similar. However, the age of diagnosis in the Chinese girl was 15 
years, whereas it was below 2 years in the present Dutch boy from family 2, so there 
might be a difference in age of onset. Again, the Dutch boy has no skin disease, but 
may develop palmoplantar keratoderma in the future. 
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Birkenhäger et al.18 reported in 2010 a p.Arg75Trp de novo mutation in a German 
boy with severe hearing impairment and palmoplantar keratoderma. Hearing 
impairment was diagnosed at the age of 12 months. The summed action potentials 
in electrocochleography were negative, and the cochlear microphonics started at 90 
dB on the right and at 110 dB on the left. CT scans of the temporal bone showed no 
morphological findings of the cochlea or vestibular apparatus. The German boy has 
been fitted with a cochlear implant.18 The hearing impairments of the German boy 
and our Dutch boy seem to be similar. However, our Dutch boy has not (yet) been 
found to have palmoplantar keratoderma. 
In conclusion, p.Arp75Trp is associated with both syndromic and nonsyndromic 
autosomal dominant hearing impairment. Patients with the identical p.Arg75Trp 
mutation exhibit a similar hearing impairment phenotype (from moderate to severe 
or profound bilateral sensorineural hearing impairment) and a wide range of 
cutaneous phenotypes. The variations in skin alterations associated with the 
p.Arg75Trp mutation may be due to the contribution of genetic background and 
environmental factors.18 The p.Arg75Trp mutation could be a hotspot mutation, as 
this mutation has already been described in three other DFNA3 families. 
Furthermore, the majority of GJB2 mutations associated with DFNA3 are described 
only in single families. Detailed audiometric findings have been reported for several 
other mutations in GJB2 that cause DFNA3 and are outlined in the Table 1.11-15, 17, 19-
25  
Vestibular function 
No vestibular evaluation was performed in previously described individuals with 
the p.Argl84Gln or the p.Arg75Trp mutation in connexin 26. Vestibular function 
tests performed by Denoyelle et al.1 in subjects with other mutations in GJB2 yielded 
normal findings. For the p.Thr55Asp mutation, vestibular failure has been reported 
to occur in affected individuals tested at ages 14 to 47 years.21 In the future, we will 
repeat vestibular evaluation of the affected family members in our study to assess 
whether DFNA3 represents a progressive cochleovestibular disorder like DFNA9,26-
28 DFNA1119 and DFNA15.30, 31 
 
 
  PHENOTYPE OF DFNA3 
71 
 
2 
Mutation Reference Audiogram 
p.Arg184Gln Hamelmann et al. 200111 Profound congenital sensorineural HI 
p.Arg75Trp Janecke et al. 200012 
Piazza et al. 200513 
Richard et al. 199815 
Profound sensorineural HI 
Feldmann et al. 200514 Moderate to severe sensorineural HI 
Yuan et al. 200817 Residual hearing levels 
p.Trp44Cys Tekin et al. 200127  
Welch et al. 200728 
Severe to profound sensorineural HI 
Denoyelle et al. 20021 Moderate to severe sensorineural HI starting 
at the high frequencies 
p.Thr55Asp Melchionda et al. 200519 Severe to profound sensorineural HI 
p.Arg143Gln Löffler et al. 200129 Moderate to severe sensorineural HI 
p.Met163Leu Matos et al. 200830 Mild to moderate sensorineural HI 
p.Cys202Phe Morlé et al. 200031 
Denoyelle et al. 20021 
Mild to moderate sensorineural HI 
p.Asp179Asn Primignani et al. 200332 Mild to moderate sensorineural HI exclusively 
at the high frequencies 
 
Table 1. Overview of mutations in GJB2 gene causing DFNA3 and audiometric data reported 
for these mutations. HI: hearing impairment. 
 
Cochlear implantation 
Our results indicate that cochlear implantation in DFNA3 patients provides 
satisfactory speech reception and seems to be a promising treatment option. 
Furthermore, bilateral cochlear implantation resulted in further improvement of 
speech reception in our patient group. 
The relatively good speech reception of GJB2 patients can be explained by the fact 
that GJB2 mutations do not affect the spiral ganglion cells stimulated by the cochlear 
implant. Normal cognitive function could also play a role. The word score 3 years 
after cochlear implantation of patients with GJB2-related hearing impairment 
reported by Sinnathuray et al.32 was 92% (range, 79% to 100%). This score is better 
than the phoneme score of our Dutch girl of family 1. Three years after activation of 
the speech processor, she had a phoneme score of 70% at 70 dB SPL. Furthermore, 
phoneme scoring gives higher percentage values than word scoring, making the 
difference in speech reception even greater. No phoneme score was available for our 
Dutch boy of family 2 from 3 years after cochlear implantation; however, his 
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phoneme score at 24 months after implantation was already comparable to the 
word score reported by Sinnathuray et al.32 
Conclusion 
It is remarkable that the majority of GJB2 mutations in autosomal dominant hearing 
impairment are described in only single small families or simplex cases. Moreover, 
the available clinical data of affected individuals are usually limited. There is no 
doubt that a thorough genotype-phenotype analysis of DFNA3 requires more data 
on DFNA3 families with several GJB2 mutations. Long-term clinical data could also 
be useful in counseling of patients and their family members. Furthermore, our 
results indicate that cochlear implantation in DFNA3 patients could be a promising 
treatment option. 
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Abstract 
In the present study, genotype-phenotype correlations in eight Dutch DFNB8/10 
families with compound heterozygous mutations in TMPRSS3 were addressed. We 
compared the phenotypes of the families by focusing on the mutation data.  
The compound heterozygous variants in the TMPRSS3 gene in the present families 
included one novel variant, p.Val199Met, and four previously described pathogenic 
variants, p.Ala306Thr, p.Thr70fs, p.Ala138Glu and p.Cys107Xfs. In addition, the 
p.Ala426Thr variant, which had previously been reported as a possible 
polymorphism, was found in one family.  
All affected family members reported progressive bilateral hearing impairment, 
with variable onset ages and progression rates. In general, the hearing impairment 
affected the high frequencies first, and sooner or later, depending on the mutation, 
the low frequencies started to deteriorate, which eventually resulted in a flat 
audiogram configuration. The ski-slope audiogram configuration is suggestive for 
the involvement of TMPRSS3.  
Our data suggest that not only the protein truncating mutation p.T70fs has a severe 
effect but also the amino acid substitutions p.Ala306Thr and p.Val199Met. A 
combination of two of these three mutations causes prelingual profound hearing 
impairment. However, in combination with the p.Ala426Thr or p.Ala138Glu 
mutations, a milder phenotype with postlingual onset of the hearing impairment is 
seen. Therefore, the latter mutations are likely to be less detrimental for protein 
function. Further studies are needed to distinguish possible phenotypic differences 
between different TMPRSS3 mutations.  
Evaluation of performance of patients with a cochlear implant indicated that this is a 
good treatment option for patients with TMPRSS3 mutations as satisfactory speech 
reception was reached after implantation. 
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Introduction 
Autosomal recessive nonsyndromic hearing impairment (arNSHI) is the most 
common type of inherited hearing impairment, accounting for approximately 80% 
of inherited prelingual hearing impairment. The phenotype associated with 
nonsyndromic recessive hearing impairment is usually prelingual, non-progressive 
and severe to profound. Autosomal recessive inheritance is rare in nonsyndromic 
hearing impairment with postlingual onset.1 
Already 72 loci have been described to be involved in arNSHI and 40 causative genes 
have been identified thus far, indicating enormous genetic heterogeneity. However, 
there is little knowledge about the contribution of the different genes to arNSHI in 
the European population. GJB2 mutations are a frequent cause of arNSHI, as in most 
populations; however, the relative contribution varies per country. Other genes 
reported to be relatively important for arNSHI in populations of western European 
origin are TMC1, OTOF and CDH23.2 
Mutations in the transmembrane protease serine 3 (TMPRSS3, OMIM 605511) gene 
on chromosome 21q22 are responsible not only for arNSHI with a prelingual onset 
(DFNB10, OMIM 605316)3 but also for postlingual (DFNB8, OMIM 601072)4 arNSHI. 
TMPRSS3 mRNA has been detected in the spiral ganglion, the entire epithelium that 
supports the cells of the organ of Corti and in low levels in the stria vascularis, but 
was not detected in sensory hair cells with in situ hybridization.5 However, in a 
more recent study by Guipponi et al.6, expression of the TMPRSS3 protein was 
shown in the inner hair cells of the organ of Corti and in the cell bodies of the spiral 
ganglion neurons. The function of TMPRSS3 in the auditory pathway is currently 
poorly understood, but it has been hypothesized that lack of TMPRSS3 activity 
results in hearing impairment because of an increased sodium concentration in the 
endolymph by insufficient ENaC activation.5 However, individuals with 
pseudohypoaldosteronism type 1, which are homozygous for null alleles of ENaC 
subunits, demonstrate no hearing impairment.7 This indicates that hearing 
impairment associated with TMPRSS3 mutations cannot be explained by inactive 
ENaC. Involvement of TMPRSS3 in the proteolytic cleavage of proneurotrophins 
could play a role.5 Proneurotrophins function in the development and maintenance 
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of inner ear innervation.8 The serine protease plasmin, which belongs to the same 
family as TMPRSS3, has been shown to cleave the neurotrophic factor BDNF.5, 9 
So far, mutations in TMPRSS3 have mainly been identified in families from Asian and 
Mediterranean countries, and did not seem to contribute substantially to prelingual 
arNSHI in the Caucasian population.10 However, in the present study, we 
demonstrate that mutations in TMPRSS3 are a common cause of progressive arNSHI 
with a childhood onset in the Dutch population. We characterized the hearing 
impairment in eight Dutch families with compound heterozygous mutations in 
TMPRSS3 and described genotype–phenotype correlations. The present family E was 
previously described as family 2 in a report on autosomal recessive progressive 
high-frequency hearing impairment with childhood onset.11 
Patients and methods 
Patients 
The pedigrees of eight families with arNSHI were constructed. (Figure 1)11 After 
informed consent had been obtained from the participating family members, 
audiograms were obtained to establish the hearing impairment phenotype of these 
families. The study was approved by the medical ethics committee of the Radboud 
University Nijmegen Medical Centre, the Netherlands. 
Examination of the family members included a medical history guided by a 
questionnaire, otoscopy, pure-tone audiometry and drawing blood samples for DNA 
isolation. Some of the affected family members underwent speech audiometry, 
vestibulo-ocular examination and high-resolution spiral computed tomography 
imaging of the temporal bones. Furthermore, concomitant disease, use of medication 
and any other possible causes of acquired hearing impairment were ruled out. 
Previous medical records and audiograms were traced for individual longitudinal 
analysis. The previously published audiograms of family E were also included.11 
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Figure 1. Pedigrees of the Dutch families with autosomal recessive hearing impairment and 
segregation of the TMPRSS3 mutations. Family E is previously described by Cremers et al.11 
All unaffected sibs were either carrier of one mutant allele or of two wild-type alleles. 
Square: male; circle: female; open symbol: clinically unaffected; solid symbol: clinically 
affected; slash: deceased individuals. NT not tested. 
 
Linkage analysis 
Genomic DNA of all participating individuals was extracted from peripheral blood 
lymphocytes according to standard protocols. Families D and E were selected for 
linkage analysis. For family D, the unaffected parents, and three affected and five 
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unaffected siblings were genotyped using the Illumina 6k single nucleotide 
polymorphism (SNP) array according to the manufacturer’s protocol. Similarly, for 
family E, the unaffected mother, and four affected and five unaffected siblings were 
genotyped. Multipoint linkage analysis was performed with GeneHunter version 
2.1r5 in the Easy-Linkage software package.12 An autosomal recessive mode of 
inheritance with a penetrance of 95% and a disease allele frequency of 0.001 were 
used for limit of detection (LOD) score calculations. 
Sequence analysis and prediction of effects of mutations on protein structure 
Amplification of all coding exons and flanking intronic sequences by PCR was 
performed on 40 ng of genomic DNA with Taq DNA polymerase (Roche). Primer 
sequences and PCR conditions are available in electronic supplementary material 
Table S1. PCR fragments were purified using NucleoFast 96 PCR plates (Clontech) 
according to the manufacturer’s protocol. Sequence analysis was performed with the 
ABI PRISM Big Dye Terminator Cycle Sequencing V3.1 Ready Reaction kit and the 
ABI PRISM 3730 DNA analyzer (Applied Biosystems).  
For segregation analysis of the identified TMPRSS3 mutations in the families, 
restriction digestion could be performed. Relevant exons were amplified and PCR 
products were purified as described for sequencing. Digestion of the PCR products 
with restriction enzymes was performed according to the manufacturer’s protocol 
and restriction fragments were analyzed on 2% agarose gels. Primer sequences and 
restriction enzymes are listed in Table S1. The same approach was used for testing 
the occurrence of the c.595G9A and c.1276G9A variants in Dutch control individuals. 
As reference sequence, NM_024022 was used. 
The effects of the amino acid substitutions in TMPRSS3 on its structure were 
analyzed using the Project HOPE web server (http://www.cmbi.ru.nl/hope).13 The 
exact 3D structure of TMPRSS3 is unknown; therefore, HOPE built a model based on 
the homologous structure protein data bank entry 1z8g.14 The model was built using 
an automatic script in the Yasara and WHAT IF Twinset.15, 16 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a sound-
treated room. Air-conduction (AC) thresholds were measured in decibel hearing 
level (HL) at 0.25, 0.5, 1, 2, 4 and 8 kHz; bone-conduction thresholds were measured 
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in decibel HL at 0.5, 1, 2, 4 and 8 kHz. The individual 95th percentile threshold values 
of presbycusis in relation to the patient’s sex and age were derived for each 
frequency using the ISO 7029 method. Individuals were considered affected if the 
best hearing ear showed thresholds beyond the 95th percentile threshold values for 
presbycusis at three frequencies or more. Binaural mean air-conduction threshold 
values were calculated for each frequency. 
Individual longitudinal regression analysis of binaural mean air-conduction 
threshold values on age was performed for individual 10 of family E because the 
audiometric data of this individual were most comprehensive.11 The regression 
coefficient (slope) was called annual threshold deterioration (ATD), expressed in 
decibels per year. Progression was significant if the 95% confidence interval of the 
ATD did not include zero. 
Speech audiometry was performed under the aforementioned conditions using 
standard Dutch monosyllabic consonant–vocal–consonant word lists. The maximum 
phoneme recognition score (mean percentage correct for both ears) was retained 
from the monaural performance versus intensity curves. These maximum phoneme 
recognition scores were analyzed in relation to age and to pure-tone average (mean 
value for both ears) at frequencies of 1, 2 and 4 kHz (PTA1,2,4 kHz). Cross-sectional 
analysis was performed using linear regression analysis to determine the local 
average slope, called deterioration rate in the score-against-age plot and 
deterioration gradient in the score-against-PTA1,2,4 kHz plot. A previously described 
group of subjects with only presbycusis was used as the reference group.17 
Vestibulo-ocular examination 
Nine of 16 affected individuals (A5, B3, C4, E8, E9, E10, E13 and G3) underwent 
vestibular and ocular motor tests. The test included evaluation of the vestibulo-
ocular reflex using electronystagmography with computer analysis, and saccadic, 
smooth pursuit and optokinetic nystagmus responses. Vestibular stimulation 
comprised rotatory and caloric tests. Details and normal values have been described 
previously.18 
Genotype-phenotype correlations 
We compared the phenotype of the present families by focusing on the genotype to 
study whether the mutations differ in severity. The phenotypes of the different 
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families were compared when at least one identical mutation in TMPRSS3 was 
present. Therefore, the effect of the second mutation on the phenotype in these 
families could be determined. All family members with the same compound 
heterozygous mutations were taken together, for example, families A/G and D/F. 
The threshold values of each family member were compared to the threshold values 
of every family member of the other family. We compared the thresholds at all 
frequencies in relation to age. 
Evaluation of the effect of CI on phoneme recognition 
Nine patients underwent cochlear implantation (CI). Speech audiometry was 
performed in a quiet environment using standard monosyllabic Dutch word lists 
after cochlear implantation. Words were presented through a loudspeaker at a fixed 
distance of 1 m from the patient at a normal conversational level of 70 dB sound 
pressure level (SPL). Subject responses were scored as the percentage of phonemes 
correct. As a reference, the test results after 1 year of use in postlingually implanted 
adults were used. The first reference group (n = 70) was implanted with a 
CII/HR90K device of Advanced Bionics® and the second reference group (n = 65) 
with a Nucleus 24RCA of Cochlear®. A mean phoneme score of 64% (SD 23%) was 
demonstrated in the first reference group and the second group (n = 65) showed a 
mean phoneme score of 72% (SD 18%).19 
Results 
Compound heterozygous TMPRSS3 mutations in Dutch arNSHI patients 
Linkage analysis was performed for two arNSHI families, D and E, with progressive 
hearing impairment. For family D, five regions were found with a maximum LOD 
score of ~1.82. (Figure S1) Two of the regions contained a known deafness gene, 
namely, GRXCR1 on chromosome 4 and TMPRSS3 on chromosome 21. Mutations in 
GRXCR1 were excluded in a previous study.20 For family E, three regions with 
suggestive linkage were found with a LOD score of ~2.42. One of those regions 
harbored TMPRSS3. In both families, the LOD score for the TMPRSS3 region reached 
the theoretical maximum LOD score. 
Thus, mutation analysis was performed for all coding exons and exon–intron 
boundaries of TMPRSS3. In both families, compound heterozygous sequence variants 
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were detected. (Table 1) The variants c.413C9A, c.916G9A and c.207delC have been 
described before to be pathogenic in families with arNSHI. The c.1276G9A variant is 
present in the SNP database (http://www.ncbi.nlm.nih.gov/sites/SNP; 
rs56264519). However, this SNP has not been validated. We did not identify this 
variant in 590 Dutch control alleles and, importantly, the resulting amino acid 
change Ala426Thr has been shown to affect protein function.21 We therefore 
considered the Ala426Thr substitution to be pathogenic. All four TMPRSS3 
mutations co-segregated with the hearing impairment in the families. (Figure 1) 
To investigate the contribution of TMPRSS3 mutations in progressive hearing 
impairment, we screened a panel of 22 unrelated supposed arNSHI patients with 
progressive hearing impairment; compound heterozygous mutations were found in 
four of them, belonging to families A, B, C, and F. (Figure 1 and Table 1) The novel 
variant, c.595G9A, leading to the substitution of a methionine for a valine at position 
199 of the protein (p.Val199Met) was present in two patients. This variant was not 
found in 590 Dutch control alleles. In summary, we identified compound 
heterozygous TMPRSS3 mutations in 6 of 24 families (25%) with progressive 
arNSHI.  
To evaluate the prevalence of TMPRSS3 mutations in unselected patients with 
(putative) arNSHI in the Netherlands, we screened a panel of 212 index patients for 
whom GJB2 mutations had been excluded as the cause of their hearing impairment. 
Compound heterozygous mutations were detected in two of these index patients 
(Table 1), which segregated with the hearing impairment in the corresponding 
families G and H. (Figure 1) Hearing impairment was found to be progressive in 
these families as well. 
Large variation in age of onset 
The clinical characteristics and genotypes of the patients are listed in Table 1. For 
none of the affected family members, there was evidence of other causes of hearing 
impairment, and otoscopy was normal. All affected individuals reported progressive 
bilateral hearing impairment. Some individuals had prelingual hearing impairment, 
whereas other individuals were not aware of being hearing impaired until in their 
late teens, which indicates postlingual hearing impairment. (Table 1) 
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Imaging of temporal bones 
Computed tomography (CT) of the temporal bone was performed in ten individuals 
(A5, C4, D4, E8, E9, E10, E13, F3, G3 and H3), mainly as part of a preoperative CI 
selection procedure. Magnetic resonance imaging (MRI) was accomplished in 
individual B3. The CT scans and MRI showed normal middle and inner ear 
structures in all cases. 
Vestibulo-ocular examination 
Although vestibular symptoms were not reported, testing of vestibular function in 
three affected individuals (A5, E8 and E9) revealed mild hyperreflexia of the velocity 
step responses with time constants between 28 and 32 seconds (normal limit: 26 s). 
Furthermore, individuals G3 and H3 showed significant hyporeflexia of the velocity 
step responses with time constants between 3 and 9 s for both nystagmus 
directions. Caloric tests revealed borderline bilateral caloric weakness in individual 
G3 and normal caloric functioning in individual H3. None of the relative prevalences 
of the abnormal vestibular findings was above chance level. The tests of vestibular 
function in four additional affected individuals (B3, C4, E10 and E13) demonstrated 
no abnormalities. The vestibulo-ocular examination in all nine affected individuals 
was performed before cochlear implantation. None of the patients reported by 
Bonne-Tamir et al.3 showed signs of vestibular involvement. However, formal 
vestibular tests were not performed. Information on the vestibular function of the 
other TMPRRS3 families previously reported were not available. 
Typical ski-slope audiogram configuration 
A representative selection of the available pure-tone audiograms of all 16 affected 
individuals are shown in Figure 2. The thresholds in families B and C (gray 
audiograms in Figure 2) are higher than or similar to the thresholds in the other 
families, at a much younger age. This is in accordance with the reported prelingual 
hearing impairment in these families. Most frequently, a down-sloping audiogram 
configuration was observed, indicating high-frequency hearing impairment. 
Remarkable is the typical ski-slope audiogram configuration for patients with 
postlingual hearing impairment, as seen in, for example, individuals A5, F3, D6 and 
H3. However, flatter audiogram configurations, close to residual hearing, were also 
observed (individuals D4, E8, E9, E10, E13 and G3), but only at ages above 28 years. 
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The families with postlingual hearing impairment initially presented with hearing 
impairment of the high frequencies which was followed by an increase of the low- 
and mid-frequency threshold values with advancing age. 
Figure 2. Selection of binaural mean air-conduction threshold values of clinically affected 
family members at different ages, ordered by age (from top left to bottom right) at last 
visit.11 Family number and sequence number are above each audiogram. Gray background, 
relatively poorer thresholds. 
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The thresholds in individual D4 are exceptionally high at the low and mid-
frequencies at ages between 21 and 28 years, as compared with the thresholds of 
individuals D6 and D9. The threshold of individual G3 at these frequencies are also 
remarkably high in comparison to the thresholds of individuals G4 and G7 at the 
same ages. So far, there is less variation in thresholds in families E and H at matching 
ages. However, it is not clear at this point whether the hearing impairment in 
individual H4 will show the same progression as the hearing impairment of his 
brother H3 until the age of 29 years. 
Progressive bilateral hearing impairment at all frequencies 
Regression analysis for individual E10 demonstrated a significant deterioration of 
threshold levels with advancing age for all frequencies. The longitudinal threshold 
data of individual E10 covered approximately 36 years (from age 9 to 45 years). 
Figure 3a shows the threshold data for all frequencies separately. A nonlinear 
regression model of a dose-response curve with a variable slope fitted far better to 
the data than a linear regression model (comparative data not shown); the fitted 
curves are included in Figure 3a. The maximum local slope (ATD) was about 6 
dB/year at 0.25 kHz at ages between 25 and 35 years. This maximum ATD can also 
be derived from the age related typical audiogram (ARTA; Figure 3b); the threshold 
at 0.25 kHz increases from about 40 dB at 25 years to about 95 dB at 35 years. 
Figure 3 illustrates that most of the progression at the higher frequencies, in the 
absence of a pronounced congenital hearing impairment, already occurred before 
the age of 10 years. If that indeed was the case in individual E10, the threshold levels 
at around 9 years of age would suggest an average progression of about 10 dB/year 
at 2–8 kHz. (Figure 3a-b) 
Figure 3a also shows all the longitudinal threshold data of individuals A5, D4, D6, 
D7, E8, E9, E13, F3, G3, H3 and H5 (postlingual DFNB8 patients; see below). The 
available audiograms of individual A5 were measured between 6 and 13 years of 
age. The hearing impairment in this individual indeed demonstrated progression 
only at 2–8 kHz, which is on the order of about 10 dB/year. Figure 3a also 
demonstrates that the longitudinal data for individual E10 are, more or less, 
representative for the whole group of DFNB8 patients in the present collection of 
families. The sigmoidal regression curve for individual E10 takes a fairly median 
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position; however, some of the other individuals are represented by threshold 
values that indicate major deviations from that position. (Figure 3a) 
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b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. a Longitudinal individual measurements of individuals A5, D4, D6, D7, E8, E9, E10, 
E13, F3, G3, H3 and H5 for each frequency separately (different symbols for each 
individual).11 A dose-response curve with a variable slope could be obtained for the 
longitudinal data of individual E10 for each frequency (bold line). b ARTA derived from a 
longitudinal regression analysis of mean AC threshold levels of individual E10. Italics 
indicate age in years. 
 
Relatively good speech recognition scores 
Figure 4 shows the available single-snapshot measurements of the phoneme scores 
in the affected members of families A, D, E, F, G, and H. For the more severely 
affected families B and C (see below), we only had one score for individual C4. 
Speech recognition in the patients with a TMPRSS3 mutation was severely impaired, 
even at young ages. The 50% score was attained at the age of 25 years, whereas in 
the presbycusis group, this score was attained at 89 years. At approximately 55 
years of age, there was no remaining speech recognition. The PTA1,2,4 kHz levels at 
which speech recognition scores of 50% were attained in the TMPRSS3 and the 
presbycusis patients were 95 and 87 dB, respectively. Therefore, the TMPRSS3 
patients tended to have somewhat higher scores than the presbycusis patients at 
similar PTA1,2,4 kHz levels. The deterioration rate in the score-against-age plot was 
1.6% per year and the deterioration gradient in the score-against-PTA1,2,4 kHz plot 
was 2.1% per decibel. The presbycusis group showed a higher deterioration rate 
(3.3% per year) and a lower deterioration gradient (1.1% per decibel). Compared 
with matching scores of the other family members, the speech recognition score of 
individual C4 was observed at a younger age and a higher PTA1,2,4 kHz level. (Figure 4) 
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Unfortunately, speech recognition scores were not reported for previously 
described families with TMPRSS3 mutations. 
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Figure 4. Single-snapshot measurements of the affected family members of binaural mean 
phoneme recognition scores against age (left) and against binaural mean pure-tone average 
at 1, 2 and 4 kHz (right).11 The solid regression line covers the cross-sectional analysis. The 
dotted curve represents presbycusis and was previously established for patients with 
presbycusis. See text for the meaning of the figures, and the straight horizontal and vertical 
lines. 
 
Genotype–phenotype correlations 
In the present eight families, four different missense mutations and two frameshift 
mutations were detected. Four of these mutations were recurrent and present in 
two to four of the eight families. To study whether the mutations differ in severity, 
we compared the phenotypes of the families with one identical mutation in 
TMRPSS3. This allows a comparison of the effect of the second mutation in these 
families. For example, patients in families B and E have the p.Thr70fs mutation in 
common (Table 1); therefore, a comparison of the phenotypic effect of the 
p.Ala306Thr mutation in family B and the p.Ala426Thr mutation in family E is 
possible. Thresholds in family B at age 3–4 years are poorer than those in family E at 
ages between 9 and 30 years, but fairly similar to those in family E at age 24–37 
years and better than those in family E at age 36–49 years. (Figure 2) This implies 
that threshold levels similar to those shown by family B in the first decade of life are 
unlikely to be found in family E before the third or fourth decade of life and that 
poorer levels are only likely to be found in family E from the fourth to the fifth 
decade of life onwards. This suggests that the p.Ala426Thr mutation has a milder 
effect than the p.Ala306Thr mutation.  
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The same procedure was repeated for the other mutations. The p.Ala306Thr 
mutation has a fairly similar phenotypic effect as p.Val199Met (families A/G versus 
D/F) and p.Cys107fs (families D/F versus family H), whereas p.Val199Met has a 
fairly similar effect as p.Thr70fs (family B versus C) and p.Cys107fs (families A/G 
versus family H): this suggests that also p.Ala306Thr and p.Thr70fs must have fairly 
similar phenotypic effects. Both p.Ala426Thr and p.Ala138Glu have milder 
phenotypic effects than p.Ala306Thr (family B versus E and family C versus families 
A/G, respectively); this suggests that p.Ala426Thr and p.Ala138Glu have fairly 
similar phenotypic effects. Furthermore, p.Ala138Glu has a milder effect than 
p.Val199Met (family C versus families D/F) and also a milder effect than p.Thr70fs 
(family B versus families D/F).  
The thresholds of individuals D4 and G3 were higher compared with the thresholds 
of their sibs, and therefore individuals D4 and G3 were excluded from the genotype-
phenotype assessment. Nevertheless, the classification of mutations did not change 
when individuals D4 and G3 were included. In line with these considerations and the 
levels of the thresholds in the various families, we suggest that the mutations in 
TMPRSS3 can be classified in mild and severe mutations. Our classification of 
TMPRSS3 mutations is in accordance with the two types of hearing impairment 
phenotypes: 
1. DFNB10: a severe congenital or early childhood type with prelingual hearing 
impairment (families B and C) caused by the presence of two severe mutations 
2. DFNB8: a later-onset progressive but initially milder type with postlingual hearing 
impairment (families A/G, D/F and E) caused by the presence of one mild and one 
severe mutation 
Predicted effects of amino acid substitutions on TMPRSS3 structure 
Genotype–phenotype correlations in the present study suggest that the amino acid 
substitutions p.Ala138Glu and p.Ala426Thr have a less severe effect as compared 
with p.Val199Met and p.Ala306Thr. Both substitutions p.Ala306Thr and 
p.Ala426Thr are within the serine protease domain. These changes result in the 
substitution of a larger residue for a conserved amino acid, predicted to result in the 
destabilization of the protein. The difference in severity of the effect of the two 
mutations might well be explained by the location of the substituted residue. The 
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p.Ala306Thr is located close to one of the active residues, Asp304, and therefore this 
substitution can be predicted to directly disturb the function of the serine protease 
domain. Moreover, the alanine at position 426 is predicted to be semi-buried in the 
protein and the side chain of threonine is only slightly bigger than the alanine side 
chain. Therefore, there could be enough space for the side chain of the threonine at 
this position. (Figure 5a) Both substitutions p.Ala138Glu and p.Val199Met occur 
within the scavenger receptor cysteine-rich (SRCR) domain, which is thought to be 
involved in interactions with extracellular molecules. Also, these two mutations 
affect evolutionary conserved residues and substitute a larger amino acid for the 
wild-type residue, which is predicted to cause steric clashes with other residues and 
hence to destabilize the protein. (Figure 5b) The 3D modeling could not directly 
explain the difference in the effect of p.Ala138Glu and p.Val199Met mutations, since 
the exact function and binding partners of the SRCR domain are still unknown. 
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Figure 5. Molecular modeling for TMPRSS3 missense mutations. Graphic representation of 
the effect of the p.Ala306Thr and p.Ala426Thr mutations in the serine protease domain (A) 
and of the p.Ala138Glu and p.Val199Met in the SRCR domain (B). The wild-type residues are 
depicted in green, while the mutant residues are shown in red. The yellow structure 
represents a substrate for the serine protease domain (figure made using the model for 
TMPRSS and YASARA). 
 
Good speech reception after cochlear implantation 
Eight family members underwent cochlear implantation in our hospital. 
Implantation was uneventful and the implant was fully inserted on the left side in all 
cases. Individuals B3, C4 and H3 were implanted with a Nucleus Freedom 
(Cochlear), individuals E8 and G3 with a Nucleus Contour CI24R (Cochlear), and 
individuals E9, E10 and E13 with a Clarion AB-5100H (Advanced Bionics). 
Individual 4 of family D was implanted in another hospital with a Nucleus CI24M 
(Cochlear) and complete insertion was reported. Phoneme and word scores were 
unavailable for individuals D4 and H3. Individual H3 was implanted less than a year 
ago. The available phoneme and word scores of sound presented at 70 dB SPL 1 year 
after activation of the speech processor are presented in Table 2. We compared 
these results with the results of our two reference groups 12 months after use. The 
phoneme and word scores in the seven patients were above the average phoneme 
and word scores of our two reference groups. The mean phoneme score of 84.1% 
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(SD = 5.4) is significantly higher than the phoneme score of reference group 1 (p = 
0.0001) and reference group 2 (p = 0.0005). Elbracht et al.22 also reported good 
results with bilateral cochlear implantation, but unfortunately, there were no 
phoneme or word scores available to compare with our results. 
 
Individual Preoperative Postoperative 
Phoneme score Phoneme score Word score 
B3 - 91% - 
C4 - 80% - 
D4 5% - - 
E8 20% 89% 75% 
E9 5% 76% 60% 
E10 0% 82% 58% 
E13 0% 83% 62% 
G3 2.5% 88% 68% 
H3 10% - - 
 
Table 2. Available phoneme and word scores preoperative and one year after activation of 
the speech processor of the cochlear implant. Sound was presented at 70 dB sound pressure 
level. 
 
Discussion 
This report presents the clinical and genetic analyses of eight Dutch DFNB8/10 
families with compound heterozygous mutations in TMPRSS3. (Table 1) Our study 
suggests genotype-phenotype correlations for the detected mutations.  
Phenotype of TMPRSS3 mutations 
The reported age of onset and severity of hearing impairment in the present families 
showed a wide variation. Also within the families, variation was seen. This is 
frequently demonstrated in hereditary hearing impairment, however mainly in the 
dominantly inherited forms. At a young age, TMPRSS3-associated hearing 
impairment was more pronounced at the high frequencies, and sooner or later, 
depending on the mutation, thresholds for the low frequencies deteriorated, 
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eventually resulting in a flatter audiogram configuration (i.e. residual hearing). 
Prelingual as well as postlingual hearing impairments were reported. A ski-slope 
audiogram configuration was indicative for postlingual hearing impairment. 
Twenty-two families with a mutation in TMPRSS3 had been reported previously.3, 4, 
10, 22-29 (Table 3) Since the clinical data provided for most of these TMPRSS3 families 
are very limited, a thorough comparison with our data is not possible. However, the 
available clinical data seem to be in line with those of the present families. All 
families with the TMPRSS3 mutations described in the literature showed either 
severe to profound prelingual (DFNB10) or postlingual (DFNB8) progressive 
bilateral sensorineural hearing impairment.3, 4, 10, 22-28 
Genotype-phenotype correlations 
In the homozygous state, the previously described TMPRSS3 mutations lead to either 
postlingual progressive (DFNB8) or prelingual severe to profound (DFNB10) 
hearing impairment (Table 3), with one exception, namely the p.Pro404Leu 
mutation.25, 26 Although, Wattenhofer et al.26 described an age of detection of hearing 
impairment of 6-7 years in a family with a homozygous p.Pro404Leu mutation, the 
average threshold levels (0.5-4 kHz) at that age were already 85-99 dB. Since 
members of this family were reported to have had a normal hearing until the age of 
detection, it can be concluded that hearing impairment in this family exhibited a 
very fast progression in childhood. Wattenhofer et al.26 did not report on the speech 
development of the affected family members and hearing impairment might still be 
classified as prelingual, which is defined as a delayed speech development. Hearing 
impairment in the second family with a homozygous p.Pro404Leu mutation was 
reported to be congenital and severe to profound, and therefore probably 
prelingual.25 Based on these data, we conclude that p.Pro404Leu is likely to be a 
severe mutation. Modifying genetic factors may explain the difference in onset 
between the two families with this mutation. 
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Both in the present and previously described families, the severe classified 
mutations p.Ala306Thr, p.Val199Met and p.Thr70fs result in postlingual hearing 
impairment when present in combination with mutations only described to be 
associated with postlingual hearing impairment (p.Arg216Cys, p.Ala138Glu and 
p.Ala426Thr mutations). Prelingual hearing impairment is seen by us and others 
when the p.Ala306Thr, p.Val199Met and p.Thr70fs mutations are present in the 
compound heterozygous state with other mutations associated with prelingual 
hearing impairment (p.Thr70fs and p.Ala306Thr). However, there is an 
inconsistency in this classification of the c.323-6G9A (p.Cys107fs) mutation. 
According to our classification, the c.323-6G9A mutation is (relatively) severe, which 
means that a homozygous c.323-6G9A mutation could be expected to result in 
prelingual (DFNB10) hearing impairment. However, a homozygous c.323-6G9A 
mutation has been described to be the underlying cause of postlingual (DFNB8) 
hearing impairment by Veske et al.4 When the Berkeley Drosophila Genome Project 
Splice Site Prediction Program (http://www.fruitfly.org/seq_tools/splice.html) was 
used, the c.323-6G9A mutation is predicted to introduce a novel splice acceptor site 
with a score of 0.96 (on a scale from 0 to 1) in addition to the normal splice acceptor 
site (score of 0.94). Therefore, both normal and abnormal splicing may occur in 
relative amounts of transcripts that vary between individuals, which may then lead 
to phenotypic variation. Testing this hypothesis on patient samples is not possible 
since the level of transcription of TMPRSS3 is low in blood cells. 
We can conclude that our study, combined with previous data, suggests the 
classification of TMPRSS3 mutations into relatively mild and severe, which are 
associated with DFNB8 (postlingual hearing impairment) or DFNB10 (prelingual 
hearing impairment), respectively. Furthermore, our study suggests that compound 
heterozygosity for a mild and severe mutation leads to postlingual hearing 
impairment. The intrafamilial variation indicates that these data do not allow 
prediction of the phenotypic outcome for individual cases. Analysis of more families 
is necessary to confirm our conclusions and to address whether a subclassification 
of the mutations associated with DFNB8 is possible. Also, other (epi)genetic and 
nongenetic factors are likely to influence the severity of the phenotype. This has to 
be considered especially for families with a single affected individual. For the 
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families of this type in our study, these factors did not seem to have a major effect 
since the phenotype corresponded to the previously reported phenotype of patients 
with the same mutations. 
Conclusion 
In patients with progressive hearing impairment and a possible autosomal recessive 
mode of inheritance, TMPRSS3 mutations should be considered. The ski-slope 
audiogram configuration is suggestive for mutations in this gene. The age of onset 
and the rate of progression are variable. Our analyses suggest that mutations in 
TMPRSS3 can probably be classified as mild and severe mutations according to their 
phenotypic effect. Furthermore, our results demonstrate that cochlear implantation 
is a good treatment option for patients with TMPRSS3 mutations since satisfactory 
speech reception was observed. 
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Supplemental table and figure 
 
Fragment Oligonucleotides 
Size 
(bp) 
Annealing 
Temperature (°C) 
Primers for PCR and sequence analysis Enzyme 
TMPRSS3 exon 2 Forward: accgtatgaccaagatgcac 
Reverse: tctagggaagtgcaggtgtc 
361 57  
TMPRSS3 exon 3 Forward: tagagaatgtgccccttgg 
Reverse: tgctgggatgagagggg 
365 57  
TMPRSS3 exon 4 Forward: ggggacagttgttagtgttgc 
Reverse: aagggtcagggttggcttc 
249 57  
TMPRSS3 exon 5 Forward: tgcctatggtctcagggttc 
Reverse: cgttaaagcacccaatagtgc 
286 57  
TMPRSS3 exon 6 Forward: acatcccccatgtacaatcc 
Reverse: catcacaaatccagcaggtg 
293 57  
TMPRSS3 exon 7 Forward: gaccaatgttgagttcagcc 
Reverse: agccacattgtccaggatac 
674 57  
TMPRSS3 exon 8 Forward: cccttgcagcacttgtcttag 
Reverse: cttctcaccacccaaagcag 
395 57  
TMPRSS3 exon 9 Forward: ttcaggatacctgaggtcaatg 
Reverse: caactgatgccaacaccaac 
400 57  
TMPRSS3 exon 10 Forward: tcctcagaggcagaagcatag 
Reverse: cccatgggaacatcacaatg 
279 57  
TMPRSS3 exon 11 Forward: tgttgcgacacaccagagag 
Reverse: cttgagcaaatttcttctccac 
400 57  
TMPRSS3 exon 12 Forward: gtccacagaaagcaatctcg 
Reverse: agcacaagcgtctgacacc 
380 57  
TMPRSS3 exon 13 Forward: gtcatcatgttggacggatg 
Reverse: agacccctggagagaaaacc 
663 57  
Primers for PCR of products used for restriction analysis  
TMPRSS3 exon 4 Forward: gaaacaggctgctgacagg 
Reverse: cagctcgatacacttaaaggatg 
204 57 MaeIII 
TMPRSS3 exon 5 Forward: tgcctatggtctcagggttc 
Reverse: cgttaaagcacccaatagtgc 
286 57 MwoI 
TMPRSS3 exon 7 Forward: gtgtgacctcatcctcatgg 
Reverse: agagtgatgggacatcatgg 
483 57 PmlI 
TMPRSS3 exon 9 Forward: tttccctgttggacaatcc 
Reverse: gcaaatcctcttgaaacaaag 
186 57 MslI 
TMPRSS3 exon 12 Forward: gtccacagaaagcaatctcg 
Reverse: agcacaagcgtctgacacc 
380 57 HhaI 
 
Table S1. Primer sequences, PCR conditions and restriction enzymes. Reference sequence: 
NM_024022 transmembrane protease, serine 3 isoform 1. 
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Figure S1. Result of linkage analysis for families D and E. Multipoint linkage analysis was 
performed with GeneHunter version 2.1r5 in the EasyLinkage software package. An 
autosomal recessive mode of inheritance with 95% penetrance and a disease allele 
frequency of 0.001 were used for linkage analysis. 
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Abstract 
In the present study, we investigated the audiometric characteristics of a large 
Dutch DFNX4 family with a p.Glu72X mutation in the SMPX gene. Sixty family 
members participated in this study and examination consisted of medical history, 
otoscopy, pure-tone and speech audiometry. Linkage and mutation analysis revealed 
a pathogenic mutation in the SMPX gene. 
All 25 mutation carriers exhibited hearing impairment, except one woman aged 25 
years. The men (n = 10) showed more severe hearing impairment than the women 
(n = 14) and already at a younger age. The age of onset according to history was 2-
10 years (mean: 3,3 years) in men and 3-48 years (mean: 26,4 years) in women. In 
the men, severe threshold deterioration mainly occurred during the first two 
decades of life, especially at the higher frequencies. The women showed milder 
threshold deterioration, and more pronounced across-subjects and individual inter-
aural variation, especially at 2-8 kHz. Longitudinal linear regression analysis 
demonstrated significant progression of at least two frequencies in five individuals 
(3 men and 2 women). 
The speech recognition scores of the mutation carriers with hearing impairment 
were decreased at relatively young ages compared to a reference group of patients 
with only presbycusis, especially in men. However, all these patients tended to have 
better speech recognition scores than the presbycusis patients at matching PTA1,2,4 
kHz levels. 
This study demonstrates the phenotypic heterogeneity in this large family with an X-
linked pattern of inherited sensorineural hearing impairment. The men showed 
more severe hearing impairment at a younger age with more pronounced 
progression during the first two decades of life, while women demonstrated less 
severe hearing impairment with more gradual progression, and a wider variation in 
age of onset, degree of hearing impairment and inter-aural asymmetry in thresholds. 
  
AUDIOMETRIC AND VESTIBULAR FINDINGS IN DFNX4 
111 
 
4.1 
Introduction 
Hearing impairment is the most common birth defect and the most prevalent 
sensorineural disorder in developed countries.1 More than 50% of prelingual 
hearing impairment has a genetic cause and more than 70% of hereditary hearing 
impairment is nonsyndromic.2 Only 1-5% of cases with nonsyndromic hereditary 
hearing impairment exhibit X-linked inheritance. In syndromic hearing impairment 
X-linked inheritance is seen far more often.3 
X-linked nonsyndromic hearing impairment (DFNX) can be either pre- or postlingual 
with an age of onset varying from congenital (DFNX2 and DFNX3) to childhood 
(DFNX4). The type of hearing impairment is sensorineural, except for DFNX2 that 
shows mixed hearing impairment. In most patients hearing impairment is 
progressive and severely affects all frequencies.4 
DFNX4, formerly designated DFN6, was first documented as bilateral high-frequency 
hearing impairment in a Spanish family with ten affected male and seven affected 
female individuals. Hearing impairment in male mutation carriers started between 
the age of five and seven years, and progressed before adulthood to severe or 
profound hearing impairment across all frequencies. Female carriers demonstrated 
more variable expression and incomplete penetrance of about 70%. Seven out of ten 
female carriers exhibited moderate to severe hearing impairment at the high 
frequencies with an onset in the fourth decade of life. Vestibular function was 
reported to be normal.5 
The DFNX4 locus mapped to Xp22 in a 15 cM interval.6 Recently, a nonsense 
mutation (p.Gly59X) in the SPMX gene was identified in the previously described 
patients from the Spanish DFNX4 family.6, 7 Another nonsense mutation (p.Glu37X) 
in SMPX was detected in a large German DFNX4 family.7 Here, we report the clinical 
features of a large Dutch DFNX4 family with a c.214G>T (p.Gly72X) mutation in the 
SMPX gene. A more detailed description of the genetic analysis of this family is 
reported elsewhere.8 
 
 
CHAPTER 4.1   
112 
 
Patients and methods 
Patients 
A Dutch family with sensorineural hearing impairment was studied and the pedigree 
was constructed. (Figure 1) The pattern of inheritance suggested X-linked 
inheritance. After informed consent, the family was clinically as well as genetically 
studied. The study was approved by the local medical ethics committee of the 
Radboud University Nijmegen Medical Centre, the Netherlands. 
All participating family members were invited to the outpatient clinic. Examination 
of the participants included medical history guided by an questionnaire, otoscopy 
and pure-tone audiometry. A number of mutation carriers with hearing impairment 
also underwent speech audiometry and vestibulo-ocular examination. Attention was 
paid to the presence of syndromic features. Furthermore, concomitant disease, the 
use of medication and any other possible cause of acquired hearing impairment 
were identified. Previous medical records and audiograms were retrieved for 
individual longitudinal analyses. 
 
 
 
Figure 1. Pedigree of a Dutch family with X-linked inheritance of sensorineural hearing 
impairment. Square: male; circle: female; open symbol: no hearing impairment; solid 
symbol: hearing impairment; half-shaded symbol: unilateral hearing impairment; grey 
symbol: phenocopy; slash: deceased individuals. Person IV:15 is indicated as a non-
manifesting mutation carrier. 
 
Pure-tone audiometry 
Audiometric examination comprised conventional pure-tone audiometry in a sound-
treated room according to common clinical standards. Air-conduction (AC) and 
bone-conduction (BC) thresholds were measured in dB hearing level (HL) at 0.25, 
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0.5, 1, 2, 4 and 8 kHz. BC thresholds were measured to exclude conductive hearing 
impairment. The individual 95th percentile (P95) threshold values of presbycusis in 
relation to the patient’s sex and age were derived for each frequency using the ISO 
7029 method.9 Individuals were considered affected if at least one ear showed 
threshold values beyond the P95 threshold for presbycusis at three or more 
frequencies. 
Regression analysis of audiometric data 
Analysis of audiometric data was performed on AC threshold values of mutation 
carriers with hearing impairment. The key analysis parameter for threshold-on-age 
regression analysis was the binaural mean AC threshold. The men showed non-
linear progression of hearing impairment and an arbitrary equation of a saturation 
hyperbola was used for non-linear regression analysis using Prism software 
(GraphPad, San Diego): 
Y = Bmax * ((age – onset)/(Kd + (age – onset))) 
where Y = threshold (dB HL), Bmax = saturation level (dB HL), onset = onset age (y); 
Kd is age (y) at half saturation for onset = 0, for onset > 0 half saturation occurs at 
(age – onset) = Kd and thus age = onset + Kd. We also used the option offered by 
Prism to find out which of the two different regression models, in this case the 
present non-linear model and a simple linear regression model, fits best to a given 
set of data. In addition, evaluation of the distribution of residuals from regression 
around the fitted line or curve was performed to evaluate whether these showed a 
pseudo-random distribution rather than any systematic deviations. Progression of 
hearing impairment was more gradual in women and linear regression analysis was 
applied. The regression coefficient (slope) is called annual threshold deterioration 
(ATD), expressed in dB per year. Age Related Typical Audiograms (ARTAs) were 
derived for men and women by using the results of regression analyses as described 
by Huygen et al.10 
Individual longitudinal linear regression analysis of binaural mean AC threshold 
values on age was only performed in hearing impaired mutation carriers with five or 
more consecutive measurements and an overall follow-up period of at least five 
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years. Again, the ATD was calculated. Progression was significant if the 95% 
confidence interval did not include zero. 
Across-subjects variation was appreciated from the threshold-on-age regression 
plots. Individual inter-aural (I-A) variation was evaluated by using the I-A standard 
deviation (SD) in AC threshold for each separate frequency. Plots of the SD against 
age were inspected to assess whether this type of variation depended on age. 
Furthermore, we studied the parameter behavior of the individual I-A difference in 
more detail by using the absolute value of the I-A differences |Difference|. This 
difference was plotted against the individual binaural mean threshold for each 
frequency separately. The across-subjects mean and the SD of the individual I-A 
difference were calculated (GraphPad, San Diego). 
Speech audiometry and data analysis 
Speech audiometry was performed in a sound-treated room according to common 
clinical standards using standard Dutch monosyllabic consonant-vocal-consonant 
word lists. The maximum phoneme recognition score (mean value averaged for both 
ears) was obtained from monaural performance versus intensity curves. These 
maximum phoneme recognition scores were analyzed in relation to age and to pure-
tone average (mean value for both ears) at 1, 2, and 4 kHz (PTA1,2,4 kHz). Cross-
sectional analysis was performed using linear regression analysis and nonlinear 
regression analysis (a sigmoidal dose-response curve with a variable slope) to fit the 
phoneme recognition scores of the mutation carriers with hearing impairment. The 
average tangent slope around the inflection point of the curve was called 
deterioration rate in the score-against-age plot and deterioration gradient in the 
score-against-PTA1,2,4 kHz plot. A previously described group of subjects with only 
presbycusis (P50) was used as a reference group.11 
Vestibulo-ocular examination and data analysis 
Five of the 24 mutation carriers with hearing impairment underwent vestibular and 
ocular motor tests including evaluation of the vestibulo-ocular reflex, using 
electronystagmography with computer analysis, and saccadic, smooth pursuit and 
optokinetic nystagmus responses. Vestibular stimulation comprised rotatory and 
caloric tests. Test conditions and normal values have been described previously.12 
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Results 
Family members 
A five-generation pedigree was established for the present family, suggesting an X-
linked pattern of inheritance. (Figure 1) We identified 28 affected family members 
by history and 24 of them were alive. Sixty family members participated in this 
study. Next generation sequencing (NGS) of X-chromosomal genes was performed 
and a nonsense mutation, c.214G>T, in exon 4 of the SPMX gene was detected. This 
mutation introduces a premature stop codon and is predicted to result in a 
truncated protein after residue 71 (p.Glu72X). Furthermore, the mutation 
segregated with the hearing impairment in the family. Genetic analysis identified 25 
mutation carriers.8 
Individuals III:3 and IV:18 showed hearing impairment but did not carry the 
mutation and were excluded from further regression analyses. Hearing impairment 
of individual III:3 was less severe than usual in this family and started much later, at 
an age of 60 years. Therefore, his hearing impairment may have been caused by 
reported noise exposure. The audiogram of individual IV:18 showed a mild 
threshold elevation at 0.25-1 kHz. The cause of her hearing impairment could not be 
identified. Individual IV:15 showed no signs of hearing impairment, but did carry the 
mutation. She was 25 years of age at the last visit and may still develop hearing 
impairment. 
The mutation carriers with hearing impairment showed no evidence of other causes 
of hearing impairment. Otoscopy was normal in all family members. Most affected 
family members reported bilateral progressive hearing impairment. First symptoms 
of hearing impairment were reported by men (n = 10) at ages ranging from 2 to 10 
years with a mean onset age of 3.3 years. Women (n = 14) reported first symptoms 
of hearing impairment at ages ranging from 3 to 48 years with a mean onset age of 
26.4 years. 
Vestibular function 
Two of the 24 mutation carriers with hearing impairment (individuals IV:3 and IV:8) 
reported varying vestibular symptoms, including dizziness and instability, especially 
in the dark. The other family members mentioned no vestibular symptoms. 
Vestibular examination in individuals IV:3, IV:8 and V:2 revealed no abnormalities at 
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the ages of 35, 38 and 7 years, respectively. Caloric tests in individual III:7 at age 62 
years revealed asymmetric responses with right unilateral weakness, combined with 
normal rotatory test results. Individual III:11 demonstrated bilateral caloric 
weakness and hyporeflexia on rotatory testing at age 55 years. 
Pure-tone audiograms 
The most recent pure-tone audiograms of mutation carriers with hearing 
impairment are shown in Figure 2. The men had more severe hearing impairment 
than the women, already at a younger age. Individual audiograms of the left and 
right ear in men were fairly symmetric, except for individual IV:12. All frequencies 
were affected and a downsloping audiogram configuration was seen in the majority 
of cases. Fairly flat audiogram configurations were also seen (individuals IV:17 and 
V:2). (Figure 2a) 
The women showed more pronounced across-subjects variation in audiogram 
configuration, as well as in degree of hearing impairment. Furthermore, a number of 
women demonstrated a large individual I-A variation in AC threshold (individuals 
III:7, IV:1, IV:3, IV:10 and IV:14). The women IV:6, IV:10 and IV:14 exhibited close to 
normal thresholds for the right or left ear at the age of 32 years, at the ages of 25-28 
and 5-26 years, respectively. (Figure 2b and 3) A downsloping threshold 
configuration was again most frequently observed. Fairy flat audiogram 
configurations were also seen (individuals III:14 and III:16). (Figure 2b) 
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Figure 2. Last-visit audiograms of clinically affected male (a) and female (b) participants 
carrying the mutation, ordered by age (from top left to bottom right) at last visit. Shown are 
the AC threshold levels for the right (open circles and solid line) and for the left (crosses and 
dashed line) ears. Above each audiogram: pedigree number, age in years (y). 
 
Progression of hearing impairment 
All threshold data of mutation carriers with hearing impairment, combining 
individual longitudinal and single-snapshot measurements, are plotted against age 
in Figure 3. Again, more severe hearing impairment at younger age is visible in men 
when compared to women. The degree of across-subjects variation in threshold was 
clearly smaller in male family members than in female family members. (Figure 3). 
In men, major progression in threshold occurred during the first two decades of life, 
especially at higher frequencies. Longitudinal threshold data for some men clearly 
suggested non-linear progression during this age interval. (Figure 3) Threshold 
progression in women was milder than in men. (Figure 3) 
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Figure 3. Mixed single-snapshot and longitudinal individual measurements (binaural mean 
AC threshold) of men (open symbols) and women (solid black and shaded symbols) are 
shown in relation to age for each frequency separately. Open circles are the most recent 
measurements of men and dots are the most recent measurements of women. For the 
longitudinal measurements (n > 1), the different symbols are shown in the symbol key. The 
regression lines fitted to the individual longitudinal measurements are also included. A bold 
line indicates significant progression. 
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Longitudinal regression analysis of audiometric data of individuals III:11, III:13, 
VI:12, IV:14 and IV:17 revealed significant progression for all individuals at at least 
two frequencies. (Figure 3) The significant ATD values for the men (individuals 
III:11, IV:12 and IV:17) ranged from 0.8 to 3.7 dB/year. The high frequencies 
showed the highest ATD values. For the women (individuals III:13 and IV:14) the 
significant ATD values ranged from 0.5 to 1.2 dB/year. This progression rate is 
approximately the same as the progression rate of all women combined. (Figure 4b) 
Figure 4 shows the results of cross-sectional non-linear regression analysis for men 
and linear regression analysis for women of binaural mean AC threshold on age. 
(Figure 4) Presumably, the large across-subjects variation in threshold in women 
prohibited the demonstration of significant progression in the linear regression 
analysis. It is noteworthy that in women the threshold range around the regression 
line was wider than the threshold range covered by age-related progression, 
especially at the higher frequencies. (Figure 4b) The ATD values of women ranged 
from 0.5 to 1.3 dB/year, with the highest values at the high frequencies. 
In order to obtain stable non-linear regression results for men, we decided to prefix 
the Bmax values. Reasonable fits, as judged by eye, were obtained using values 
increasing from 80 dB at 0.25 kHz to 130 dB at 8 kHz, as is shown in the separate 
panels of Figure 4a. The initial curvature of the saturation hyperbolas appeared to fit 
in a satisfactory way when the supposed onset age was fixed at 2 years and the Kd 
values were fitted at each frequency (to values of 1-3 years) by the non-linear 
regression program. The results of the test (data not shown) comparing between the 
fit produced by the present non-linear regression model and a simple linear 
regression model favoured the non-linear model at each frequency. The nonlinear 
model generally produced the smaller residual sum of squares at a higher R-squared 
value (0.59-0.79, as opposed to 0.35-0.58) at 0.25-4 kHz. Systematic inspection of 
the residuals from regression showed that residuals from linear regression were 
distributed along the line in a systematic, clearly non-random way, whereas the 
residuals from non-linear regression were neatly distributed in pseudo-random 
fashion along the regression curve (data not shown). 
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b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Single-snapshot (open circles) threshold values (binaural mean AC threshold 
measured at last visit) of men (a) and women (b) are shown in relation to age for each 
frequency separately. The line in left panels represents the results of the cross-sectional 
non-linear regression analysis in men (a) and the line in the right panels represent the 
results of the cross-sectional linear regression analysis in women (b) for each frequency. 
The number in the lower right corner of each panel of the men is the prefixed Bmax level (dB 
HL). 
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In Figure 5 the ARTA for men and women are depicted. Even before the age of five 
years, the threshold values of all frequencies were severely elevated in the men. The 
ARTA for men illustrate the substantial progression in the first two decades of life, 
mainly at higher frequencies. (Figure 5a) The more gradual progression in women is 
also illustrated by their ARTA. Predicted threshold values showed slightly more 
progression at the high frequencies than at the low frequencies. (Figure 5b) 
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Figure 5. Age-related typical audiograms (ARTAs) derived from cross-sectional regression 
analysis of mean AC threshold values for men (a: non-linear fit) and women (b: linear fit). 
Numbers in italic indicate age in years. 
 
Variation in hearing impairment 
In Figure 6, the individual I-A SDs of the AC thresholds are plotted against age at 0.5 
and 4 kHz for men and women separately. The plots for 0.25 kHz and 1 kHz (not 
shown) were fairly similar to those for 0.5 kHz, and the plots for 2 kHz and 8 kHz 
(not shown) were fairly similar to the plots for 4 kHz. None of the plots of I-A SD 
against age, i.e. those shown in Figure 6, but also those not included in this Figure, 
showed any substantial tendency for significant regression on age in across-subjects 
evaluation. However, in individual longitudinal analyses, men IV:12 and IV:17 
showed significant progression in I-A SD at  0.25-1 kHz and 0.5-1 kHz, respectively, 
whereas woman IV:14 showed significant progression in I-A SD at all frequencies 
except for 0.25 kHz. (shown in part Figure 6) In men IV:12 and IV:17, this 
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progression in SD was associated with significant, substantial threshold progression. 
(Figure 3) Serial audiograms of woman IV:14 (data not shown) demonstrated that 
from age 5-26 years the left ear never showed any substantial hearing impairment, 
whereas the right ear developed a gradual increasing impairment. (Figure 2b only 
shows age 26 years) In the two men IV:12 and IV:17 asymmetry in hearing 
threshold indeed increased somewhat with increasing age, but to a lesser extent. 
(Figure 2a only shows last visit) 
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Figure 6. Individual inter-aural (I-A) standard deviation (SD) of AC threshold values plotted 
against age at the frequencies 0.5 kHz and 4 kHz for men (left panels) and women (right 
panels) separately. Open circles are the most recent measurements of men and dots are the 
most recent measurements of women. For the longitudinal measurements (n > 1), different 
symbols are used for each family member, as shown in the symbol key. 
 
Instead of the individual I-A SD, the I-A difference might have been plotted in Figure 
6. It should be realized, however, that this would have influenced only the scale of 
the graphs, because |I-A Difference| = SD(2)1/2 ≈ 1.414 SD. Nevertheless, we thought 
it could be worthwhile to study into more detail parameter behavior of the I-A 
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difference (more simply, |Difference|) and see whether statistical tests comparing 
between men and women could be performed. Figure 7 shows plots of the individual 
|Difference| against the individual binaural mean threshold for similar panels as in 
Figure 6 (men vs. women at 0.5 kHz and 4 kHz). The data have now been limited to 
the last-visit threshold measurements pertaining to the cross-sectional analyses. 
Linear regression analysis demonstrated that at all frequencies (data not shown for 
0.25, 1, 2, and 8 kHz) there was no significant regression of individual |Difference| 
on individual binaural mean threshold in men or women. Regression of the 
parameters mean |Difference| and SD(|Difference|) on binaural mean threshold 
could therefore be ignored.  
The bottom panel of Figure 7 shows that in men neither the across-subjects mean 
|Difference| or the across-subjects SD(|Difference|) depended significantly, as 
demonstrated by linear regression analysis on audio frequency. The across-subjects 
mean |Difference| and SD(|Difference|) varied, independently from audio frequency, 
at the various frequencies between 4 and 13 dB (mean 8.3 dB) and between 3 and 
10 dB (mean 5.3 dB), respectively. In contrast, the women showed a systematic, 
significant (S) increase in both the across-subjects mean |Difference| (from 8 to 32 
dB) and the across-subjects SD(|Difference|) (from 4 to 27 dB) with increasing audio 
frequency. Using Student’s t tests, including Welch’s correction if Bartlett’s test 
disclosed unequal variances, the across-subjects mean |Difference| appeared to be 
significantly greater for women than for men at 2-8 kHz. Bartlett’s test 
demonstrated that the across-subjects SD(|Difference|) was significantly greater for 
women than for men at 1-8 kHz. Thus it appeared that not only the degree of 
individual asymmetry in threshold between the ears was, on average (i.e. the across-
subjects mean |Difference|), substantially greater in women, but also the across-
subjects variation in this asymmetry (i.e. SD(|Difference|) was substantially greater 
in women as compared to men. 
 
 
 
AUDIOMETRIC AND VESTIBULAR FINDINGS IN DFNX4 
125 
 
4.1 
Figure 7. Upper 4 panels: individual inter-aural (I-A) difference in threshold (|Difference|) at 
0.5 kHz (top row of panels) and 4 kHz (second row of panels) plotted against the individual 
binaural mean threshold at the last visit for men (circles in left panels) and women (dots in 
right panels) separately. The values for the across-subject mean |Difference| and 
SD(|Difference|) are indicated. Bottom panel: across-subjects mean |Difference| and 
SD(|Difference|), including the values indicated for 0.5 and 4 kHz in the upper 4 panels, 
plotted against audio frequency for men (open circles and triangles) and women (dots and 
filled triangles). The lines in each panel are the straight lines resulting from linear 
regression analysis (data not shown). S: significant regression (bold line); ns: non-
significant regression. 
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Speech recognition 
Figure 8 shows the available single-snapshot measurements of phoneme scores of 
all the hearing impaired male mutation carriers (except for IV:2, IV:6 and IV:8) and 
female mutation carriers (except for III:4, IV:17, IV:21 and V:3). Speech 
discrimination was severely decreased at a relatively young age in men. The women 
had far better speech discrimination scores than men, but their scores were 
substantially lower than those of presbycusis patients at matching ages. The 50% 
speech recognition score in men was attained at the age of 33 years, whereas in the 
presbycusis group this score was attained at 89 years. In women all scores were well 
above 50% but the 90% score was attained at 50 years of age, compared to 74 years 
in presbycusis patients. The men remarkably never showed scores as high as 90%. 
(Figure 8, left panel) 
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Figure 8. Single-snapshot measurements of maximum phoneme recognition scores 
(binaural means) plotted against age (left) and binaural mean pure-tone average at 1, 2, and 
4 kHz (right). The continuous lines are the regression curves fitted to these measurements 
(left panel: lower linear regression line for men, upper linear regression line for women; 
right panel: common non-linear regression curve for men and women). The dashed curves 
represent the presbycusis data, previously established for patients with presbycusis. The 
dotted lines mark the 50% and 90% score levels (bold scores along Y axis) attained at the 
ages (left panel) or PTA levels (right panel) indicated by bold scores along X axis. Square: 
male family member; circle: female family member; triangle: presbycusis patient. 
 
Quite remarkably, male and female mutation carriers had relatively good speech 
recognition scores in relation to their PTA1,2,4 kHz levels. The relatively high speech 
recognition scores in women seemed to align with the lower scores in men, as 
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judged from their positions relative to the common regression curve. The 90% score 
was attained at a PTA1,2,4 kHz level of 61 dB in the DFNX4 patients (men and women 
combined), whereas this score was already attained at a PTA1,2,4 kHz level of 48 dB in 
presbycusis patients. The 50% scores were attained at PTA1,2,4 kHz levels of 102 dB 
and 86 dB in DFNX4 and in presbycusis patients, respectively. (Figure 8, right panel) 
The deterioration rate in the score-against-age plot was about 0.6% per year for 
men and 0.4% per year for the women. The deterioration gradient in the score-
against-PTA1,2,4 kHz plot was approximately 1.0% per dB for men and women 
combined. The presbycusis group showed a higher deterioration rate (3.3%/y) and 
approximately the same deterioration gradient (1.1%/dB). 
Discussion 
This report presents the clinical features of a Dutch DFNX4 family with a p.Glu72X 
mutation in SMPX. All 25 mutation carriers demonstrated hearing impairment, 
except for one female. 
DFNX4 families 
Del Castillo et al. described the first DFNX4 family and were the first to emphasize 
the difference in hearing impairment between men and women. Affected men 
showed mainly high-frequency hearing impairment with an onset age of 5-7 years. 
Hearing impairment became severe to profound and involved all frequencies before 
adulthood. Affected women demonstrated an age of onset in the fourth decade of 
life, with the earliest manifestation of hearing impairment at 30 years of age. 
Hearing impairment manifested as bilateral moderate high-frequency hearing 
impairment. Comparison of the 3 audiograms published by Del Castillo et al. with 
the present audiograms at matching ages, indicated by the ARTA in Figure 5(a, b), 
shows a fair similarity in both men and women.5, 6 
The German DFNX4 family is described by Huebner et al.7 The men exhibited 
postlingual hearing impairment with an age of onset of 3-7 years. Moderate hearing 
impairment of especially the high frequencies progressed with age to affect all 
frequencies. The onset of hearing impairment in female carriers was in the second to 
third decades of their lives and hearing impairment progressed to severe hearing 
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loss in 10-15 years. Asymmetrical hearing impairment was seen in a number of 
women. Imaging of temporal bones showed no abnormalities.7 
Del Castillo et al.6 reported incomplete penetrance of 70% in the female carriers. 
The penetrance in the present family was 93% (14/15). Nevertheless, the unaffected 
female mutation carrier (individual IV:15) in the present family was only 25 years of 
age at last visit and might still develop hearing impairment because only five of the 
fourteen affected females reported hearing impairment before the age of 25 years. 
The audiometric characteristics of the present DFNX4 family is largely similar to 
those of the previously described DFNX4 families, however, subtle differences in age 
of onset and rate of progression of hearing impairment exist. The presence of 
different mutations in the present family and the previously described Spanish 
DFNX4 family might explain the possible differences in phenotype, but also other 
genetic and environmental factors might be involved.5-7 
Variation of hearing impairment 
In the present family the men showed more severe hearing impairment than the 
women at a younger age. Figure 3 clearly shows that, not depending on any specific 
regression model, there were substantial differences in the degree of and the 
progression in hearing impairment between the men and the women. In addition, 
the women showed more pronounced across-subjects and I-A variation than the 
men at 1-8 kHz and 2-8 kHz, respectively. X-inactivation in women might explain 
such findings. 
X-inactivation in mammals is a process by which one of the two copies of the X-
chromosome present in females is inactivated. Such inactivation occurs randomly, 
but once a given X-chromosome is inactivated it will remain inactive in that cell and 
its descendants.13 This may well explain the occurrence of unilateral hearing 
impairment in some women of the present family. In affected men, all cells have the 
mutated allele active and consequently the men show more severe and more similar 
clinical features of the disease. 
Good speech recognition performance 
The DFNX4 patients of the present family tended to have better speech recognition 
scores than the presbycusis patients at matching PTA1,2,4 kHz levels. DFNA211, 14, 
DFNA515, DFNA1116, 17 and DFNA1518, 19 have been documented as autosomal 
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dominant hearing impairment disorders with relatively good speech recognition 
scores. Schraders et al.8 hypothesised that SMPX is important in the development 
and/or maintenance of sensory hair cells. Huebner et al.7 suggested that the long-
term maintenance of mechanically stressed inner-ear cells critically depends on 
SPMX function because response to physical force is a characteristic feature of the 
protein. Further studies are required to establish the pathogenic pathway of DFNX4. 
It is particularly appealing that for the combination of speech recognition scores of 
both men and women one, common dose-response curve could be fitted to describe 
the relationship between the performance of speech recognition and the degree of 
hearing impairment. (right panel of Figure 8) For the lower scores pertaining to the 
men, the underlying source of variation in the degree of impairment clearly was age-
dependent progression. For the higher scores pertaining to the women, X-
inactivation apparently constituted a substantial source of variation in the degree of 
impairment, next to age-dependent progression. From Figure 4b the observation 
could be made that in the women the threshold range covered by scatter around the 
regression line was wider than the threshold range covered by age-related 
progression, especially at the higher frequencies. This may indicate X-inactivation as 
a major source of variation in pure-tone threshold, and it is not unlikely that this 
also entails most of the variation in speech recognition performance in the women. 
Normal vestibular function 
Only two of the five tested family members demonstrated reduced vestibular 
responses, namely individuals III:7 and III:11 at age 62 and 55 years, respectively. 
Del Castillo et al.5 and Huebner et al.7 reported normal vestibular function, but it is 
unclear whether formal testing was performed. At present there is no evidence that 
DFNX4 is a progressive cochleovestibular disorder, such as DFNA9 and DFNA1120, as 
well as DFNA1519, 21, 22. In situ hybridization in the mouse demonstrated SMPX 
expression in the inner ear, presumably in the sensory epithelium of the vestibular 
organs.8 More DFNX4 patients of various ages should be tested to assess whether 
vestibular dysfunction is a feature of DFNX4. 
Remarkable progression 
It is noteworthy that the men affected by the present mutation in SMPX showed 
remarkable progression in hearing impairment in the first two decades of their lives 
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and thereby attained severe to profound levels of hearing impairment at a relatively 
young age. (Figure 5a) Among the DFNA loci, only DFNA20/26 caused by ACTG1 
mutations and DFNA36 caused by TMC1 mutation exhibited fairly similar degrees of 
progression and impairment (in both men and women).23, 24 
Conclusion 
The present study describes the phenotype of a DFNX4 family with a c.214G>T 
(p.Glu72X) mutation in SMPX. The phenotypic heterogeneity was remarkable and 
was probably related to X-inactivation in female mutation carriers. Men showed 
severe hearing impairment at a young age with more pronounced progression 
during the first two decades of life, whereas women demonstrated mild to severe 
hearing impairment with more gradual progression and a higher, variable age of 
onset. The across-subjects and I-A variations in thresholds were more pronounced 
in women than in men, especially at 2-8 kHz. Speech recognition in men and women 
was remarkably well preserved. 
The phenotype of the present family is largely similar to the phenotype of the 
previously described DFNX4 families. However, subtle differences in onset age and 
rate of progression of hearing impairment seem to exist and could be caused by the 
different mutations in SMPX. However, a thorough genotype-phenotype analysis of 
DFNX4 requires more data on DFNX4 families harbouring different SMPX mutations. 
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Abstract 
In a Dutch family with an X-linked postlingual progressive hearing impairment, a 
critical linkage interval was determined to span a region of 12.9 Mb flanked by the 
markers DXS7108 and DXS7110. This interval overlaps with the previously 
described DFNX4 locus and contains 75 annotated genes. Subsequent next-
generation sequencing (NGS) detected one variant within the linkage interval, a 
nonsense mutation in SMPX. SMPX encodes the small muscle protein, X-linked 
(SMPX).  
Further screening was performed on 26 index patients from small families for which 
X-linked inheritance of nonsyndromic hearing impairment (NSHI) was not excluded. 
We detected a frameshift mutation in SMPX in one of the patients. Segregation 
analysis of both mutations in the families in whom they were found revealed that 
the mutations cosegregated with hearing impairment.  
Although we show that SMPX is expressed in many different organs, including the 
human inner ear, no obvious symptoms other than hearing impairment were 
observed in the patients. SMPX had previously been demonstrated to be specifically 
expressed in striated muscle and, therefore, seemed an unlikely candidate gene for 
hearing impairment. We hypothesize that SMPX functions in inner ear development 
and/or maintenance in the IGF-1 pathway, the integrin pathway through Rac1, or 
both. 
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Hereditary nonsyndromic hearing impairment (NSHI) is genetically extremely 
heterogeneous, as is illustrated by the currently associated genes, numbering more 
than 50, and the large number of loci for which the gene harboring the causative 
mutation(s) is still elusive (Hereditary Hearing Loss Homepage).1 This hampers DNA 
diagnostics and adequate mutation-based genetic counseling. Inheritance patterns 
of monogenic NSHI can be (in order of decreasing prevalence) autosomal recessive, 
autosomal dominant, X-linked or mitochondrial, and digenic inheritance has also 
been indicated.2, 3 Age-related hearing loss is a complex disorder, although variants 
in genes involved in monogenic forms of NSHI have been found to be among the 
genetic factors.4 Genes in which variation is associated with deafness have a wide 
variety of functions and have contributed significantly to our understanding of the 
molecular biology of hearing.1, 5 Because of this functional diversity, bioinformatics 
tools such as ENDEAVOUR or Prospectr have been of limited value in the positional 
cloning of deafness genes.6 Currently, next-generation sequencing (NGS) is an 
excellent strategy for identification of disease-causing variants.7, 8  
In the present study, we identified mutations in the gene encoding the small muscle 
protein, X-linked (SMPX [MIM 300226]) as a cause of nonsyndromic hearing 
impairment by using a two-step strategy of linkage analysis and NGS. 
This study was approved by the medical ethics committee of the Radboud University 
Nijmegen Medical Centre and adhered to the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from all subjects or, in case of children, from 
their parents. 
Affected subjects of a large, five-generation family (W08-1701) of Dutch origin 
presented with postlingual progressive hearing impairment. (Figure 1) An X-linked 
pattern of inheritance was suggested by the absence of male-to-male transmission 
and the fact that hearing impairment developed earlier and was more severe in men 
than in women.  
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Figure 1. Pedigrees and genetic analysis. Only those family members of the large pedigree 
who were relevant for the study are depicted. The haplotype associated with the hearing 
impairment is indicated by the gray bar. In individual V:1, allele 3 of marker DXS1043 might 
be derived from the affected haplotype. The segregation of the c.214G>T is presented above 
the haplotypes. Family W08-1701 is of Dutch origin and family W05-049 is of Netherlands 
Antilles’ origin. The following symbols are used: black squares: affected males; black circles: 
affected females; half-shaded circles: females with unilateral hearing impairment; half-
shaded square: male with unilateral hearing impairment; gray shaded square: male with 
hearing impairment less severe than the other affected males. 
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The majority of affected family members reported bilateral, (slowly) progressive 
hearing impairment. Pure-tone audiometry and otoscopy were performed for all 
depicted individuals by standard procedures. There was no evidence for nongenetic 
causes of hearing impairment except for individual III:3, who reported noise 
exposure. Also, hearing impairment in this individual was less severe and had a late 
onset at about age 60. The reported age at which hearing impairment was first 
noticed was 2–10 years old for men (with a mean of 3.3 years old) and 3–48 years 
old for women (with a mean of 28.2 years old). In males, the largest increase of 
threshold values occurred in the first two decades and progression to profound 
hearing impairment was already seen in the second decade in one of the affected 
males. (Figure 2) Hearing impairment in women exhibited a large inter-individual 
variation with regard to the severity and also with regard to interaural variation. 
(Figure 2) Brainstem Evoked Response Audiometry (BERA) for the proband, 
individual V:2, revealed normal waveform responses at an intensity level of 45 dB. 
There was no indication of conductive hearing impairment. Furthermore, pure-tone 
audiometry never revealed a persistent air-bone gap or pseudoconductive hearing 
impairment in any of the affected family members. (Figure S1). A more detailed 
description of the audiometric evaluation of the family will be reported elsewhere. 
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A. Family W08-1701 women 
 
Figure 2. Audiometric characteristics of the families. (A) Representative audiograms (air-
conduction) of affected men (showing the means of thresholds of the left and right ears) and 
women (thresholds of left (x) and right ear (o) shown separately) of family W08-1701 
demonstrate progressive hearing loss in males within the first two decades and the 
variability of the hearing loss in females. (B) Representative audiograms of individual IV:1 
from family W05-049 at different ages (means of thresholds of the left and right ears are 
shown). Pure-tone audiometry was performed in a sound-treated room according to current 
clinical standards. y is an abbreviation for years. 
 
Genetic studies in this family were initiated by linkage analysis for the known X-
chromosomal NSHI loci, recently renamed DFNX1-5 (Hereditary Hearing Loss 
Homepage).9-13 Twenty-eight individuals from this family were genotyped for 
microsatellite markers from the loci DFNX1 (MIM 304500), DFNX3 (MIM 300030), 
and DFNX4 (MIM 300066). (Table S1) After exclusion of DFNX1 and DFNX3, 
evidence of linkage with the disease was found for marker DXS8022, derived from 
the DFNX4 locus that was previously described as DFN6 for a family with similar 
audiometric features.12 Subsequent genotyping of nine additional markers defined a 
critical region of 12.9 Mb flanked by the markers DXS7108 and DXS7110. (Figure 1) 
In this region, chrX:10,192,226-23,111,851, 75 genes have been annotated (UCSC 
Genome Browser, hg19). We calculated two-point LOD scores with SuperLink 
version 1.6 in the Easy-Linkage software package by using the genotypes of males 
only.14, 15 Penetrance was assumed to be 99%, and a disease allele frequency of 
0.001 was employed for the calculations. Individual III:3 was included in the 
calculations as an individual with an unknown phenotype. A significant maximum 
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LOD score of 4.87 (θ = 0.000) was obtained for marker DXS8022; LOD scores are 
presented in Table S2. 
Three candidate genes, PRPS2 (MIM 311860), SHROOM2 (MIM 300103) and GPM6B 
(MIM 300051), were selected for a mutation search by conventional Sanger 
sequencing because of homology with a known deafness gene or expression in the 
inner ear, but no pathogenic variant was identified. Subsequently, we performed 
targeted enrichment by using the Agilent SureSelect Human X Chromosome Kit and 
single-read 76 nt NGS on the Illumina GAII sequencer for individual III:4.16 In total, 
28,363,277 reads were obtained, of which 23,339,533 could be mapped, and 95.1% 
of the targeted bases were covered at least 10-fold. After analysis of the sequence 
data with in-house-developed tools and filtering of the predicted sequence variants 
against dbSNP, the 1000 Genome Project, and 200 Danish control individuals,17 two 
variants remained, chrX:117960412T>G and chrX:21755734C>A (base-pair 
positions according to the NCBI37/hg19 assembly of the human genome), and only 
the latter was located within the critical region. This variant, c.214G>T, is located in 
exon 4 of SMPX (NM_014332.1) and introduces a premature stop codon predicted to 
result in a truncated protein after residue 71 (p.Glu72X). The presence of this 
candidate disease-causing variant was confirmed by Sanger sequencing in the 
affected males III:1, III:4 and V:2 and a female carrier, IV:10. (Figure 3) 
 
A 
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Figure 3. Mutation and expression analysis of SMPX. (A and B) Partial SMPX sequence 
chromatograms are shown for normal controls (upper panels), affected males (middle 
panels), and female carriers (bottom panels). The predicted amino acid changes and the 
surrounding amino acids are indicated above the sequence. Mutated nucleotides are marked 
by an arrowhead. As a reference, we employed sequence NM_014332.1 by using the first 
ATG translation initiation codon for numbering of the nucleotide change. (C and D) Relative 
SMPX mRNA expression as determined by quantitative PCR in fetal (C) and adult (D) human 
tissues. Because this was performed for adult and fetal tissues in two separate experiments, 
fetal inner ear was included in both for comparison.  
 
The c.214G>T transversion removes a restriction site for Hpy188I. Therefore, we 
performed restriction digestion of exon 4 amplicons according to the manufacturer’s 
protocol (New England Biolabs) to test all family members and ethnically matched 
controls for the presence of the mutation. DNA fragments were analyzed on 2% 
agarose gels. (Figure S2). None of the 172 control individuals carried the mutation, 
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whereas in the family, the mutation was found to fully cosegregate with hearing 
impairment in males, as expected from the linkage analysis, and individual III:3 
indeed did not carry the mutation. (Figure 1) Therefore, his hearing impairment 
might well be caused by the reported noise exposure. For females the mutation also 
coincides with the mutation-carrying haplotype, indicating that individual IV:18 is 
either a phenocopy or a genocopy. She has a mild increase in thresholds in the pure-
tone audiogram for the frequencies 0.25–1 kHz. On the other hand, individual IV:15 
shows no signs of hearing impairment but does carry the mutation as does her twin 
sister (monozygotic). The latter exhibits unilateral hearing impairment. Both sisters 
were 25 years old at the last visit in the clinic and because the age at onset for 
females from this family is variable (3–48 years), individual IV:15 could well develop 
hearing impairment in the coming years. 
To investigate the involvement of SMPX in other families with hearing impairment, 
we performed Sanger sequencing of the three protein-coding exons (2–4) and the 
flanking intronic sequences in 26 index patients of small families for which X-linked 
inheritance of NSHI was not excluded. Sequence analysis was performed as 
described,18 and primer sequences and conditions for PCR amplification are 
provided in Table S3. In one of the index patients (individual VI:1 of family W05-
049, Figure 1), a deletion of a single base pair, c.130delG, was found in exon 3. This 
variant leads to a frameshift and a premature stop codon, p.Glu44ArgfsX37. The 
patient’s mother (III:2 in Figure 1) was found to carry the deletion as well. No DNA 
samples from other family members were available for testing. The mutation was 
not detected in 129 Dutch control individuals who are not ethnicity matched 
because the family is of Netherlands Antilles’ origin. Audiograms of the index patient 
are presented in Figure 2B. Hearing impairment was first suspected around the age 
of 4 and has progressed since then. (Figure 2) No air-bone gap was detected (Figure 
S2) and BERA revealed normal waveform responses at 65 dB. The proband’s mother 
(III:2 in Figure 1) did not report any signs of hearing impairment at her last visit at 
clinic at the age of 38. Also, no hearing impairment was reported for obligate female 
carriers in the previous generations. 
In an independent study of two additional families with X-linked hearing 
impairment, two different truncating mutations have been detected in SMPX. The 
CHAPTER 4.2   
144 
 
family in which the DFNX4 locus was determined was one of these.12 The results are 
presented in the accompanying paper by Huebner et al. in this issue.19 
Because of its high and preferential expression in striated muscle, SMPX was not an 
obvious candidate for NSHI.20, 21 As a first step to identify the function of SMPX in the 
inner ear, we analyzed SMPX transcription by RT-PCR on RNA isolated from human 
inner ear of an embryo at 8 weeks gestation. Indeed, SMPX mRNA could easily be 
amplified and sequence verified (data not shown). Further evidence for SMPX 
expression in the inner ear is provided by RNA in situ hybridization in the mouse 
embryos at 14.5 days of gestation (Eurexpress database assay 006968 and 
Genepaint assay DC27). In addition to being present in developing muscle, Smpx 
transcripts are present in a region that presumably corresponds to the developing 
sensory epithelium of the vestibular organs. Immunohistochemistry with an Smpx 
antibody on sections of an adult mouse’s organ of Corti revealed staining in different 
cell types, including Böttcher cells, root cells, pillar cells and interdental cells of the 
limbus spiralis. Low levels of staining were detected in hair cells.19 Transcription of 
SMPX was further addressed by quantitative PCR (qPCR) on cDNA derived from 
various fetal and adult human tissues as described previously.18 (Table S3) In Figure 
3 the relative amounts of SMPX transcripts in the tissues as compared to that in the 
spleen (set to 1) are depicted. The housekeeping gene GUSB (MIM 611499) was used 
as a reference gene. SMPX mRNA levels were highest in both fetal and adult skeletal 
muscle and heart, which is in agreement with previous studies.20, 22 No transcripts 
were detected in fetal brain or in adult kidney and spleen tissues. Importantly, 
relatively high SMPX transcript levels are detected in fetal inner ears, which 
supports the involvement of SMPX in X-linked NSHI. Retinas derived from adult 
humans also exhibits a relatively high level of SMPX transcripts. Despite the 
indications for significant expression levels of SMPX in heart skeletal muscles and 
retinas, no clear symptoms indicating an adverse effect of a truncating SMPX 
mutation in these tissues are reported by affected individuals from family W08-
1701. Although one of the males reported mild muscle injury upon heavy exercise, a 
causative link to a defective SMPX remains to be determined by detailed testing of 
muscle function. No information is available for family W05-049. For heart and 
skeletal muscle, functional redundancy was already indicated by studies of a 
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conditional knock-out allele of Smpx in mice.22 This conditional knockout allele 
appeared to be null because immunoblot analysis revealed no detectable Smpx 
protein. However, the knockout mice displayed no overt developmental or 
structural deficits in their skeletal muscles or hearts, suggesting a genetic or 
functional redundancy. 
Smpx, previously also called Csl, is proline-rich and was described to contain a 
nuclear localization signal, two casein kinase II phosphorylation sites, and a proline, 
glutamic acid, serine and threonine-rich (PEST) sequence that suggests Smpx 
undergoes rapid degradation.20 From late-fetal to neonatal stages of murine cardiac- 
and skeletal-muscle development onward, Smpx becomes associated with the 
costameres.22 Costameres are subsarcolemmal protein assemblies at the sarcomere-
sarcolemma attachment sites.23 Three actin-associated costameric protein 
complexes have been distinguished: the focal adhesion-type complexes, the 
spectrin-based complex and the dystrophin-based complex, all of which tether 
molecules that control, among other processes, mechanoreception and cytoskeletal 
remodeling.24 Smpx is likely to be part of the actin-associated complex because it 
was found, upon expression in mouse myoblasts, to influence actin turnover and to 
induce lamellipodia in a Rac1-dependent manner.22, 25 Furthermore, Smpx 
colocalizes with focal adhesion proteins at the membrane of these lamellipodia, 
suggesting a link to integrin signaling.25 Interestingly, both Rac1 and integrins 
(α8β1) are essential for normal cochlear development and function.26, 27 Conditional 
inactivation of Rac1 (MIM 602048) leads to a shortened cochlea and abnormal 
cellular organization of the sensory epithelium. Furthermore, planar cell polarity of 
cochlear hair cells and the morphogenesis of the hair bundle are affected.26 Integrin 
(type α8β1) was found to be essential for normal hair-bundle development and/or 
maintenance, and colocalizes with its ligand fibronectin and the integrin-regulated 
focal adhesion kinase in the apical region of developing vestibular hair cells.27 On the 
basis of all these data, we hypothesize that Smpx functions in the development 
and/or maintenance of the sensory hair cells. 
A second link between SMPX and cochlea development and function is provided by 
insulin-like growth factor-1 (IGF-1) (MIM 147440). Smpx modifies cell shape and 
promotes myocyte fusion when expressed in C2C12 mouse myogenic cells in an IGF-
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1 dependent manner.22 Igf-1-deficient mice have multiple cochlear abnormalities, 
including an abnormal differentiation, a reduced survival of spiral ganglia neurons 
and an abnormal tectorial membrane.28, 29 MEF2 (MIM 600663) has been indicated 
to be a target gene of IGF-1 in the mouse cochlea in both the sensory cells and the 
spiral ganglia neurons. Interestingly, the IGF-1-mediated increase of MEF2 activity 
in myoblasts is augmented by Smpx.22 Furthermore, the consensus sequence for 
MEF2 binding is present twice in the highly conserved 50 upstream region of 
SMPX.20 IGF1 mutations in humans cause syndromic, severe to profound and 
congenital or very early-onset sensorineural hearing impairment (MIM 608747).30-32 
This inner ear phenotype is more severe than that in the families included in this 
study. 
In-depth studies are required for the discernment of which cell types and pathways 
in the cochlea are affected by mutations in SMPX. Fast deterioration of hearing in the 
first decades of life, as seen in family W08-1701, has been reported previously for 
patients with mutations in a number of genes, including ACTG1 (MIM 102560) 
encoding the cytoskeletal γ-1-actin.33, 34 Interestingly, this is thought to be the major 
cytoskeletal actin in costameres.35 
In conclusion, this study identifies SMPX as a gene in which variation is associated 
with X-linked deafness and illustrates that NGS is instrumental in the efficient 
identification of disease-causing variants in unexpected genes. Our results will 
contribute to adequate mutation-based genetic counseling of patients and their 
relatives. Because females can be affected, although generally not in childhood, 
SMPX should also be considered in small pedigrees with dominantly inherited 
hearing impairment and those pedigrees in which X-linked inheritance cannot be 
excluded. Further analysis of the function of SMPX will provide insights into inner 
ear development and function, and SMPX might well be a player in the regulation of 
stereocilia development and/or maintenance. 
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Supplemental tables and figures 
 
Locus Marker Marshfield position 
DFNX1 DXS8048 66.58 cM 
DXS1230 67.12 cM 
DXS6797 67.12 cM 
DFNX3 DXS8039 30.84 cM 
DXS1036 33.54 cM 
DFNX4 DXS8022 22.18 cM 
 
Table S1. Microsatellite Markers from the Loci DFNX1, DFNX3, and DFNX4. 
 
Marker Marshfield 
position 
Recombination fractions (θ)  
0.00 0.01 0.05 0.10 0.20 0.30 0.40 Zmax θmax 
DXS8051 17.29 cM -13.69 -1.00 0.60  1.11  1.27  0.99  0.51  1.28  0.171  
DXS7108 18.37 cM 0.30 1.29 1.77  1.81  1.56  1.13  0.58  1.81  0.084  
DXS1043 18.37 cM  -0.15 -0.16  -0.14  -0.12  -0.09  -0.05  -0.02  0.00  0.500  
DXS8022 22.18 cM 4.87 4.79  4.47  4.05  3.16  2.17  1.08  4.87  0.000  
DXS9902 22.18 cM 1.66 1.64  1.52  1.37  1.06  0.72  0.36  1.67  0.000  
DXS8036 22.72 cM 1.90 1.86  1.72  1.55  1.18  0.80  0.39  1.90  0.000  
DXS999 23.26 cM  2.16 2.12  2.00  1.84  1.46  1.03  0.53  2.16  0.000  
DXS7593 25.97 cM 4.31 4.24  3.95  3.58  2.79  1.92  0.94  4.31  0.000  
DXS7110 29.22 cM 0.22 1.22  1.72  1.78  1.52  1.03  0.45  1.79  0.087  
DXS989 29.76 cM -1.01 0.02  0.62  0.82  0.84  0.66  0.37  0.87  0.154  
 
Table S2. Two-point LOD scores between polymorphic markers on Xp22 and the disease 
gene. 
 
Fragment Oligonucleotides Size (bp) Annealing 
Temperature (°C) Primers for PCR and sequence analysis 
SMPX exon 2 Forward: aatatatggccagtgaaaggg  
Reverse: agctaggagtgaacaatcgc 
245 58 
SMPX exon 3 Forward: cttcacaacgattactgtctcag  
Reverse: ctcccttgtcctggatagc 
273 58 
SMPX exon 4 Forward: ctcaacaacacaagggacag  
Reverse: cttaaattgaaggcacctgg 
418 58 
 Primers for qPCR   
SMPX exon 3-4 Forward: aatgtactcctgaagtggagg  
Reverse: tggatttccgatagattgactg 
113 NA 
GUSB Forward: agagtggtgctgaggattgg  
Reverse: ccctcatgctctagcgtgtc 
80 NA 
 
Table S3. Sequences of primers for amplification of exons, intron-exon boundaries and 
transcripts of SMPX. NA: not applicable. As reference sequence NM_014332.1 and 
NT_167197.1 were employed. 
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Figure S1. Representative audiograms of air- and bone-conduction thresholds of the right 
ear, with open circles indicating the air-conduction thresholds and filled circles the bone-
conduction thresholds. No air-bone gaps were detected. 
 
 
Figure S2. Segregation analysis of the c.214G>T SMPX mutation in family W08-1701. 
Pedigree numbers as in Figure 1 of the main manuscript. The c.214G>T transversion 
removes a restriction site for Hpy188I (New England Biolabs). Therefore restriction 
digestion of exon 4 amplicons was performed according to the manufacturer’s protocol. The 
exon amplicon is 418 base pairs (bp) in length. Hpy188I digestion of a wildtype product 
results in fragments of 192 bp, 163 bp and 63 bp, while digestion of a mutant fragment 
results in fragments of 255 bp and 163 bp. A wildtype restriction pattern is seen for 
individuals III:3, III:5, III:6, III:8, III:9, III:10, III:12, III:15, III:19, III:21, IV:5, IV:7, IV:9, IV:11, 
IV:13, IV:16, IV:18, IV:20 and V:1. A mutant restriction pattern is seen for individuals III:1, 
III:4, III:11, IV:12, IV:17, IV:19, IV:21, IV:22, V:2 and V:3. A heterozygous digestion pattern 
(wildtype + mutant bands) is seen for individuals III:7, III:13, III:14, III:16, III:18, III:20, IV:1, 
IV:2, IV:3, IV:4, IV:6, IV:10, IV:14 and IV:15. M: 100 bp DNA ladder. 
 
  
CHAPTER 4.2   
150 
 
Web Resources 
The URLs for data presented herein are as follows: 
1000 Genome Project, http://www.1000genomes.org/ 
Eurexpress, A Transcriptome Atlas Database for Mouse Embryo, 
http://www.eurexpress.org/ee/ 
Genepaint, a Digital Atlas of Gene Expression Patterns in the Mouse, 
http://www.genepaint.org  
Hereditary Hearing Loss Homepage, http://hereditaryhearingloss.org/ 
Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim 
UCSC Human Genome Browser, Build hg19, March 2006, http://www.genome.ucsc.edu 
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Abstract 
In this paper, we describe the audiometric and vestibular characteristics of a Dutch 
family with Muckle-Wells syndrome (MWS). Examination of all family members 
consisted of pure-tone audiometry, otoscopy and genetic analysis. In addition, a 
selected group underwent speech audiometry, vestibulo-ocular examination, 
acoustic reflex testing, tests assessing loudness scaling, gap detection and difference 
limen for frequency, and speech perception in noise. Linear regression analyses 
were performed on the audiometric data. 
Six clinically affected family members participated in this study and all were carriers 
of a p.Tyr859His mutation in the NLPR3 gene. Most affected family members 
reported bilateral, slowly progressive hearing impairment since childhood. Hearing 
impairment started at the high frequencies and the low- and mid-frequency 
threshold values deteriorated with advancing age. Annual threshold deterioration 
(ATD) ranged from 1.3 to 1.9 dB/year with the highest values at the lower 
frequencies. Longitudinal linear regression analysis demonstrated significant 
progression for a number of frequencies in five individuals. Speech recognition 
scores were clearly affected. However, these individuals tended to have higher 
speech recognition scores than presbycusis patients at similar PTA1,2,4 kHz levels. The 
loudness growth curves were steeper than those found in individuals with normal 
hearing, except for one family member (individual IV:6). Suprathreshold 
measurements, such as difference limen for frequency (DLf), gap detection and 
particularly speech perception in noise were within the normal range or at least 
close to data obtained in two groups of patients with a so-called conductive type of 
hearing loss, situated in the cochlea. 
Hearing impairment in MWS is variable and shows resemblance to previously 
described intra-cochlear conductive hearing impairment. This could be helpful in 
elucidating the pathogenesis of hearing impairment in MWS. Other associated 
symptoms of MWS were mild and nonspecific in the present family. Therefore, even 
without any obvious syndromic features, MWS can be the cause of sensorineural 
hearing impairment, especially when combined with (mild) skin rash and 
musculoskeletal symptoms. An early diagnosis of MWS is essential to prevent 
irreversible damage from amyloidosis. The effect of IL-1β inhibitors on hearing 
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impairment is more controversial, but an early start of treatment seems to be 
essential. Therefore, our results are of importance in patient care and counseling. 
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Introduction 
Muckle-Wells syndrome (MWS; OMIM 191900) is an autoinflammatory disease that 
belongs to the inherited cryopyrin-associated periodic fever syndromes (CAPS), 
including familial cold autoinflammatory syndrome (FCAS; OMIM 120100) and the 
chronic infantile neurologic cutaneaous and articular (CINCA; OMIM 607115) 
syndrome.1 MWS is a rare autosomal dominant disorder characterized by 
intermittent episodes of fever, urticarial rash, and muscle and joint pains 
(arthralgias or arthritis). Furthermore, the syndrome is associated with late-onset 
progressive sensorineural hearing impairment. In general, episodic fever occurs at 
irregular intervals every few weeks, lasting 12-36 h before resolving spontaneously. 
The onset age of clinical symptoms is variable and precipitating factors cannot 
always be identified.2, 3 In addition, prolonged inflammation can lead to deposition of 
proteins, especially in the kidney, and secondary amyloidosis (type AA) can occur in 
a subset of patients, leading to nephropathy.4-7 Blood and cerebral fluid analysis can 
also demonstrate signs of inflammation during acute outbursts of the disease.2, 5 
MWS arises from mutations in a single gene: NLRP3 (OMIM 606416) located on 
chromosome 1q44,8 which encodes a protein called cryopyrin. This protein consists 
of several distinct motifs, including a pyrin domain, a central nucleotide binding site 
domain (NBS; NACHT subfamily) and a C-terminal domain containing seven leucin-
rich repeats (LRR).1, 9, 10 Cryopyrin is part of the multiprotein inflammasome 
complex, the formation of which is triggered by “cellular danger” including infection 
and metabolic dysregulation.11, 12 The NLRP3 inflammasome activates caspase 1, 
leading to the processing and secretion of the pro-inflammatory cytokines 
interleukin-1β (IL-1β) and IL-18.13 Mutations in NLRP3 are thought to cause 
abnormal formation of the inflammasome complex and inappropriate production of 
active IL-1β, possibly due to defective self-inhibition by the mutant cryopyrin 
protein.14 Recent studies in mice carrying mutations in the Nlrp3 gene indicated that 
IL-1β indeed has a pivotal role in the CAPS disease spectrum and that it leads to 
Th17 cell-dominant immunopathology in autoinflammation.15-17 
The importance of IL-1β in the pathogenesis of MWS is further confirmed by the 
effectiveness of treatment with IL-1 inhibitors.18 IL-1 inhibitors can control the 
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symptoms of systemic inflammation in patients with MWS.14, 19 However, the effect 
on hearing impairment remains uncertain.20 
Two other autoinflammatory disorders, FCAS and CINCA, are also caused by 
mutations in the NLRP3 gene.1, 9, 21, 22 The overlapping symptoms among these 
different syndromes indicate a continuum in severity of the disease,9, 23-25 with 
CINCA syndrome being the most severe, FCAS the mildest and MWS the 
intermediate phenotype.26 The majority of these mutations were missense 
mutations occurring in exon 3, which encodes the central NBS domain, indicating 
that this domain is crucial to cryopyrin function. However, there is no apparent 
correlation between disease severity and the particular domain in which the 
mutation occurs, the specific residue mutated or the conservation of amino acids.27, 
28 
In the present paper, audiometric characteristics of a Dutch MWS family with a 
novel mutation in NLRP3 are presented. As it is yet unknown how MWS affects the 
cochlea, a broad set of audiological tests was administered to assess cochlear 
function in some detail. 
Patients and methods 
Patients 
A Dutch family (n = 15) with autosomal dominant sensorineural hearing impairment 
(W07-1001) was studied. The pedigree is shown in Figure 1. After informed consent 
had been obtained from the participating family members, a family investigation 
was performed. The study was approved by the local medical ethics committee of 
the Radboud University Nijmegen Medical Centre, the Netherlands. 
The examination of all family members included medical history guided by a 
questionnaire, otoscopy, pure-tone audiometry and collection of blood samples for 
genetic analysis. Clinically affected family members also underwent speech 
audiometry. Vestibulo-ocular examination was performed in three clinically affected 
family members. Furthermore, concomitant disease, the use of medication and any 
other possible cause of acquired hearing impairment were ruled out. Previous 
medical records and audiograms were traced for individual longitudinal analysis. 
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Figure 1. Pedigree of a Dutch family with Muckle-Wells syndrome. Square: male; circle: 
female; open symbol: clinically unaffected; solid symbol: clinically affected; slash: deceased 
individuals. 
 
Linkage analysis 
Genomic DNA of all participating individuals was extracted from peripheral blood 
lymphocytes according to standard protocols. Microsatellite markers flanking the 
NLRP3 gene, more specifically D1S2836, D1S2215 and D1S2682, were genotyped 
under standard PCR conditions and were analyzed on an ABI Prism 3730 Genetic 
Analyzer with the GeneMapper program according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA, USA). Multipoint linkage analysis was 
performed with GeneHunter version 2.1r5 in the EasyLinkage software package. An 
autosomal dominant mode of inheritance with a penetrance of 100% and a disease 
allele frequency of 0.001 were used for LOD score calculations. 
Mutation analysis 
Amplification of all coding exons and flanking intronic sequences by polymerase 
chain reaction (PCR) was performed on 40 ng of genomic DNA with Taq DNA 
polymerase (Roche, Indianapolis, USA). Primer sequences and PCR conditions are 
available in Table S1. PCR fragments were purified by using NucleoFast 96 PCR 
plates (Clontech, Mountain View, CA, USA) according to the manufacturer’s protocol. 
Sequence analysis was performed with the ABI PRISM Big Dye Terminator Cycle 
Sequencing V3.1 Ready Reaction kit and the ABI PRISM 3730 DNA analyzer (Applied 
IV:6
II:11
I:1
II:3 II:4
III:2III:1
IV:1 IV:2
III:3 III:4 III:5 III:6
IV:4
I:2
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Biosystems, Foster City, CA, USA). NM_004895.4 and NT_167186.1 were used as 
reference sequences. 
The segregation of the c.2575T>C transition in the family and presence of this 
transition in healthy controls was tested via an amplification refractory mutation 
system (ARMS) approach; primer sequences are provided in Table S1. 
Pure-tone audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a sound-
treated room according to common clinical standards. Air-conduction (AC) and 
bone-conduction (BC) thresholds were measured in dB hearing level (dB HL) at 
0.25, 0.5, 1, 2, 4 and 8 kHz. Bone-conduction was measured to rule out conductive 
hearing impairment. The individual 95th percentile (P95) threshold values of 
presbycusis in relation to the patient’s sex and age were derived for each frequency 
using the ISO 7029 method.29 Individuals were considered affected if the best 
hearing ear showed thresholds at three or more frequencies beyond the P95 for 
presbycusis. 
Analyses of audiometric data were performed on the data pertaining to the mutation 
carriers of the present family. Binaural mean AC threshold values were calculated 
for each frequency. All binaural mean AC threshold values of the six affected family 
members were included to establish a trend line for the progression of hearing 
impairment with advancing age for each frequency separately. The regression 
coefficient (slope) was called annual threshold deterioration (ATD), expressed in dB 
per year. Age Related Typical Audiograms (ARTA) were drawn by using age-related 
threshold data derived from the results of the linear regression curves as described 
by Huygen et al.30 
Individual longitudinal linear regression analysis of binaural mean AC threshold 
values on age was only performed in clinically affected persons with three or more 
consecutive measurements and an overall follow-up period of at least three years. 
Again, the ATD was calculated. Progression was significant if the 95% confidence 
interval did not include zero. 
Speech audiometry and data analysis 
Speech audiometry was performed under above-mentioned conditions using 
standard Dutch consonant-vocal-consonant word lists. The maximum phoneme 
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recognition score was obtained from monaural performance versus intensity curves 
and represents the mean phoneme recognition score of both ears. These maximum 
phoneme recognition scores were analyzed in relation to age and to pure-tone 
average (mean value for both ears) at 1, 2 and 4 kHz (PTA1,2,4 kHz). Cross-sectional 
analysis was performed using linear regression analysis. The age of onset and the 
onset level were defined at a recognition score of 90% in cross-sectional 
performance versus age and performance versus impairment plots, respectively. 
The average slopes were called deterioration rate and deterioration gradient, 
respectively. A previously described group of subjects with only presbycusis (P50) 
was used as a reference group. The phoneme recognition scores in this group had 
been fitted using nonlinear regression analysis based on a dose-response curve with 
variable slope.31 
Additional audiological testing 
Five affected family members (III:3, III:5, IV:4, IV:5 and IV:6) were also evaluated 
with additional audiological tests, namely loudness scaling, gap detection, difference 
limen for frequency and speech perception in noise, as described previously by 
Plantinga et al.32 Loudness scaling was performed at 0.5 and 2 kHz using a 7-point 
categorical scale.33 The slope of the loudness versus stimulus level graph was used 
as outcome measure. Gap detection was measured with gated white noise at 0.5 kHz 
and 2 kHz. Difference limen for frequency (DLf) discrimination was measured with 
frequency-modulated pure-tones ranging from 0.1% to 5% presented at the 
individual listener’s most comfortable level at 0.5 kHz and 2 kHz. Speech perception 
in noise was measured with short, everyday Dutch sentences.34 Speech reception 
threshold (SRT) was measured with an adaptive procedure. All tests were 
performed with headphones on the ear with the best hearing, at the patient’s most 
comfortable listening level (except for loudness scaling). The mean outcomes were 
compared to those of normal-hearing individuals as well as to those of patients with 
autosomal dominant nonsyndromic sensorineural hearing impairment originating 
from tectorial membrane abnormalities, namely patients with DFNA8/12 (TECTA 
gene)32 and DFNA13 (COL11A2 gene).35 
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Vestibulo-ocular examination and data analysis 
Three affected family members (III:3, III:5 and IV:3) also underwent vestibulo-
ocular examination. Vestibular and ocular motor tests included evaluation of the 
vestibulo-ocular reflex, using electronystagmography with computer analysis, and 
evaluation of saccadic, smooth pursuit and optokinetic nystagmus responses. 
Vestibular stimulation comprised rotatory and caloric tests. Details and normal 
values have been described previously.36 
Results 
Symptoms of the family members 
A four-generation pedigree was established for the present family, in which hearing 
impairment segregated in a pattern that suggested autosomal dominant inheritance. 
(Figure 1) Twelve family members were affected, four of whom only by history. 
Fifteen family members participated in this study. No informed consent could be 
obtained from individuals II:10 and II:11. 
Clinically affected family members (individuals III:3, III:5, IV:3, IV:4, IV:5 and IV:6) 
showed no evidence of other causes of hearing impairment. Most affected family 
members reported bilateral, slowly progressive hearing impairment. First 
symptoms of hearing impairment were reported at ages ranging from 4 to 25 years 
(mean subjective age of onset: 12 years). 
The proband of the present family (individual III:5) reported intermittent episodes 
of headache, urticarial rash and joint pains in addition to her hearing impairment. 
Furthermore, blood and cerebral fluid analysis showed signs of an inflammatory 
process. These symptoms in combination with progressive sensorineural hearing 
impairment raised the suspicion of MWS. More detailed history revealed also 
frequent conjunctivitis and hypoesthesia with tingling sensations of her hands. 
Furthermore, Anakinra (interleukin-1 receptor antagonist) treatment resolved her 
symptoms and normalized her erythrocyte sedimentation rate. When specifically 
asked for, the other affected family members (individuals III:3, IV:3, IV:4, IV:5 and 
IV:6) also reported other symptoms besides hearing impairment, such as urticarial 
rash, joint pains, conjunctivitis and tingling sensations of their hands. However, 
these symptoms were less severe than the symptoms reported by the proband. 
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No relation with cold temperature could be demonstrated and FCAS was considered 
to be unlikely. Furthermore, gradual hearing impairment is not a common symptom 
of FCAS. Severe inflammatory damage, for example joint deformities, is frequently 
seen in CINCA, but not in de present family. Moreover, the present family members 
had no mental or cognitive disorders and no gradual loss of eyesight, which is often 
present in CINCA. Therefore, CINCA was also considered not likely. 
Genetic analysis 
Genotyping of microsatellite markers was performed to test the segregation of the 
NLRP3 locus with the disease phenotype in the present family. As shown in Figure 
S1 the markers segregated perfectly with the disease, yielding a maximum 
multipoint LOD score of 2.99. Mutation analysis in individual III:3 revealed a 
heterozygous nucleotide substitution, c.2575T>C in exon 6 of the NLRP3 gene 
leading to the substitution of histidine for tyrosine at position 859 of the protein 
(p.Tyr859His). The mutation co-segregated with the disease in the family and was 
not found in 114 ethnically matched controls. 
Vestibular function 
Variable vestibular symptoms were reported by three of the six affected family 
members (individuals III:3, IV:3 and III:5), including dizziness and instability, 
especially in the dark. Evaluation of vestibular function in individual III:3 at age 47 
years revealed no abnormalities. Individual IV:3 at age 21 years showed remarkable 
hyporeflexia of velocity-step responses with time constants of 7 and 10 s for both 
nystagmus directions. Furthermore, caloric testing revealed bilateral caloric 
weakness. Vestibular function tests in individual III:5 at age 44 years showed 
hyporeflexia in the rotatory tests, however, caloric testing revealed no 
abnormalities. More patients with MWS should be tested to assess whether 
vestibular dysfunction indeed can be part of MWS. 
Pure-tone audiograms 
A representative selection of available pure-tone audiograms of the six clinically 
affected family members is shown in Figure 2. Pure-tone audiometry never revealed 
a persisting air-bone gap in any of the family members. The individual audiograms 
of the left and right ear were fairly symmetric and within limits of 20 dB. Therefore, 
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mean values of binaural AC thresholds were calculated. However, some inter-
individual variation in audiometric configuration, as well as in the degree of hearing 
impairment was observed. Most frequently, high-frequency hearing impairment was 
observed with a down-sloping audiogram configuration. Flat audiogram 
configurations were, however, also seen. In general, hearing impairment started at 
the high frequencies, the low- and mid-frequency threshold values deteriorated with 
advancing age. A downsloping audiometric configuration applies to the audiograms 
at young ages (IV:3, IV:4, IV:5 and IV:6). More flat audiometric configurations are 
mainly seen at more advanced ages (III:3 and III:5). High-frequency hearing 
impairment appeared to start even before the age of 5 years in individual IV:4. 
(Figure 2) Before the age of 30 years, the low-frequency threshold values started to 
deteriorate, resulting in low-frequency threshold values in the range of 60-80 dB at 
40 years of age. High-frequency threshold values deteriorated to about 100 dB at the 
age of 40 years. (Figure 2) 
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Figure 2. Selection of binaural mean air-conduction threshold values of six clinically affected 
family members at different ages, ordered by age (from top left to bottom right) at last visit. 
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Figure 3. Mixed single-snapshot and longitudinal individual measurements with connection 
lines (different symbols for each family member) of affected family members are shown for 
each frequency separately. The black dashed line (overall ‘trend line’) represents the cross-
sectional linear regression analysis. The number in the lower right of each panel represents 
the average threshold deterioration value in dB/year derived from cross-sectional linear 
regression analysis. The regression lines fitted to the individual longitudinal measurements 
are also included (straight lines). A bold line indicates significant progression. 
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Progression of hearing impairment 
All threshold data of the examined individuals are plotted against age in Figure 3. 
The individual regression lines are included and an overall trend line could be 
established for each frequency. ATD values ranged from 1.3 to 1.8 dB/year with the 
highest values at the lower frequencies. The trend lines seemed to provide a reliable 
estimation of the overall progression in this family. (Figure 3) 
All affected family members showed a slowly progressive type of sensorineural 
hearing impairment. However, longitudinal regression analysis of audiometric data 
revealed significant progression for all individuals at some frequencies, except for 
individual IV:6. (Figure 3) This is probably because the available audiograms 
covered only a relatively short age range. The longitudinal regression analyses and 
the trend lines showed fairly similar progression rates with advancing age. (Figure 
3) 
The ARTA derived from the (dashed) overall trend line in Figure 3 is shown in 
Figure 4. Even before the age of ten years, the threshold values at the high 
frequencies were substantially affected. However, the threshold values at the low 
frequencies showed more progression than the threshold values of the high 
frequencies with advancing age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Age-related typical audiograms (ARTA) derived from the (dashed) overall trend 
lines in Figure 3. The italic numbers indicate age in years. 
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Speech recognition 
Figure 5 shows the available single-snapshot measurements of the phoneme scores 
of the affected family members examined. Speech recognition was remarkably well 
preserved in the present family. The age of onset (X90) was 35 years with a 
deterioration rate of 0.5% per year, whereas the onset age in presbycusis patients 
was 74 years with a deterioration rate of 3.3% per year. The speech recognition 
scores related to the level of hearing impairment in the present family members 
appeared to be better than those of the presbycusis patients at similar levels of 
hearing impairment. (Figure 5, right panel) The 90% recognition scores were found 
at a PTA1,2,4 kHz level of 71 dB and 48 dB in the affected family members and the 
presbycusis patients, respectively. The deterioration gradient in the score-against-
PTA1,2,4 kHz plot was approximately 0.3% per dB, compared to the deterioration 
gradient of 1.1% per dB in the presbycusis patients. 
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Figure 5. Single-snapshot measurements of maximum phoneme recognition scores against 
age (left) and against mean pure-tone average at 1, 2, and 4 kHz (right). The solid lines are 
the linear regression curves fitted to these measurements. The dotted curves represent the 
P50 presbycusis line, previously established for patients with presbycusis. 
 
Figure 6 shows speech perception scores in noise for sentences in relation to PTA at 
2 and 4 kHz. Reference data were obtained from Smoorenburg,37 who studied a 
large group of subjects with moderate to severe sensorineural hearing impairment. 
Individual data points of the present family members are displayed in the Figure, as 
well as the best fit through the data of Smoorenburg37 with its two standard 
deviations region. The lower the score, the better. Even for patients with severe to 
profound hearing impairment (individuals III:3 and III:5), speech recognition in 
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noise scores were remarkably good and significantly better than those of the control 
patients. This suggests that indeed, speech perception is better than expected when 
related to hearing thresholds. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Speech Reception Thresholds (SRT) in noise for sentences in relation to PTA at 2 
and 4 kHz. The symbols are the data for the present family members. The straight line 
represents the average SRT values in noise as a function of the average pure tune thresholds 
at 2 and 4 kHz. The dashed lines represents two times the standard deviation of this 
regression curve.37 
 
Additional audiological measurements 
Table 1 shows the mean results (and standard deviations) of loudness scaling, gap 
detection and difference limen for frequency experiments at 2 kHz. For comparison, 
results of normal hearing individuals, DFNA8/12 patients and DFNA13 patients 
taken from previous studies are included.32, 35 In several affected family members, 
tests at 0.5 kHz did not reveal remarkable results because the thresholds at 0.5 kHz 
were close to normal. Therefore, it was decided to disregard the results of the tests 
at 0.5 kHz. Loudness growth curves of affected family members showed steeper 
slopes than that of the individuals with normal hearing. The mean loudness growth 
slopes of DFNA8/12 and DFNA13 patients are also steeper than the loudness growth 
curves of the normal hearing individuals, and comparable to those of the present 
MWS patients. The mean gap detection result of the affected family members was 
close to normal and comparable to those reported for DFNA8/12 patients. The 
DFNA13 patients demonstrated a poorer result on gap detection testing. Compared 
to individuals with normal hearing, who achieve a DLf of approximately 0.3% in 
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response to a 2 kHz tone, the mean performance of the present family members was 
clearly poorer, also in comparison with that of the DFNA13 patients. The DLf of the 
DFNA8/12 patients was fairly similar to those of the present patients. Unfortunately, 
the number of MWS patients (n = 5) and DFNA8/12 patients (n = 5) included in 
additional audiological testing was very small. Furthermore, the results of the MWS 
patients, DFNA8/12 patients and DFNA13 patients showed a wide variation. 
Nevertheless, it could be concluded that the results of the present MWS patients are 
comparable to the results of DFNA13 patients and mainly to the results of 
DFNA8/12 patients with intra-cochlear conductive hearing impairment.32, 35 
 
Patients Loudness growth in loudness 
category/dB (SD) 
GAP detection at 
2 kHz in ms (SD) 
DLf at 2 kHz in % 
(SD) 
MWS 0.08 (0.03) 4.2 (3.5) 1.2 (0.7) 
Normal hearing 0.05 4 (0.5) 0.3 (0.3) 
DFNA8/12 0.09 (0.02) 4.4 (2.5) 1.1 (1.0) 
DFNA13 0.07 (0.02) 6.6 (4.0) 0.5 (0.3) 
 
Table 1. Results of loudness scaling, GAP detection and difference limen for frequency (DLf) 
at 2 kHz of the five affected family members (individuals III:3, III:5, IV:4, IV:5 and IV:6), 
normal hearing individuals, DFNA8/12 patients and DFNA13 patients. SD: standard 
deviation. 
 
Discussion 
This report presents the audiometric characteristics and genetic analysis of an MWS 
family with a c.2575T>C mutation in the NLRP3 gene. In the present family, a 
heterozygous missense mutation, p.Tyr859His, was identified in exon 6 of NLRP3, 
which encodes the LRR domain of the cryopyrin protein. This is a novel mutation, 
but the previously described p.Tyr859Cys mutation affects the same amino acid.38, 39 
This amino acid is highly conserved throughout evolution. Several studies have 
revealed the importance of the LRR domain in the proper functioning of NLPR310, 40-
42 and Jéru et al.43 demonstrated the mild functional effects of the p.Tyr859Cys 
mutation by structural analysis.44 
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Hearing impairment in MWS 
Sensorineural hearing impairment is one of the diagnostic criteria of MWS, but the 
degree of hearing impairment can be very variable. Mild hearing impairment is 
described but also profound hearing impairment. The severity of hearing 
impairment depends on the age of the patient and on the moment that treatment 
with an IL-1 inhibitor was started.45 Hearing impairment is progressive and more 
pronounced at the high frequencies, but may involve all frequencies with advancing 
age. Usually hearing impairment starts in the second decade of life, but also onset in 
early childhood as well as midlife onset have been described.3, 45, 46 Large variation is 
found in hearing impairment phenotype between and within CAPS families. 
Nevertheless, hearing impairment of the present family seemed relatively severe 
and started already at a young age (mean subjective onset age: 12 years, range: 4-25 
years). In the second decade of life, most family members required a hearing aid. 
This was also demonstrated by the ARTA in Figure 4. Because of the good speech 
recognition scores, the present family members are not appropriate candidates for 
cochlear implantation. 
Phenotypic heterogeneity in CAPS 
The large intra-familiar phenotypic heterogeneity of CAPS suggests possible 
involvement of modifier genes and environmental factors in expression of the 
phenotype. This variable expression is also seen in the present family. Individuals 
III:3, IV:3, IV:4, IV:5 and IV:6 reported, besides hearing impairment, only mild 
symptoms, whereas individual III:5 showed a more severe autoinflammatory 
response. Kuemmerle-Deschner et al.47 demonstrated that female patients 
presenting with hearing impairment have the highest likelihood of manifesting 
severe symptoms of MWS and should be considered a high-risk group. However, the 
affected women in the present family do not demonstrate other severe symptoms 
besides hearing impairment. 
Pathogenesis of hearing impairment in MWS 
Muckle and Wells reported in 1962 the results of postmortem examinations of 
temporal bones of two patients with MWS and progressive hearing impairment 
since childhood. In both these patients degeneration of the cochlear nerve, the organ 
of Corti and the vestibular sensory epithelium was demonstrated. These findings 
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may have been caused by postmortem autolysis or by ischemia due to vascular 
amyloid deposits. However, amyloid deposits were not detected anywhere in the 
temporal bone sections.2 Furthermore, in the present family hearing impairment 
was already present at young age, in the absence of amyloidosis. Speech recognition 
was relatively good compared to the severity of hearing impairment in the present 
family and this suggests sparing of the cochlear nerve. Unfortunately, speech 
recognition scores were not reported for previously described families with MWS. 
Taken together, this suggests that the degenerative changes of the cochlear nerve 
and organ of Corti described by Muckle and Wells have been caused by postmortem 
autolysis and cannot be the main cause of hearing impairment in MWS.2 
Hypofunction of the vestibular labyrinth demonstrated in some family members of 
the present family could, however, be caused by degeneration of the vestibular 
sensory epithelium. 
Muckle and Wells also demonstrated ossification of the basilar membranes in 
patients with MWS. Since ossification did not occur in other parts of the temporal 
bone, an otosclerotic pathogenesis was excluded.2 The cause of hearing impairment 
in MWS is still unknown, but the basilar membrane could be involved in the 
pathogenesis of hearing impairment, as is the case in the pathogenesis of Alport 
syndrome.48-50 The structurally defective basement membrane in Alport syndrome 
probably provides inadequate adhesion between the organ of Corti and the 
underlying basilar membrane. It is suggested that basilar membrane motion is not 
properly adjusted by the outer hair cells and this inappropriate tuning probably 
results in sensorineural hearing impairment by interfering with cochlear 
micromechanics.50 Furthermore, pathology at the level of the basilar membrane 
could be responsible for the good speech recognition scores seen in the present 
family, which is also found in Alport syndrome.48, 49 Results of the audiometric 
evaluation also indirectly support the hypothesis of improper motion of the basilar 
membrane in patients with MWS. Suprathreshold measures such as DLf and gap 
detection were within the normal range or at least close to data obtained in two 
groups of patients with known abnormalities of the tectorial membrane.32, 35 The 
speech perception in noise scores of all family members were better than those of 
the control patients. These findings demonstrate remarkably good cochlear function 
even in severe hearing loss and contrasts to results often found in sensorineural 
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hearing impairment that results from loss of outer and/or inner hair cells (e.g. 
presbycusis, noise induced hearing loss). In conclusion, our results indicate that 
MWS related hearing impairment might be considered as a cochlear conductive 
hearing impairment, similar to hearing impairment in DFNA8/12 and DFNA13.32, 35 
Decreased motion transmission may be a common factor to the hearing deficits in 
Alport syndrome and the type of mid-frequency hearing impairment found in 
DFNA8/12 and DFNA13. In the latter two the loss of transmission occurs between 
the tectorial membrane and the outer hair cells, whereas in the former it occurs at 
the level between the basilar membrane and the organ of Corti. In both conditions 
the proper function of outer hair cell motion is jeopardized. 
However, hearing impairment in the present family members III:3 and III:5 was 
more severe than the 60-70 dB threshold values reported in Alport syndrome,48 
which may indicate the influence of additional causative factors. Inflammatory 
processes in the cochlea and leptomeninges are probably also contributing to 
sensorineural hearing impairment in MWS.51 Improvement of hearing impairment 
with Anakinra therapy also suggests the contribution of a local inflammatory 
response caused by IL-1β secretion.52 Unfortunately, the expression of NLRP3 in the 
inner ear is not known, but this information could be helpful to elucidate the 
pathogenesis of hearing impairment. 
Treatment with IL-1 inhibitors 
The proband of the present family has been treated with Anakinra 100 mg daily 
subcutaneously for the last year. This treatment has controlled the clinical and 
serologic symptoms of an active inflammatory process, however her hearing 
impairment has not improved. The other family members have only recently started 
treatment with IL-1 inhibitors. Kuemmerle-Deschner et al.20 described the effects of 
Anakinra treatment on hearing in ten MWS patients. Audiometric thresholds 
improved by 10-30 dB in the 0.25-4 kHz range to normal hearing levels in one 
patient, aged 15 years at start of therapy. One adult of 44 years of age had gradual 
improvement. Hearing worsened in two other adult patients, while treated with 
Anakinra. In the six remaining patients, hearing stabilized.20 Rynne et al.53 also 
reported improvement of 15-30 dB in the frequency range of 0.25-4 kHz after 18 
weeks of Anakinra therapy. The patient started with Anakinra therapy at the age of 
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59 years, after 15 years of progressive hearing impairment.53 In addition, Mirault et 
al.54 described a case of complete recovery of hearing impairment in a 22-year-old 
patient, who had been hearing impaired since the age of 12 years. After 3 months of 
therapy, threshold values improved from 50 dB to approximately 10 dB.54 The 
patient described by Dalgic et al.55 showed improvement of threshold values of 
about 20 dB after 2 months of Anakinra treatment. Audiometric evaluation at the 
age of 13 years revealed sensorineural hearing impairment and the patient started 
with Anakinra therapy one year later.55 Moreover, Yamazaki et al.52 described an 8-
year-old patient with asymmetrical hearing impairment. Threshold values improved 
to approximately 10 dB for both ears after 3 months of treatment.52 Nevertheless, 
there are also numerous reports of no significant improvement in threshold values 
after treatment with Anakinra.19, 26, 43, 56,  An accurate early diagnosis before the 
occurrence of irreversible hearing impairment seems to be crucial for the possibility 
of stopping deterioration or even improve hearing with Anakinra treatment. 
Conclusion 
The present study describes a Dutch family with MWS caused by a p.Tyr859His 
mutation in the NLRP3 gene. Hearing impairment was progressive and more 
pronounced at the high frequencies, but involved all frequencies with advancing age. 
Despite the severe hearing impairment, speech recognition was remarkably good, 
even in noise. 
The cause of hearing impairment in MWS is not yet understood, but the basilar 
membrane of the cochlea may be involved in the pathogenesis of hearing 
impairment. The present data suggest that hearing impairment in MWS can be 
characterized as an intracochlear conductive hearing impairment. This could be 
helpful in elucidating the pathogenesis of hearing impairment in MWS. 
An early diagnosis of MWS is essential to possibly prevent profound hearing 
impairment and irreversible damage from amyloidosis. Treatment with the IL-1β 
inhibitors has proven to be effective in reducing the symptoms of systemic 
inflammation. The effect on hearing impairment is more controversial, but an early 
start of treatment seems to be essential. Therefore, our results are important in 
patient care and counseling.  
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In every patient with sensorineural hearing impairment in combination with skin 
rash and musculoskeletal symptoms, MWS should be considered. However, these 
symptoms can be mild and nonspecific, as was the case in the present family. 
Therefore, the diagnosis of MWS can be easily missed. 
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Supplemental table and figure 
 
Fragment Oligonucleotides Size 
(bp) 
Annealing 
Temperature (°C) Primers for PCR and sequence analysis 
NLRP3 exon 1 Forward: gctggtcttgaattcctcag 
Reverse: tttaaaagtcttccttccactcac 
589 58 
NLRP3 exon 2 Forward: gaaatgctcccaaccagac 
Reverse: agtatggccaagttacccag 
385 56 
NLRP3 exon 3_1 Forward: attctcggcacctttcctac 
Reverse: gaggaagaggattctggagg 
650 58 
NLRP3 exon 3_2 Forward: tgtgacacagaggagcctg 
Reverse: aaggaagaagacgtacaccg 
544 58 
NLRP3 exon 3_3 Forward: tcctcttcaccatgtgcttc 
Reverse: agtaggaggtcctctcctgg 
564 56 
NLRP3 exon 3_4 Forward: agacgtgacagtccttctgg 
Reverse: tctcaaacagacagtggtgg 
632 56 
NLRP3 exon 4 Forward: ggcatttctctgaactggtg 
Reverse: tggtcctgaagatctttctcc 
360 60 
NLRP3 exon 5 Forward: caggtgtgttctgatgctttc 
Reverse: acactcactgaccgcaatg 
505 66 
NLRP3 exon 6 Forward: tagagcttgtgtccactccc 
Reverse: taccttcagctctgcctgac 
403 58 
NLRP3 exon 7 Forward: tgagagaggacgaggcac 
Reverse: tgatcctgtaacaaggcaaac 
397 58 
NLRP3 exon 8 Forward: ttagtcctgtgctcctgtgc 
Reverse: aggcccaacctaatcttgag 
387 60 
NLRP3 exon 9 Forward: tgtgtggagtttagggaaatg 
Reverse: gtcggcaagctctcttctc 
347 60 
Wildtype exon 6 
c.2575T>C 
Forward: attgagcaccagccattccctgaccagactat 
Forward: attgagcaccagccattccctgaccagactac 
Reverse: ccctcaacaggcaattgggctgcac 
387 60 
 
Table S1. Sequences of primers for amplification of exons, intron-exon boundaries and 
transcripts of NLPR3. NM_004895.4 and NT_167186.1 were used a reference sequences. 
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Figure S1. Pedigree and genetic analysis. The haplotype associated with the Muckle-Wells 
syndrome is indicated with a box. Square: male; circle: female; open symbol: clinically 
unaffected; solid symbol: clinically affected; slash: deceased individuals. 
 
  
CHAPTER 5   
178 
 
References 
1. Hoffman HM, Mueller JL, Broide DH et al., Mutation of a new gene encoding a putative 
pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells 
syndrome, Nat Genet 2001;29:301-5. 
2. Muckle TJ, Wells M, Urticaria, deafness, and amyloidosis: a new heredofamilial syndrome, 
Q J Med 1962;31:235-48. 
3. Hawkins PN, Lachmann HJ, Aganna E et al., Spectrum of clinical features in Muckle-Wells 
syndrome and response to anakinra, Arthritis Rheum 2004;50:607-12. 
4. Aganna E, Martinon F, Hawkins PN et al., Association of mutations in the 
NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold 
sensitivity, sensorineural deafness, and AA amyloidosis, Arthritis Rheum 2002;46:2445-52. 
5. Aganna E, Hawkins PN, Ozen S et al., Allelic variants in genes associated with hereditary 
periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis, 
Genes Immun 2004;5:289-93. 
6. Van der Hilst JC, Simon A, Drenth JP, Hereditary periodic fever and reactive amyloidosis, 
Clin Exp Med 2005;5:87-98. 
7. Dode C, Cuisset L, Delpech M et al., TNFRSF1A-associated periodic syndrome (TRAPS), 
Muckle-Wells syndrome (MWS) and renal amyloidosis, J Nephrol 2003;16:435-7. 
8. Cuisset L, Drenth JP, Berthelot JM et al., Genetic linkage of the Muckle-Wells syndrome to 
chromosome 1q44, Am J Hum Genet 1999;65:1054-9. 
9. Dode C, Le Dû N, Cuisset L et al., New mutations of CIAS1 that are responsible for Muckle-
Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes, Am 
J Hum Genet 2002;70:1498-1506. 
10. Albrecht M, Domingues FS, Schreiber S et al., Structural localization of disease-associated 
sequence variations in the NACHT and LRR domains of PYPAF1 and NOD2, FEBS Lett 
2003;554:520-8. 
11. Latz E, The inflammasomes: mechanisms of activation and function, Curr Opin Immunol 
2010;22:28-33. 
12. Schroder K, Tschopp J, The inflammasomes, Cell 2010;140:821-32. 
13. Sutterwala FS, Ogura Y, Szczepanik M et al., Critical role for NALP3/CIAS1/Cryopyrin in 
innate and adaptive immunity through its regulation of caspase-1, Immunity 2006;24:317-
27. 
14. Agostini L, Martinon F, Burns K et al., NALP3 forms an IL-1beta-processing 
inflammasome with increased activity in Muckle-Wells autoinflammatory disorder, 
Immunity 2004;20:319-25. 
15. Meng G, Zhang F, Fuss I et al., A mutation in the Nlrp3 gene causing inflammasome 
hyperactivation potentiates Th17 cell-dominant immune responses, Immunity 
2009;30:860-74. 
16. Brydges SD, Mueller JL, McGeough MD et al., Inflammasome-mediated disease animal 
models reveal roles for innate but not adaptive immunity, Immunity 2009;30:875-87. 
17. Meng G, Strober W, New insights into the nature of autoinflammatory diseases from 
mice with Nlrp3 mutations, Eur J Immunol 2010;40:649-53. 
18. Gattorno M, Tassi S, Carta S et al., Pattern of interleukin-1beta secretion in response to 
lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 
mutations, Arthritis Rheum 2007;56:3138-48. 
  AUDIOMETRIC CHARACTERISTICS IN MWS 
179 
 
5 
19. Leslie KS, Lachmann HJ, Bruning E et al., Phenotype, genotype, and sustained response to 
anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 
mutations, Arch Dermatol 2006;142:1591-7. 
20. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al., Efficacy and safety of anakinra 
therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome, 
Arthritis Rheum 2010;63:840-9. 
21. Feldmann J, Prieur AM, Quartier P et al., Chronic infantile neurological cutaneous and 
articular syndrome is caused by mutations in CIAS1, a gene highly expressed in 
polymorphonuclear cells and chondrocytes, Am J Hum Genet 2002;71:198-203. 
22. Arostegui JI, Aldea A, Modesto C et al., Clinical and genetic heterogeneity among Spanish 
patients with recurrent autoinflammatory syndromes associated with the 
CIAS1/PYPAF1/NALP3 gene, Arthritis Rheum 2004;50:4045-50. 
23. Maksimovic L, Stirnemann J, Caux F et al., New CIAS1 mutation and anakinra efficacy in 
overlapping of Muckle-Wells and familial cold autoinflammatory syndromes, Rheumatology 
(Oxford) 2008;47:309-10. 
24. McDermott MF, Aganna E, Hitman GA et al., An autosomal dominant periodic fever 
associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q, 
Arthritis Rheum 2000;43:2034-40. 
25. Hentgen V, Despert V, Lepretre AC et al., Intrafamilial variable phenotypic expression of 
a CIAS1 mutation: from Muckle-Wells to chronic infantile neurological cutaneous and 
articular syndrome, J Rheumatol 2005;32:747-51. 
26. Koike R, Kubota T, Hara Y et al., A case of Muckle-Wells syndrome caused by a novel 
H312P mutation in NALP3 (cryopyrin), Mod Rheumatol 2007;17:496-9. 
27. Aksentijevich I, Putnam D, Remmers EF et al., The clinical continuum of 
cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin 
model, Arthritis Rheum 2007;56:1273-85. 
28. Neven B, Callebaut I, Prieur AM et al., Molecular basis of the spectral expression of CIAS1 
mutations associated with phagocytic cell-mediated autoinflammatory disorders 
CINCA/NOMID, MWS, and FCU, Blood 2004;103:2809-15. 
29. International Organization for Standardization, ISO 7029, Acoustics: Threshold of 
hearing by air conduction as a function of age and sex for ontologically normal persons, 
1984, Geneva, Switzerland. 
30. Huygen PLM, Pennings RJE, Cremers CWRJ, Characterising and distinguishing 
progressive phenotypes in nonsyndromic autosomal dominant hearing impairment, 
Audiological Med 2003;1:37-46. 
31. De Leenheer EM, Huygen PL, Coucke PJ et al., Longitudinal and cross-sectional 
phenotype analysis in a new, large Dutch DFNA2/KCNQ4 family, Ann Otol Rhinol Laryngol 
2002;111:267-74. 
32. Plantinga RF, Cremers CW, Huygen PL et al., Audiological evaluation of affected members 
from a Dutch DFNA8/12 (TECTA) family, J Assoc Res Otolaryngol 2007;8:1-7. 
33. Moser LM, The Wurzburg auditory field, a test for prosthetic audiometry, HNO 
1987;35:318-21. 
34. Plomp R, Mimpen AM, Improving the reliability of testing the speech reception threshold 
for sentences, Audiology 1979;18:43-52. 
35. De Leenheer EM, Bosman AJ, Kunst HP et al., Audiological characteristics of some 
affected members of a Dutch DFNA13/COL11A2 family, Ann Otol Rhinol Laryngol 
2004;113:922-9. 
CHAPTER 5   
180 
 
36. Marres H, Van Ewijk M, Huygen P et al., Inherited nonsyndromic hearing loss. An 
audiovestibular study in a large family with autosomal dominant progressive hearing loss 
related to DFNA2, Arch Otolaryngol Head Neck Surg 1997;123:573-7. 
37. Smoorenburg GF, Speech reception in quiet and in noisy conditions by individuals with 
noise-induced hearing loss in relation to their tone audiogram, J Acoust Soc Am 
1992;91:421-37. 
38. Jeru I, Hayrapetyan H, Duquesnoy P et al., PYPAF1 nonsense mutation in a patient with 
an unusual autoinflammatory syndrome: role of PYPAF1 in inflammation, Arthritis Rheum 
2006;54:508-14. 
39. Frenkel J, Van Kempen MJ, Kuis W et al., Variant chronic infantile neurologic, cutaneous, 
articular syndrome due to a mutation within the leucine-rich repeat domain of CIAS1, 
Arthritis Rheum 2004;50:2719-20. 
40. Manji GA, Wang L, Geddes BJ et al., PYPAF1, a PYRIN-containing Apaf1-like protein that 
assembles with ASC and regulates activation of NF-kappa B, J Biol Chem 2002;277:11570-5. 
41. O’Connor Jr. W, Harton JA, Zhu X et al., Cutting edge: 
CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator 
with NF-kappa B suppressive properties, J Immunol 2003;171:6329-33. 
42. Dowds TA, Masumoto J, Zhu L et al., Cryopyrin-induced interleukin 1beta secretion in 
monocytic cells: enhanced activity of diseaseassociated mutants and requirement for ASC, J 
Biol Chem 2004;279:21924-8. 
43. Jeru I, Marlin S, Le Borgne G et al., Functional consequences of a germline mutation in the 
leucine-rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder, 
Arthritis Rheum 2010;62:1176-85. 
44. Matsushima N, Tachi N, Kuroki Y et al., Structural analysis of leucine-rich-repeat variants 
in proteins associated with human diseases, Cell Mol Life Sci 2005;62:2771-91. 
45. Biswas D, Stafford N, Otolaryngological manifestations of ’Muckle-Wells syndrome, Int J 
Pediatr Otorhinolaryngol 2010;74:553-5. 
46. Legent F, Prost A, Beauvillain C et al., Deafness in the Muckle-Wells syndrome, Ann 
Otolaryngol Chir Cervicofac 1976;93:355-65. 
47. Kuemmerle-Deschner JB, Tyrrell PN, Reess F et al., Risk factors for severe Muckle-Wells 
syndrome, Arthritis Rheum 2010;62:3783-91. 
48. Moon IS, Bang MY, Shim DB et al., Severe to profound hearing loss in patients with 
progressed Alport’s syndrome, Acta Otolaryngol 2008;129:982-7. 
49. Alves FR, De Quintanilha Ribeiro A, Revision about hearing loss in the Alport’s 
syndrome, analyzing the clinical, genetic and bio-molecular aspects, Braz J Otorhinolaryngol 
2005;71:813-9. 
50. Merchant SN, Burgess BJ, Adams JC et al., Temporal bone histopathology in Alport 
syndrome, Laryngoscope 2004;114:1609-18. 
51. Montealegre Sanchez GA, Hashkes PJ, Neurological manifestations of the Mendelian-
inherited autoinflammatory syndromes, Dev Med Child Neurol 2009;51:420-8. 
52. Yamazaki T, Masumoto J, Agematsu K et al., Anakinra improves sensory deafness in a 
Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin 
inflammasome, Arthritis Rheum 2008;58:864-8. 
53. Rynne M, Maclean C, Bybee A et al., Hearing improvement in a patient with variant 
Muckle-Wells syndrome in response to interleukin 1 receptor antagonism, Ann Rheum Dis 
2006;65:533-4. 
  AUDIOMETRIC CHARACTERISTICS IN MWS 
181 
 
5 
54. Mirault T, Launay D, Cuisset L et al., Recovery from deafness in a patient with Muckle-
Wells syndrome treated with anakinra, Arthritis Rheum 2006;54:1697-1700. 
55. Dalgic B, Egritas O, Sari S et al., A variant Muckle-Wells syndrome with a novel mutation 
in CIAS1 gene responding to anakinra, Pediatr Nephrol 2007;22:1391-4. 
56. Hawkins PN, Lachmann HJ, McDermott MF, Interleukin-1-receptor antagonist in the 
Muckle-Wells syndrome, N Engl J Med 2003;348:2583-4. 
 
 
  
  
 6.1 
 
Phenotype of the first otosclerosis family linked to 
OTSC10 
N.J.D. Weegerink, I. Schrauwen, P.L.M. Huygen, R.J.E. Pennings, 
C.W.R.J. Cremers, G. van Camp, H.P.M. Kunst 
The Laryngoscope 2011; 121: 838-845 
CHAPTER 6.1   
184 
 
Abstract 
In the present study, we report the audiometric findings in the first otosclerosis 
family linked to OTSC10. A family study in a large otosclerosis family was performed 
and a pedigree was constructed. Examination of all family members consisted of 
medical history guided by a questionnaire, pure-tone audiometry, otoscopy and 
collection of blood samples for genetic linkage analysis. In addition, a selected group 
underwent stapedial reflex measurements and tympanometry. Cross-sectional as 
well as longitudinal analyses of audiometric data were performed. 
Eleven family members were identified as clinically affected and were all carriers of 
the disease haplotype. Twelve clinically unaffected family members carried the 
disease haplotype as well. Cross-sectional analyses of clinically affected family 
members showed no significant progression of air-conduction (AC) thresholds, 
bone-conduction (BC) thresholds and air-bone gap (ABG) levels with increasing age. 
Longitudinal regression analyses in one family member revealed significant 
deterioration of AC thresholds at all frequencies. The BC thresholds showed a 
significant increase with advancing age at 0.5 kHz, 2 kHz and 4 kHz. A significant 
progression of ABG was seen at 8 kHz. 
The intersubject variation, in terms of age of onset, level of progression and 
audiogram configuration was remarkable, probably due to reduced penetrance and 
variable expression of the disease. Long-term audiometric data in one patient, 
however, were useful to demonstrate progression of hearing impairment. 
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Introduction 
Otosclerosis is a unique form of bone dysplasia exclusively affecting the temporal 
bone. The pathologic process is characterized by abnormal bone remodeling at 
specific sites of predilection confined to the endochondral layer of the otic capsule.1 
Otosclerosis can be divided into a histologic and clinical type. Histologic otosclerosis 
is defined as asymptomatic disease that can only be discovered in histologic 
temporal bone sections. Clinical otosclerosis is characterized by progressive 
conductive hearing impairment due to stapes ankylosis. Histologic otosclerosis is 
about 10 times more common than clinical otosclerosis and is found in 10% of the 
Caucasian population. In other races, the prevalence is much lower. The disease is 
bilateral in 70% to 80% of patients usually with a symmetrical extension and 
distribution of otosclerotic foci. The symptoms depend on the site of the otosclerotic 
foci. The most common site is anterior to the oval window (fissula ante fenestram), 
followed by the round window niche and the apical and medial cochlear wall, 
respectively. Other sites of involvement are posterior to the oval window, the 
internal auditory canal, around the cochlear aqueduct, around the semicircular 
canals and within the footplate.1, 2 
Furthermore, cochlear otosclerosis is recognized as a separate entity characterized 
by progressive sensorineural hearing impairment (SNHI) due to otosclerotic 
involvement of the cochlea.1, 3 The literature provides conflicting information 
regarding prevalence and cause of SNHI in patients with otosclerosis, but long-term 
follow-up studies suggest that about 10% of patients with conductive hearing 
impairment develop SNHI. Cochlear otosclerosis can exist in the absence of 
conductive hearing impairment, although isolated cochlear otosclerosis is rare.4, 5 
The diagnosis of otosclerosis is in most cases based on clinical findings combined 
with audiometry results. However, the development of spiral computed tomography 
(CT) scanners with high-resolution images has increased the detection of 
otosclerosis and is a valid tool to confirm, localize and determine the size of 
clinically suspected otosclerotic foci. In most cases, CT can detect otospongiotic foci, 
characterized by hypodense lesions in the otic capsule. However, sclerotic foci may 
not be detected by CT, because these foci have the same density as normal bone 
tissue of the otic capsule.6 
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Conductive hearing impairment can be corrected by a hearing aid as well as by 
stapedotomy. Stapes microsurgery has proven to be highly successful in restoring 
the normal conduction mechanism and can improve hearing thresholds by as much 
as 50 dB.7 
Otosclerosis is considered to be a multifactorial disease, caused by both genetic and 
environmental factors. However, rare monogenic forms of the disease also exist and 
several studies have reported that sporadic otosclerosis represents 40% to 50% of 
all clinical cases. Phenotype-genotype studies showed evidence for autosomal 
dominant inheritance with incomplete penetrance by approximately 40%.8, 9 Genetic 
linkage analysis has demonstrated the presence of nine loci,10 of which loci 6 and 9 
are reported to the Human Genome Organization nomenclature committee, but have 
not been published yet. (Table 1) The large number of different loci reflects the 
genetic heterogeneity of this disorder. Furthermore, the variable phenotypic 
expression of the genetic forms of otosclerosis suggests the contribution of 
environmental factors to its etiology.8, 9 Several theories have been postulated, 
including a viral etiology, disturbances of bone remodeling, disorders of endocrine 
and immune systems, and connective tissue disorders. However, despite intensive 
research and identification of a variety of factors involved in the development of the 
disease, the etiology of otosclerosis is still not fully understood.2 
 
Locus Location Reference 
Clinical Genetic 
OTSC 1 15q25-26 Not available Tomek et al., 1998 
OTSC 2 7q34-q36 Declau et al. 2007 Van den Bogaert et al., 2001 
OTSC 3 6q21.3-22.3 Ali et al. 2007 Chen et al., 2002 
OTSC 4 16q21-23.2 Brownstein et al. 2006 Brownstein et al., 2006 
OTSC 5 3q22-q24 Pauw et al. 2006 Van den Bogaert et al., 2004 
OTSC 6 Reserved 
OTSC 7 6q13-16.1 Iliadou et al. 2005;  
Pauw et al. 2007 
Thys et al., 2007 
OTSC 8 9q13.1-9q21.11 Ali et al. 2007 Ali et al., 2008 
OTSC 9 Reserved 
 
Table 1. Loci for otosclerosis derived from the Hereditary Hearing Loss Homepage 
(http://hereditaryhearingloss.org). 
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To identify the disease-causing genes in the loci, refinement of candidate regions 
and mutation analysis of candidate genes is required. Cloning and completing 
functional analysis on causative genes and their related proteins may provide new 
insights into the molecular mechanisms of otosclerosis and may reveal targets for 
prevention and treatment of the disease.8, 9 Genotype-phenotype correlation studies 
on each otosclerosis locus could be helpful to distinguish possible differences in 
clinical behavior. This article presents the clinical characteristics of the first family 
linked to OTSC10. 
Patients and methods 
Patients 
A large multigenerational Dutch family with otosclerosis was studied and its 
pedigree was constructed. (Figure 1) After informed consent had been obtained 
from the 51 participating family members, a family study was performed. The study 
was approved by the local medical ethics committee of the Radboud University 
Nijmegen Medical Centre, the Netherlands. 
Medical history was taken from all participants guided by the questionnaire, paying 
special attention to concomitant disease, use of medication and other possible 
causes of acquired hearing impairment. Medical examination included otoscopy, 
pure-tone audiometry and collection of blood samples for linkage analysis. Otoscopy 
was performed to rule out other causes of conductive hearing impairment, such as 
excessive ear wax, signs of previous otitis media and tympanic membrane 
perforation. Five family members had additional stapedial reflex evaluation. 
Previous medical records and audiograms were traced for individual longitudinal 
analysis. 
Family members who previously had a stapedotomy for otosclerosis were 
considered to be affected. In nonoperated family members, the clinical diagnosis of 
otosclerosis was considered when at least several of the following criteria were met: 
presence of conductive or mixed hearing impairment, air-bone gap (ABG) ≥20 
decibels (dB) averaged across 0.5 to 2 kHz, absent stapedial reflexes and normal 
otoscopy. 
This family was previously investigated by genetic linkage analysis, which revealed 
linkage to the OTSC10 locus on chr1q41-44 (data not shown). 
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Figure 1. Pedigree of the Dutch OTSC10 family. Square: male; circle: female; slash: deceased 
individual; open symbol: clinically unaffected; solid symbol: clinically affected; + : 
genetically affected; - : genetically unaffected; ? : unclear genetic status. 
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Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a sound-
treated room according to common clinical standards. Air-conduction (AC) 
thresholds were measured in dB hearing level (HL) at 0.25, 0.5, 1, 2, 4 and 8 kHz, 
and bone-conduction (BC) thresholds were measured in dB HL at 0.5, 1, 2, 4 and 8 
kHz. The individual 95th percentile threshold values of presbycusis in relation to the 
patient’s sex and age were derived for AC thresholds at each frequency using the ISO 
7029 method.11 
The most recent audiogram or last audiogram before stapedotomy of the clinically 
and genetically affected family members were included in the analysis. Only one ear 
per individual was included to avoid bias of the cross-sectional analysis because 
some individuals had unilateral otosclerosis. In case of bilateral otosclerosis, the 
nonoperated ear or ear with poorest hearing was included. 
Cross-sectional analysis was performed for each frequency separately using linear 
regression analysis. The regression coefficient (slope) was called annual threshold 
deterioration (ATD), expressed in dB per year. Progression was significant if the 
95% confidence interval of the ATD did not include zero. According to binomial 
distribution statistics, progression was only rated as significant if it occurred at two 
(or more) out of six frequencies. Individual longitudinal linear regression analysis of 
AC thresholds, BC thresholds and ABG levels on age was only performed in clinically 
affected persons with three or more consecutive measurements and an overall 
follow-up period of at least five years. Again, the ATD was calculated and the 
progression was significant if the 95% confidence interval did not include zero. The 
level of significance used in all tests was p < 0.05. 
Results 
Pedigree and general findings 
A five-generation pedigree was established for the present family, demonstrating an 
autosomal dominant pattern of inheritance with incomplete penetrance. (Figure 1) 
A CT scan of the temporal bones was performed in one family member at the age of 
44 years (individual III:37). Individual III:37 underwent, at the age of 39 years, a 
stapedotomy for otosclerosis of her right ear and four years later for otosclerosis of 
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her left ear. The CT scan showed demineralization at the fissula ante fenestram on 
both sides. 
Eleven clinically affected family members (II:4, II:6, II:8, II:10, II:12, III:12, III:21, 
III:34, III:37, III:39 and IV:19) were identified. Three of them (II:12, III:37 and III:39) 
previously underwent stapedotomy. Individual III:34 underwent middle ear 
inspection and the presence of otosclerosis was confirmed. In three other family 
members (II:4, III:12 and IV:19), the clinical diagnosis was based on the diagnostic 
criteria. We did not succeed in obtaining audiograms from individuals II:6, II:8, II:10 
and III:21, but according to history and their position in the pedigree, these family 
members were considered as affected. (Figure 1) Some of the clinically unaffected 
family members showed a deviating audiogram according to sex and age, but did not 
meet the clinical criteria for otosclerosis and their hearing impairment had probably 
another cause. Therefore, a total of 11 affected family members were identified for 
genetic linkage analysis. This analysis revealed a new locus for otosclerosis, OTSC10, 
localized to chromosome 1q41-44 (data not shown). 
All 11 clinically affected family members had the linked haplotype and no 
phenocopies were identified. In addition, 12 clinically unaffected family members 
(mean age: 39 years; range: 22–56) had the disease haplotype. The genetic status in 
16 family members was uncertain because these individuals carried only part of the 
linked haplotype. In total, we identified 23 genetically affected family members. 
The male:female ratio was 6:5 for clinically affected individuals and 10:13 for 
individuals with the disease haplotype. The mean subjective onset age of hearing 
impairment was 31 years (range: 16–51; standard deviation [SD] ± 14.1), and the 
mean age at first surgery was 38 years (range: 31–49; SD ± 6.9). 
Audiometric analysis 
The seven most recent or last audiograms before stapedotomy of the 11 clinically 
affected individuals are shown in Figure 2. Of four clinically affected family 
members, no audiogram could be retrieved. The characteristic audiogram of a 
patient with otosclerosis shows a dip in the BC threshold at 2 kHz, creating the 
typical Carhart notch. In general, the ABG is maximal at the lower frequencies and 
decreases with increasing frequency but may be minimal in association with the 
Carhart notch.  
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Figure 2. Seven available individual audiograms of the eleven clinically and genetically 
affected family members. Air-conduction threshold: open circles and solid line; bone-
conduction threshold: dots and dashed line. Above each audiogram are the pedigree 
number, age in years (y) and right (R) or left (L) ear. 
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Most of the audiograms show the audiogram configuration typical for clinical 
otosclerosis, except for the audiogram of the left ear of individual IV:19, which is not 
typical for otosclerosis. This audiogram shows mixed hearing impairment (MHI) 
with a conductive component at the lower frequencies. In combination with absent 
reflexes of the left ear, otosclerosis was considered very likely. The audiograms of 
the right ear of individuals III:12 and IV:19 were considered to be normal in relation 
to age and sex, and therefore excluded from further regression analysis. Individual 
II:4 was identified as a carrier of the disease haplotype because of his position in the 
pedigree; his daughter (individual III:12) was diagnosed with otosclerosis. The most 
recent audiogram shows SNHI in both ears and cochlear otosclerosis was considered 
because no other cause of SNHI could be found. (Figure 2) 
Twelve clinically unaffected family members carried the affected haplotype for 
OTSC10. Although none of these carriers met the criteria for clinical otosclerosis, 
some of them did show hearing impairment that was clinically relevant for their age, 
but probably has another etiology. 
The right ear of individuals II:4, II:12 and III:37, and the left ear of individuals III:12, 
III:34, III:39 and IV:19 were included in the cross-sectional regression analysis. The 
cross-sectional regression analysis on the threshold data of the clinically affected 
mutation carriers did not reveal significant progression with advancing age of AC, 
BC and ABG levels at any frequency. Therefore, Figure 3 shows the mean 
audiograms for AC, BC and ABG levels. 
 
 
 
 
 
 
 
 
Figure 3. Average threshold data based on audiometry results from individuals II:4, II:12, 
III:12, III:34, III:37, III:39 and IV:19 (ages 21–58 years). Air-conduction threshold: open 
circles and solid line; bone-conduction threshold: dots and dashed line; air-bone gap 
threshold: solid squares and line. 
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Sufficient longitudinal audiometric data before surgery were only available for 
individual II:12 and covered 20 years (range: 29–49 years). He underwent in 1964, 
at the age of 31 years, stapes-replacing surgery for otosclerosis of his left ear and in 
1982 (at 49 years) for otosclerosis of his right ear. Since 1992, he has worn hearing 
aids in both his ears. A selection of the available audiograms of this individual (right 
ear) are shown in Figure 4 and demonstrate the deterioration of his hearing. Mainly, 
the AC threshold increased with advancing age. The BC threshold did not deteriorate 
substantially until the age of 49 years. The ABG at 49 years is smaller at the low 
frequencies than the ABG at 32 years, but this may be due to errors of measurement. 
(Figure 4) 
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Figure 4. Selection of the available presurgery audiograms of the right ear of individual 
II:12. The third row shows the air-conduction (AC), bone-conduction (BC), and air-bone gap 
levels of the right ear of individual II:12 at different ages in the same figure. AC threshold: 
open circles and solid line; BC threshold: dots and dashed line. Above each audiogram are 
the pedigree number, age in years (y) and right (R) ear. 
 
Linear regression analysis revealed significant progression of the AC threshold with 
advancing age for all frequencies. The progression of the BC levels was significant at 
0.5 kHz, 2 kHz and 4 kHz. However, this can be caused by incorrect measurement of 
the BC threshold at the age of 49 years. The ABG did not show significant 
progression at two or more frequencies; progression was only significant at 8 kHz 
(data not shown). 
Individuals II:12, III:37 and III:39 had stapes-replacing surgery for otosclerosis in 
one or both ears. Figure 5 shows the AC and ABG levels of these individuals before 
and 4 to 6 months after surgery. As expected, the AC threshold improved and the 
ABG diminished, and all the patients reported an improvement of their hearing after 
surgery. To calculate the preoperative ABG, we used the postoperative bone-
conduction levels. We evaluated the effect of stapedotomy on AC and ABG levels a 
few months (4 to 6 months) after surgery. Later, the ongoing otosclerotic process 
may impair the results of stapedotomy,12 making it difficult to evaluate the results of 
surgery solely. 
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Figure 5. Air-conduction (AC) and air-bone gap (ABG) levels of individuals II:12, III:37 and 
III:39 before and 4 to 6 months after stapedotomy. Presurgery threshold right ear: open 
circles; postsurgery threshold right ear: dots; presurgery threshold left ear: squares; 
postsurgery threshold left ear: solid squares. 
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Discussion 
This report presents the clinical description of the first otosclerosis family linked to 
OTSC10 on chromosome 1q41-44.  
Reduced penetrance 
The present family harbors eleven patients with clinically confirmed otosclerosis 
and all of them carry the disease haplotype. An additional twelve clinically 
unaffected family members were found to carry the disease haplotype. Furthermore, 
sixteen family members had an uncertain genetic diagnosis. This would imply a 
penetrance of 48% (11 of 23) for all ages. Reduced penetrance is not uncommon in 
otosclerosis and the majority of otosclerosis studies support an autosomal dominant 
mode of inheritance with reduced penetrance of 25% to 45%, which is presumed to 
depend on age.8, 9 Ninety percent of new cases of otosclerosis are diagnosed before 
the age of 50 years.9 As a consequence, no definitive diagnosis of clinically 
unaffected family members could be given to individuals below this age. Nine of the 
twelve clinically unaffected family members with linkage to OTSC10 are under 50 
years of age and may still develop clinical otosclerosis. Three other clinically 
unaffected family members have ages of 52 to 56 years. They might still develop the 
disease or never express it due to other modifying genetic and environmental 
factors. The penetrance above 50 years of age in this family is 64% (7 of 11). In 
general, the chance to develop clinical otosclerosis for a child with an affected parent 
is 24% (50% x 48%). 
Clinical otosclerosis 
The reported age of onset in clinically affected family members ranged from 16 to 51 
years, with a mean onset age of 31 years. The age of onset reported in literature 
ranges from 20 to 40 years.1, 2, 9 The mean onset age lies within the reported age of 
onset for clinical otosclerosis. 
Clinical otosclerosis is, according to literature, more common in females than in 
males with a male:female ratio of approximately 1:2. However, histologic studies do 
not confirm the skewed sex ratio.2, 13 The male:female ratio of the present family was 
1:1 for the clinically affected individuals and 10:13 for individuals with the disease 
haplotype. We have no explanation for the difference between the male:female ratio 
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of clinical otosclerosis in the present study and the ratio found in literature. The 
unusual sex ratio of clinical otosclerosis is not fully understood. It has been 
implicated that during periods of endocrine change (e.g., pregnancy and puberty), 
otosclerosis can be initiated or progress in women, particularly with multiple 
pregnancies. However, some authors found no deleterious effect of having children 
on hearing in women with otosclerosis. Neither did breastfeeding affect the degree 
of hearing impairment.14 Nevertheless, it is well established that sex steroid 
hormones are critical regulators of bone metabolism and growth.2 In the present 
family, only one woman (individual III:37) experienced more tinnitus during 
pregnancies. The tinnitus disappeared after stapedotomy. The role of hormonal 
imbalance and the exact mechanism remains inconclusive. Otosclerosis mainly 
occurs during childbearing ages, therefore it is possible that pregnancy is just an 
intercurrent event and not the trigger of disease. 
Radiological imaging of the temporal bones 
High-resolution CT imaging of individual III:37 revealed otospongiotic foci at the 
fissula ante fenestram on both sides. Detection rates of otospongiotic foci in 
surgically confirmed otosclerosis with a CT scan prior to surgery of up to 91% have 
been reported in literature.15 The best method for detection of otosclerotic foci on 
CT is the use of submillimeter slice thickness and the assessment of the images 
directly on the workstation.6 After the use of more technically advanced CT scans, a 
significant positive correlation between the size of the ABG and the extension of the 
otosclerotic lesion on CT could be established.6, 15 Furthermore, there is also a 
relationship between degree of SNHI and level of extension in the endosteum of a 
pericochlear focus.15 
Progression of hearing impairment 
Based on the presumed natural history of otosclerosis, the clinical phenotype must 
include progression during at least a number of years prior to surgery. This was 
confirmed by the longitudinal audiometric data of individual II:12. The progressive 
conductive hearing impairment stabilized around the third decade with ABG levels 
of 50 dB and later a progressive sensorineural component developed. Conversely, 
cross-sectional analysis revealed no significant progression of hearing impairment. 
Analysis of the audiometric data of one family member may better reflect the natural 
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course of progression of hearing impairment in otosclerosis than the results of the 
cross-sectional analysis of all the affected family members because of the occurrence 
of large variability of individual thresholds and onset ages. This prominent 
intersubject variation of the audiograms prohibited significant results in cross-
sectional linear regression analyses and only a trend could be appreciated. 
Furthermore, the small number of clinically affected individuals and the lack of 
audiometric data on four clinically affected individuals (II:6, II:8, II:10 and III:21) 
also weakens the cross-sectional results. The variable audiogram configurations and 
variable progression of hearing impairment were also demonstrated in previously 
described otosclerosis families. (Table 2)  
Conclusion 
The intersubject variation, in terms of age of onset, level of progression and 
audiogram configuration, was remarkable, probably due to reduced penetrance of 
48% and variable expression of the disease. Long-term audiometric data in one 
patient, however, were useful to demonstrate progression of hearing impairment. 
There is no doubt that additional, similar studies are needed to be able to distinguish 
possible phenotypic differences between different genetic types of otosclerosis. 
Phenotype-genotype correlation studies may also help to elucidate the 
pathophysiology of otosclerosis.  
The identification of the involved genes will help to elucidate the pathophysiology of 
otosclerosis at a molecular level and may provide possible targets for prevention, 
diagnosis and therapy of this disease. However, currently the value of genetic testing 
for otosclerosis is mainly of research interest. Furthermore, insight into the natural 
course of the various phenotypes of otosclerosis may provide the opportunity for a 
proper evaluation of the efficacy of current and future therapies. 
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Locus Age of Onset (in 
years) 
Type 
of HI 
Audiometric Data 
OTSC 1 - CHI, 
MHI 
Age-dependent development of sensorineural 
component superimposed on CHI. No age-related 
increase of CHI. 
OTSC 2 - CHI, 
MHI 
Quite variable audiogram configurations. Linear 
regression analysis: limited progression with age. 
OTSC 3 Mean: 29 
(range: 18–40) 
CHI, 
MHI 
- 
OTSC 4 F: late 20s–
early 30s 
M: late 30s–
early 40s 
CHI, 
MHI, 
SNHI 
Progressive HI beginning in the late 20s to 40s. 
Large variability between affected individuals in 
age at onset, type of HI, shape of audiogram and 
symmetry of HI. Little correlation between age and 
severity. 
OTSC 5 - CHI, 
MHI, 
SNHI 
Cross-sectional linear regression: no significant 
increase of AC, BC or ABG. Longitudinal linear 
regression: deterioration of AC in the younger 
patient. 
OTSC 7 ± 10 as CHI but 
soon MHI 
CHI, 
MHI, 
SNHI 
Multiple linear regression: age-independent but 
frequency-specific ABG. Progressive BC across all 
frequencies but with frequency-specific progression 
rate. More prominent increase of BC at the higher 
frequencies. 
 Mean: 28.8 
(range: 18–45; 
SD ± 9.1) 
CHI, 
MHI 
Cross-sectional linear regression: no significant 
progression of AC, BC and ABG. Longitudinal linear 
regression: significant increase in AC, BC and ABG. 
Progressive CHI stabilized around third decade 
with ABG of 50 dB, later on progression of SNHI. 
OTSC 8 Mean: 34 
(range: 14–45) 
CHI, 
MHI, 
SNHI 
- 
OTSC 10 Mean: 31 
(range: 16–51; 
SD ± 14.1) 
CHI, 
MHI, 
SNHI 
Cross-sectional linear regression: no significant 
progression of AC, BC and ABG. Longitudinal linear 
regression: significant deterioration of AC at all 
frequencies, significant progression of BC at 0.5 
kHz, 2 kHz and 4 kHz, significant increase of ABG at 
8 kHz. 
 
Table 2. Phenotypes of the different otosclerosis loci. HI: hearing impairment; CHI: 
conductive hearing impairment; MHI: mixed hearing impairment; SNHI: sensorineural 
hearing impairment; AC: air-conduction; BC: bone-conduction; ABG: air-bone gap; F: female; 
M: male; SD: standard deviation. 
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Abstract 
Otosclerosis is a common form of hearing loss characterized by a disordered bone 
remodeling in the otic capsule. The abnormal bone remodeling can result in 
conductive hearing loss due to fixation of the stapes footplate. Although its aetiology 
remains unknown, otosclerosis can be considered a complex disease with rare 
monogenic forms. Linkage analysis in large families segregating autosomal 
dominant otosclerosis has led to the identification of 7 loci (OTSC1-5, 7-8).  
However, none of the corresponding genes has been identified, with exception to the 
OTSC2 region, where evidence was found that TCRB is the disease causing gene.  
In this study a new large Dutch otosclerosis family with autosomal dominant 
inheritance was investigated. After exclusion of the known loci, a genome scan was 
performed, which localized the gene on chr1q41-44 with a maximum LOD score of 
3.3. This locus, named OTSC10, has a candidate region of 26.1Mb, which contains 
306 genes/gene predictions. This new gene localization confirms the strong genetic 
heterogeneity of otosclerosis, as until now almost every new large family maps to a 
different locus. As no mutation for monogenic otosclerosis has been identified yet, 
this represents another opportunity to identify the first one. 
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Otosclerosis is a hearing disorder which is associated with disordered bone 
remodeling in the otic capsule. The bone remodeling can lead to conductive, mixed 
or sensorineural hearing loss, as a result of stapes footplate fixation or cochlear 
involvement, respectively. Although its etiology remains unknown, otosclerosis can 
be considered a complex disease with rare monogenic forms. Linkage analysis in 
large families segregating autosomal dominant otosclerosis has led to the 
identification of seven loci (OTSC1–5, 7–8). None of the corresponding genes has 
been identified, but in the OTSC2 region indications have been found that suggest 
TCRB as the causative gene.1 
In this study, a new large Dutch otosclerosis family with autosomal dominant 
inheritance was investigated. (Figure 1) All family members were ascertained 
through the Department of Otorhinolaryngology of the Radboud University 
Nijmegen Medical Centre (The Netherlands). The examination of family members 
included the following: a questionnaire for medical history, pure-tone audiometry 
and otoscopy. Stapedial reflex measurements were done in case of suspicion of 
otosclerosis. Otoscopic examination was performed to rule out other middle ear 
pathology. When immobility of the stapes was confirmed during stapes replacing 
surgery, patients were considered affected. In non-operated persons, patients were 
considered affected when several of the following criteria were met: presence of 
conductive or mixed hearing impairment, air-bone gap (ABG) ≥ 20 decibels (dB) 
averaged across 0.5-2 kHz, absent stapedial reflexes and normal otoscopy. Informed 
consent was obtained from all family members. 
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Figure 1. Pedigree of the Dutch family used to localize OTSC10 to chr1q41–44. The 
haplotypes are given below the symbols and the linked haplotype is shown in black. The two 
recombinant SNPs (marker rs521009 proximally (individual III:9) and rs678004 distally 
(individual IV:1)), genotyped by the Illumina cyto-12 beadchip, are indicated with an 
asterisk. Individuals III:3 and III:14 were not included in the genome scan. A question mark 
(?) indicates individuals with an uncertain diagnosis. ?- indicates individuals with hearing 
impairment abnormal for their age and sex (ISO 7029 standards), but the criteria for 
otosclerosis were not met. Although the hearing loss probably had a different cause, they 
were considered of uncertain diagnosis in the calculations of the LOD scores. The presence 
of otosclerosis was confirmed during surgery in individuals II:5, III:8, III:9 and III:10. In the 
remaining individuals, II:3, III:4 and IV:1, the clinical diagnosis was based on the diagnostic 
criteria and their position in the pedigree. 
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DNA was extracted from blood using standard procedures. Microsatellite markers 
were analyzed that are located in or near the known loci and the OTSC10 region. 
Information on all markers was taken from the NCBI (National Center for 
Biotechnology Information) database (http://www.ncbi.nlm.nih.gov/). Markers 
Chr1M239 and Chr1M245 are not in this database and were developed on the basis 
of the human genome sequence (Human genome build 37) (Table S1). One of the 
polymerase chain reaction (PCR) primers was synthesized with an M13 sequence at 
the 5’ end. PCR amplification was carried out using standard conditions. A 
fluorescently labeled M13 primer was included in the PCR reaction, thus labeling the 
PCR product. Capillary electrophoresis and pattern visualization were performed 
using an ABI 3130XL automatic DNA sequencer (Applied Biosystems Inc., Foster 
City, USA). Allele sizes were determined using the GeneMapper V3.7 software 
(Applied Biosystems Inc., Foster City, USA). 
A genome scan was performed using the HumanCytoSNP-12 BeadChips v2.0 
(Illumina Inc, San Diego, USA), following the manufacturer’s instructions. Individuals 
III:3 and III:14 were not included in the genome scan, but were included for the 
confirmation of linkage and reconstruction of the haplotypes. Fluorescent data was 
imported into Beadstudio version 3.3 for genotype calling (Illumina Inc, San Diego, 
USA).  
For the SNP-based genome search, a subset of 6,000 informative SNPs were selected 
with an average inter-SNP distance of 500 KB. Multipoint linkage analysis was 
performed using SimWalk 2 version 2.91.2  Prior to linkage analysis, unlikely 
genotypes were set to missing using the mistyping option implemented in Simwalk2. 
Data manipulation to obtain the input files for SimWalk 2 was performed using Mega 
2, version 4.2.3 As SimWalk2 uses a non-deterministic algorithm to calculate LOD 
scores, the LOD scores may fluctuate somewhat between runs. Therefore, in the non-
excluded regions the analysis was repeated multiple times using different random 
number seeds and the mean LOD scores were calculated. 
Autosomal dominant inheritance was assumed with a disease frequency of 0.0001. 
Because of the high variability in the onset of hearing loss for otosclerosis,4, 5 linkage 
analysis was performed assuming age dependent liability classes with penetrance 
values of 0.5 and 0.9 for age groups > 55 and < 55 years, respectively. The cut-off 
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value of 55 was chosen because the age of onset for the confirmed patients in the 
family varied from 16 to 51 years. Recombination frequencies were assumed to be 
equal in both females and males, and the phenocopy rate was set at 0. 
A copy number variant (CNV) analysis was done using the data from the 
HumanCytoSNP-12 BeadChips. Intensities were normalized against a reference 
panel of 120 HapMap samples. An in-house developed CNV analysis tool was used to 
detect aberrations (http://medgen.ua.ac.be/cnv/), applying a combination of 3 
Hidden-Markov-Model algorithms (QuantiSNP, PennCNV and VanillaICE ).6-8 In 
addition, the coding regions and intron–exon boundaries of selected genes were 
amplified by a standard PCR reaction. Direct sequencing of the PCR products was 
performed on forward and reverse strands using an ABI 3130XL sequencer with the 
BigDyes Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems Inc.). 
The known otosclerosis loci and the NOG gene (noggin) were excluded for linkage in 
this family by analysis of at least three informative microsatellite markers in each 
region. Linkage to the NOG gene was investigated, because it is involved in 
syndromic cases of stapes fixation.9 Subsequently, a genome wide screen was 
performed. Multipoint linkage analysis revealed only one region with a LOD score 
above 1 and 89% of the genome could be excluded (LOD<−2). This region is 
localized on chr1q41–44 and was confirmed by analysing 27 extra microsatellite 
markers. Multipoint linkage analysis showed a maximum LOD score of 3.3. Figure 1 
shows the reconstructed haplotypes of a subset of the analyzed markers in all family 
members. This locus, named OTSC10, has a candidate region of 26.1 Mb and 
contains 306 genes/gene predictions based on the latest draft of the human genome 
sequence (Build 37.1).  
Thirty-seven of these genes are reported to be expressed in the inner ear and 62 in 
bone tissue.10, 11 The complete OTSC10 region was screened for copy number 
variants (CNVs) on the basis of the SNP microarray, but we could not detect any 
aberration in the linked region in the patients (data not shown). In addition, two 
interesting genes in the region (transforming growth factor beta 2 (TGF-β2) and 
angiotensinogen (AGT)) were selected for mutation analysis by DNA sequencing. 
These genes were selected because of their important role in bone remodeling and 
on the basis of previously found associations with otosclerosis.12-14 All exons and 
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intron–exon boundaries were sequenced in two affected individuals, but no 
pathogenic variant could be identified in both genes. 
Reduced penetrance is common in otosclerosis and has been estimated to be around 
40% on average,15 although this can vary greatly between families. The families 
linked to the earlier reported loci also illustrate a reduced and diverse penetrance.16-
22 In addition, otosclerosis has a varying age of onset, which is usually between 16 
and 50 years, but development at later ages is also possible.23 Both these facts 
suggest that the presence of other modifier factors, such as environment factors 
and/or modifier genes. Reduced penetrance and a varying age of onset is also 
present in this family. (Figure 1) The mean age of onset was 31 years, but this 
ranged between 16 and 51 years. Individuals III:5, III:13, III:15 and III:16 have a 
negative clinical diagnosis, but have inherited the disease haplotype or might carry 
the disease-causing mutation because they have inherited part of the disease 
haplotype. Their ages range from 52 to 57 years, so they might still develop the 
disease, but it is also possible that they will never express it as a result of the 
interference of additional genetic or environmental factors. 
In conclusion, we were able to identify a new locus for otosclerosis on chr1q41–44 
(OTSC10). This new gene localization confirms the strong genetic heterogeneity of 
otosclerosis, as until now almost every new large family maps to a different locus. 
Currently, there is little knowledge on the pathological processes involved in 
otosclerosis. Identification of the first gene for otosclerosis will undoubtedly be an 
important step towards new insights into the pathogenic mechanisms involved in 
the disease. 
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Supplemental table 
 
MarkerID Primer Repeat Position  
(NCBI Build 37, hg19) 
Chr1M239 Forward: 
AGAGAATTGCCTCCCTTTCC 
Reverse: 
CATCAGGTCTGGAACACAGG 
CA repeat chr1:239461688+239461884 
Chr1M245 Forward: 
TAAGCCACAAGCAGCCAAG 
Reverse: 
AATATCTGTCACCCCAAAACG 
CA repeat chr1:245430887+245431134 
 
Table S1. Information on analyzed markers.  
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Discussion and conclusion 
The aim of this thesis was to contribute to our knowledge on genotype-phenotype 
correlations in hereditary hearing impairment. In the chapters of this thesis the 
clinical features of DFNA3, DFNB8/10, DFNX4, Muckle-Wells syndrome (MWS) and 
otosclerosis (OTSC10) families have been described in relation to their genotypes. 
Detailed audiometric analyses of these families have been performed and were 
compared with previously described families in literature.  
Genotype-phenotype correlations 
Identification of the genetic defects underlying hearing impairment gives the 
opportunity to determine genotype-phenotype correlations. Establishing genotype-
phenotype correlations is very important for establishing accurate diagnostic and 
prognostic information, and for genetic counseling. Identification of the mutation 
confirms the genetic cause of the hearing impairment and provides an opportunity 
to estimate the chance that other family members will be affected as well. The 
causative gene, the type of mutation, variants in other genes (modifier genes) 
and/or environmental factors may all contribute to the type of hearing impairment 
and the variation within and among families. Moreover, information on the genetic 
defect can exclude or indicate syndromic forms of hearing impairment. Associated 
symptoms in syndromic hearing impairment can therefore be recognized and 
treated in time, for example in MWS. 
In chapter 2, two small Dutch DFNA3 families with profound sensorineural hearing 
impairment are described. Mutation analysis revealed a p.Argl84Gln and a 
p.Arg75Trp mutation in GJB2 in the two families, respectively. Recently, Huang et al. 
described two DFNA3 patients of two different families carrying the same 
p.Arg184Gln mutation in GJB2. Both patients demonstrated bilateral profound 
sensorineural hearing impairment. The audiogram configuration was flat with pure 
tone thresholds of approximately 100 dB. Temporal bone CT scans showed no inner 
ear abnormalities. Moreover, neither patient had skin problems.1 The phenotype is 
consistent with the previously reported DFNA3 families carrying the p.Arg184Gln 
mutation; prelingual severe to profound sensorineural hearing impairment.1-6  
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The p.Arg75Trp mutation in GJB2 can cause autosomal dominant nonsyndromic 
hearing impairment (DFNA3) as well as syndromic hearing impairment with 
dermatologic features.7 Patients with this mutation exhibit a similar hearing 
impairment phenotype (moderate to severe or profound bilateral sensorineural 
hearing impairment) and a wide range of cutaneous phenotypes. The variations in 
skin alterations associated with the p.Arg75Trp mutation may be due to the 
contribution of genetic background and environmental factors.6, 8  
Previous reports have attempted to address GJB2 genotype-phenotype correlations 
for recessive mutations, but only a few associations have been recognized, probably 
because of the large number of genotypes and the small number of affected 
individuals in most series. Nevertheless, mutations causing an early protein 
truncation can be concluded to cause profound hearing impairment, whereas 
missense mutations were found to have a more variable effect.9-12 Truncating GJB2 
mutations include nonsense, splice and frameshift mutations and result in defective 
protein synthesis.13 The pathogenicity of missense mutations depends on many 
factors, including the position and the nature of the substitution in the protein. 
Because of the complex structure and function of gap junctions, it is extremely 
difficult to predict pathogenicity of some missense mutations.10  The variability in 
phenotype may reflect the effect of modifier genes and/or nongenetic factors that 
lead to incomplete penetrance and variable expression.10, 14 
Detailed phenotypic analyses of eight DFNB8/10 families are described in chapter 3. 
Our analyses suggest that mutations in TMPRSS3 can be classified as mild and severe 
mutations according to their phenotypic effect. Recently, Lee et al. demonstrated six 
TMPRSS3 mutations in ten consanguineous Pakistani families. Four novel variants, of 
which three missense (p.Glu104Lys, p.Ala256Val and p.Cys425Arg) and one 
nonsense (p.Glu104Stop), were identified. Additionally, the previously reported 
deletion c.207delC (p.Thr70fs) was identified in one family and the previously 
reported p.Cys407Arg mutation was found in five families. All affected family 
members demonstrated bilateral severe to profound hearing impairment affecting 
all frequencies. Unfortunately, the age of onset of hearing impairment is not 
reported by Lee et al. and therefore, these mutations cannot be classified as 
relatively mild or severe, resulting in DFNB8 (postlingual hearing impairment) or 
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DFNB10 (prelingual hearing impairment), respectively.15, 16 The deletion c.207delC 
and the p.Cys407Arg mutation have previously been shown to cause severe to 
profound prelingual (DFNB10) hearing impairment. Analysis of more DFNB8/10 
families is necessary to confirm our classification of TMPRSS3 mutations into 
relatively mild and severe and to address whether a subclassification of the 
mutations associated with DFNB8 is possible.  
TMPRSS3 is a type II transmembrane serine protease, consisting of a 
transmembrane domain located near the N-terminus, a low density lipoprotein 
receptor A domain which binds calcium and low density lipoprotein, a scavenger 
receptor cysteine-rich domain that is involved in protein-protein interaction and a 
C-terminal serine protease domain for which the prototype is chymotrypsin. 
TMPRSS3 mutations are found in all functional domains and all tested mutations 
disrupt the proteolytic activity of TMPRSS3.15, 17, 18 The disruption of the proteolytic 
activity of TMPRSS3 is tightly correlated with the pathogenesis of hearing 
impairment. The low-density lipoprotein receptor A domain and the scavenger 
receptor cysteine-rich domain are involved in interactions with extracellular 
molecules. To date, it is unknown how mutations in these domains affect the 
proteolytic activity of TMPRSS3. It may be possible that these domains are necessary 
for proper folding or assembly of the catalytic domain (structural stability) or 
protease substrate recognition and binding.15, 19 Further research is needed to 
establish whether a correlation exists between disease severity and the particular 
domain in which the mutation occurs, the specific residue mutated or the 
conservation of amino acids. 
The establishment of thorough genotype-phenotype correlations is constrained by 
the limited clinical data reported and by the small number of patients in most 
studies. There is no doubt that more clinical data of more patients with hereditary 
hearing impairment need to be published in order to create a more reliable and 
precise phenotype characterization. An Age Related Typical Audiograms (ARTA) 
gives a comprehensive phenotype presentation and can be used to compare the type 
of hearing impairment, the age of onset and the progression of hearing impairment 
in relation to the genotype. Therefore, an ARTA can be helpful in selecting 
potentially interesting loci for linkage analysis or genes for mutation analysis and 
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can be valuable for individual counseling.20 However, intra-familial phenotypic 
variation for a specific genotype is not visible in an ARTA and prediction of the 
phenotypic outcome for individual cases should be made with caution. Moreover, 
mutations in different genes can lead to a very similar ARTA. In that case, additional 
distinguishing phenotypic features are very important, for example additional 
audiometric test results. The program AudioGene can perform automatic 
audioprofile analysis of the audiometrical data of an individual or a family.21 Very 
similar phenotypes of different genotypes and limited clinical data of some 
genotypes limit the genotypic predictions of the programs. Nevertheless, in some 
cases the program was able to predict the correct causative loci or gene.22, 23 
Hearing impairment associated with DFNA3 (OMIM 601544) is more easily to 
recognize because prelingual onset of hearing impairment is rare in autosomal 
dominant nonsyndromic hearing impairment, which is frequently postlingual and 
progressive. DFNA8/12 (OMIM 602574), DFNA19, DFNA23 (OMIM 605192), 
DFNA24 (OMIM 606282) and DFNA59 (OMIM 612642) are other types of autosomal 
dominant nonsyndromic hearing impairment reported to cause early childhood 
onset of hearing impairment. In DFNA3 all frequencies are severely affected, in 
contrast to primarily the mid-frequencies or high-frequencies in DFNA8/12, 
DFNA19, DFNA23 and DFNA24. DFNA59 causes congenital, bilateral, non-
progressive, severe-to-profound sensorineural hearing impairment, similar to 
hearing impairment seen in DFNA3.24 Especially in combination with skin 
abnormalities, DFNA3 should be considered. However, it is not always possible to 
distinguish DFNA3 from DFNA59 based on the phenotype. Moreover, the causative 
gene for DFNA59 has not yet been identified and routine DNA diagnostic screening 
is not possible for DFNA59.24  
In autosomal recessive nonsyndromic hearing impairment postlingual progressive 
hearing impairment is not very common. Many patients with autosomal recessive 
inherited hearing impairment show prelingual severe to profound hearing 
impairment. Postlingual onset of hearing impairment is seen in DFNB4 (OMIM 
600791), DFNB7/11 (OMIM 600974), DFNB8/10 (OMIM 601072), DFNB25 (OMIM 
613285), DFNB30 (OMIM 607101), DFNB77 (OMIM 613079) and DFNB91 (OMIM 
613453). The most common form of inner ear abnormality, namely enlarged 
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vestibular aqueduct (EVA), is associated with mutations in SLC26A4 (DFNB4). The 
characteristic clinical findings include fluctuating and often progressive 
sensorineural hearing impairment, and vestibular symptoms in a minority of 
patients. Radiological examination can confirm the presence of EVA. Hearing 
impairment associated with DFNB25 has a very early postlingual onset and is stable. 
DFNB7/11, DFNB8/10, DFNB30, DFNB77 and DFNB91 patients demonstrate 
progressive severe to profound downsloping hearing impairment with a later 
postlingual onset. In addition, the ski-slope audiogram configuration is suggestive 
for DFNB8. 
TMC1 (DFNB7/11), TMPRSS3 (DFNB8/10), MYO3A (DFNB30), LOXHD1 (DFNB77) 
and SERPINB6 (DFNB91) are all expressed in the inner and/or outer hair cells and 
are essential for their normal function.18, 25-29 Fasquelle et al. developed a Tmprss3 
deficient mouse model. Homozygous mutant mice exhibited severe hearing 
impairment. In situ hybridization localized Tmprss3 mRNA in sensory hair cells in 
the cochlea and the vestibule, in the supporting cells of the organ of Corti and in 
lesser degree in the spiral ganglion cells. Histological examination showed 
degeneration of the organ of Corti in these adult mice after initial normal 
development. Cochlear hair cell degeneration started at the onset of hearing in the 
basal turn and progressed very rapidly toward the apex within two days. 
Otoacoustic emissions were absent in the mice with a homozygous Tmprss3 
mutation, indicating outer hair cell damage. These results suggest that Tmprss3 is 
essential in the functional maturation of cochlear hair cells. Both inner and outer 
hair cells degenerated following the same pattern, suggesting that Tmprss3 function 
is equally important in both hair cell types. Moreover, homozygous mutant mice 
exhibited normal development of ganglion neurons at early postnatal stages, but 
later on progressive loss of ganglion neurons occurred. The stria vascularis of these 
mutant mice showed normal histology and physiology.18 Degeneration of hair cells, 
after initial normal development, could result in the postlingual onset of hearing 
impairment in DFNB8. Mutations in TMC1, LOXHD1 and SERPINB6 also cause 
hearing impairment by progressive hair cell degeneration.26, 28, 29 A common 
pathogenetic pathway may be responsible for hearing impairment in these 
postlingual progressive autosomal recessive hearing disorders, but further research 
is needed to unravel the molecular pathogenesis.   
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A clear-cut genotype-phenotype correlation would enhance straight-forward DNA 
diagnostic screening. Although the intra-familial variation in hereditary hearing 
impairment is high, selective DNA diagnostic screening is already possible for some 
patients with specific phenotypic characteristics, for example skin symptoms, a ski-
slope audiogram configuration or low- or mid-frequency hearing impairment. 
Unfortunately, the presence of specific phenotypic characteristics is no guarantee for 
identification of the genetic defect, because this genetic defect can be in a novel 
deafness gene. There are probably many of these deafness genes yet to be identified. 
For example, we identified compound heterozygous TMPRSS3 mutations in 25% of 
the families with progressive autosomal recessive nonsyndromic sensorineural 
hearing impairment. Since progressive hearing impairment with an autosomal 
recessive mode of inheritance is not common, yet unknown deafness genes are likely 
to be involved in these remaining families. Whole exome sequencing in these 
families would be a good tool to identify these genes. Moreover, genetic 
characterization of families with hereditary hearing impairment can give important 
information about the contribution of specific hearing impairment causing genes in 
the Dutch population and can be helpful to develop a cost-effective strategy for 
routine DNA diagnostics in patient care. 
Hearing rehabilitation 
More elaborate audiometric testing than only pure-tone audiometry and speech 
perception, of patients with hereditary hearing impairment may be helpful to 
predict the outcome of hearing rehabilitation with a hearing aid or a cochlear 
implant. However, there is currently insufficient knowledge to select the best 
rehabilitation method in different forms of hereditary hearing impairment. 
Knowledge about the pathogenesis of hearing impairment may provide important 
information for adequate hearing rehabilitation. Insight in differences in inner ear 
function can be useful to determine the type of sound amplification in hearing aid 
rehabilitation. 
The cause of hearing impairment in MWS is not yet understood, but the basilar 
membrane of the cochlea may be involved in the pathogenesis of hearing 
impairment, as is the case in Alport syndrome.30-32 Muckle and Wells demonstrated 
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ossification of the basilar membranes in patients with MWS.33 Furthermore, 
pathology at the level of the basilar membrane could explain the good speech 
recognition scores seen in the present MWS family and in previously reported 
families with Alport syndrome.31, 32 Results of the audiometric evaluation of the 
present MWS family also indirectly support the hypothesis of improper motion of 
the basilar membrane in patients with MWS. Suprathreshold measurements, 
particularly speech in noise, were preserved rather well and it seems that a defect in 
the basilar membrane results primarily in an attenuation of sound by a shift in the 
operation point of the outer hair cells with near intact function at high levels. This 
preservation of stimulus fine structure at higher levels is also found in conductive 
middle ear hearing impairment. This contrasts to results often found in 
sensorineural hearing impairment, that results from loss of outer and/or inner hair 
cells (e.g. presbycusis, noise induced hearing loss). In conclusion, our results 
indicate that MWS related hearing impairment might be considered as a intra-
cochlear ‘conductive’ hearing impairment, similar to hearing impairment in 
DFNA8/12 and DFNA13.34, 35 
Decreased motion transmission may be a common causative factor in the hearing 
deficits in Alport syndrome and in the type of mid-frequency hearing impairment 
found in DFNA8/12 and DFNA13. In the latter two the loss of transmission occurs 
between the tectorial membrane and the outer hair cells, whereas in the former it 
occurs at the level between the basilar membrane and the organ of Corti. Reduced 
sound transduction results in sound attenuation and in all conditions the proper 
stimulation of outer hair cell motion is jeopardized. Because of the affected 
threshold sensitivity with little suprathreshold consequences in MWS, it is possible 
to successfully rehabilitate hearing in MWS patients with hearing aid amplification. 
The MWS patients described in chapter 5 also demonstrated effective hearing 
rehabilitation with a hearing aid. As long as sounds are presented hard enough, the 
results of speech recognition will be good in MWS patients. Moreover, given the 
good speech recognition scores of the MWS patients, cochlear implantation is not a 
suitable treatment option for these patients. 
Most DFNX4 patients are also not appropriate candidates for cochlear implantation 
because of the good speech recognition scores of these patients. The presence of 
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Smpx in hair cells and supporting cells of the murine cochlea indicates its role in the 
inner ear.36, 37 Moreover, SMPX is associated with the cytoskeleton like many other 
hearing impairment causing genes encoding actin or actin-binding proteins, motor 
proteins of the myosin family or proteins that are otherwise linked to the 
cytoskeleton.38, 39 SMPX is probably involved in the response to mechanical force. 
Therefore, Huebner et al. suggested that the long-term maintenance of mechanically 
stressed inner ear cells critically depends on SMPX function.36 SMPX might also 
contribute to actin turnover and length regulation in stereocilia, as these features 
are closely regulated by extrinsic biomechanical forces.40 However, expression 
studies failed to demonstrate localization of Smpx in the stereocilliar bundles of the 
inner and outer hair cells.36 Despite these indications for the function of SMPX in the 
inner ear, the exact pathogenic mechanism of hearing impairment in DFNX4 is not 
fully understood and further studies are required to determine the best hearing 
rehabilitation method. 
Cochlear implantation has become a common treatment for patients with profound 
hearing impairment. Results of cochlear implantation are highly variable, depending 
on numerous factors, such as onset age of hearing impairment, age at implantation, 
duration of implant use and probably etiology of hearing impairment.41 Neural 
and/or central damage to the auditory system probably gives poorer outcomes after 
cochlear implantation than hearing disorders that primarily affect the hair cells, like 
in many types of hereditary nonsyndromic hearing impairment.42 Cochlear implants 
by-pass the hair cells in the cochlea and stimulate the auditory nerve fibers 
directly.43  
Several studies have investigated the auditory performance after cochlear 
implantation for patients with and without GJB2 mutations, but the overall results 
are inconclusive.44-62 Nevertheless, all the studies demonstrated good results of 
cochlear implantation in patients with GJB2 related hearing impairment and these 
patients can be expected to perform on average. However, cutaneous manifestations 
associated with DFNA3 can pose a major challenge to successful cochlear 
implantation. Eczematous dermatitis constitutes a risk factor for wound healing and 
skin necrosis.63-65 
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Successful rehabilitation with cochlear implants is possible in patients with GJB2 
related hearing impairment because GJB2 mutations do not affect the spiral ganglion 
cells stimulated by the cochlear implant. Histopathologic examination of temporal 
bones associated with GJB2 related hearing impairment revealed preservation of 
spiral ganglion cells.66, 67 Propst et al. performed electrically evoked compound 
action potential testing of the auditory nerve in patients with a cochlear implant and 
demonstrated consistent spiral ganglion cell survival throughout the length of the 
cochlea in the patients with GJB2 related hearing impairment when compared to 
patients with non-GJB2 related hearing impairment.68  
Evaluation of performance of TMPRSS3 patients with a cochlear implant indicated 
that this is a good treatment option for these individuals, as satisfactory speech 
reception was reached after implantation.69 Degeneration of ganglion neurons in 
Tmprss3 deficient mice has been demonstrated and this could result in 
disappointing results after cochlear implantation. However, ganglion degeneration 
occurred after degeneration of hair cells and could be secondary to the pathogenic 
changes in the inner ear.18 Therefore, it might well be important not to postpone 
cochlear implantation too much after it is indicated based on the severity of hearing 
impairment. More research is needed to establish the effect of ganglion neuron 
degeneration on the speech reception after cochlear implantation. 
Before progression of hearing impairment in the low frequencies, TMPRSS3 patients 
seem suitable candidates for an Electric Acoustic System (EAS) to rehabilitate the 
high frequencies. However, considering the progression for the low frequencies, EAS 
is less suitable for DFNB8/10 patients. Therefore, mutations in TMPRSS3 should be 
excluded before considering an EAS in patients with a ski-slope audiogram 
configuration and a possible recessive mode of inheritance. 
Cochlear implantation with a hypo-traumatic electrode (Nucleus 422, Cochlear) is a 
good treatment option for DFNB8/10 patients. This cochlear implant preserves 
residual hearing at the lower frequencies and enables electro-acoustic stimulation 
with a hearing aid. In general, DFNB8 patients have relatively low threshold levels at 
the low-frequencies, but progression of hearing impairment occurs. When electro-
acoustic stimulation becomes insufficient, the hypo-traumatic electrode can take 
over and stimulate the low-frequencies as well.  
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Therapeutic interventions of hearing impairment 
Genotype-phenotype correlations can provide additional insight in the involved 
pathogenic mechanism of hearing impairment. Understanding of the pathogenic 
processes will not only provide important information for rehabilitation but may 
also reveal important targets for prevention and treatment. If the causative genes of 
hearing impairment are not identified, many molecular pathways might remain 
elusive. Additional audiometric evaluation can also contribute to the localization of 
the defect in the inner ear and thereby the identification of the defective protein. 
Defects at particular parts in the inner ear can result in specific phenotypic 
characteristics. The knowledge obtained by genetic studies may also contribute to 
the development of novel gene-specific or mutation-specific therapeutic approaches.  
Besides the disturbed function of the basiliar membrane, inflammatory processes in 
the cochlea and leptomeninges probably also contribute to sensorineural hearing 
impairment in MWS as well.70 The inflammation in the inner ear could also be the 
cause of the basilair membrane dysfunction. Ahmadi et al. demonstrated cochlear 
enhancement on fluid attenuated inversion recovery magnetic resonance imaging 
(FLAIR-MRI) in patients with MWS. Cochlear inflammation was significantly 
associated with hearing impairment.71  
MWS is caused by gain of function mutations in the NLRP3 gene encoding 
cryopyrin.72 Cryopyrin is involved in the assembly of the inflammasome, a 
multiprotein complex implicated in innate immunity. The inflammasome activates 
the caspase-1 enzyme, which in turn cleaves pro-IL-1β and pro-IL-18 into their 
active proinflammatory forms, IL-1β and IL-18.72, 73 The binding of IL-1β to its 
receptor initiates a cascade of signals resulting in early inflammatory responses. The 
balance between IL-1β and its receptor is essential in regulation of proinflammatory 
and anti-inflammatory responses.74 In MWS, cryopyrin-mediated inflammasome and 
caspase-1 activation might cause inappropriate sustained secretion of inflammatory 
cytokines including IL-1β. The overproduction of activated IL-1β can cause chronic 
aseptic meningitis and probably subsequent increased permeability for cytokines 
between perilymph and cerebrospinal fluid via the highly porous modiolus. These 
cytokines can stimulate the spiral ligament fibrocytes to produces additional 
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mediators, that might induce an uncontrolled chronic inflammation responsible for 
cochlear dysfunction and therefore hearing impairment.75 However, hearing 
impairment is also observed in MWS patients without detectable aseptic 
meningitis.71 This suggests that NLRP3 mutations might result in unregulated local 
production of cytokines, such as activated IL-1β, and chronic inflammatory 
responses within the cochlea. Local production of proinflammatory cytokines in the 
spiral ligament, stria vascularis and spiral ganglion neurons after acoustic trauma to 
the cochlea is also demonstrated by Fuijoka et al.76 Improvement of hearing 
impairment by therapy with IL-1 inhibitors in some studies also suggests the 
contribution of a local inflammatory response caused by IL-1β secretion.77-83 
Treatment with IL-1 inhibitors has also proven to be effective in reducing the 
symptoms of systemic inflammation.82-85 Nevertheless, an early diagnosis of MWS is 
essential for an immediate start of treatment to prevent irreversible damage from 
amyloidosis and possibly profound hearing impairment.81 Currently, the expression 
pattern of NLRP3 in the inner ear is not known, but this information could be helpful 
to elucidate the pathogenesis of hearing impairment. 
Therapeutic interventions that block the expression of mutated copies of GJB2 or 
GJB6 genes and thereby prevent the dominant-negative mechanism could 
rehabilitate hearing impairment. Overexpression of Cx26 in the cochlea of Cx30 
deficient mice could prevent hearing impairment by avoiding hair cell death in these 
mice. These results suggest that the function of Cx30 is not essential for normal 
hearing.86 Together with Cx26, Cx30 is probably required for producing sufficient 
quantities of gap junctions in the cochlea, for the initiation and maintenance of the 
endocochlear potential.87 In the early cochlear development, Cx26 is the only gap 
junction protein detected in many key supporting cells in the organ of Corti. Qu et al. 
demonstrated severe hearing impairment in Cx26 deficient mice, regardless of 
whether Cx30 was over-expressed. The essential developmental functions of Cx26 
required for normal hearing is unique and not replaceable by Cx30.88 
Overexpression of Cx26 and its effect on hearing is not yet investigated in humans. 
The OTSC10 locus contains 306 genes/gene predictions. This new locus confirms the 
strong genetic heterogeneity of otosclerosis, as the disease gene in almost every new 
large family maps to a different locus. The identification of the involved genes will 
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help to elucidate the pathophysiology of otosclerosis at a molecular level and may 
provide possible targets for prevention, diagnosis and therapy of this disease. 
Furthermore, insight into the natural course of the various phenotypes of 
otosclerosis may provide the opportunity for a proper evaluation of the efficacy of 
current and future therapies. Two interesting genes in the region, transforming 
growth factor beta 2 (TGF-β2) and angiotensinogen (AGT), were selected for 
mutation analysis by DNA sequencing. These genes were selected because of their 
important role in bone remodeling and on the basis of previously found associations 
with otosclerosis.89-91 
The first gene, TGF-β2, plays an important role in the chondrogenesis of the otic 
capsule.92 Members of the transforming growth factor-β (TGF-β) superfamily, 
including TGF-bs, bone morphogenetic proteins (BMPs) and activins, are 
fundamental in the process of bone remodeling. The related TGF-β1 has been 
demonstrated to be associated with otosclerosis. TGF-β1 contributes to the 
embryonic development of the otic capsule. In early stages, the otic epithelium 
produces TGF-β1 to stimulate the chondrogenesis and to promote growth. Later on, 
TGF-β1 selectively inhibits this process to allow capsular modeling. In human 
otosclerotic bone cell cultures, TGF-β1 can modify the expression of 
glycosaminoglycan (GAG), fibronectin and collagen of the extracellular matrix.92 The 
variant T263I of TGF-β1 is biologically more active by inducing transcription of the 
TGF-β1 receptor gene. This variant decreases the susceptibility to otosclerosis by 
inhibiting osteoclast differentiation and activation in the first otospongiotic phase of 
otosclerosis. This variant has been found to be under-represented in otosclerosis 
patients.89, 93, 94 Thus, TGF-β1 may be involved in the pathogenesis of otosclerosis by 
modulating extracellular matrix production.95 Camurati-Engelmann disease (CED) 
or progressive diaphyseal dysplasia is also caused by mutations in TGF-β1. CED is 
very rare sclerosing bone dysplasia characterized by a rapid bone turnover. Some of 
the CED patients demonstrated stapes fixation at stapes surgery. Therefore, some 
researchers suggested that otosclerosis could be part of the CED phenotype.96, 97 
Furthermore, inhibition of extracellular matrix in cell cultures is possible with a 
novel inhibitor of the TGF-type I receptor kinase activity: SB-431542. A concern with 
kinase inhibitors is nonspecific toxicity caused by inhibition of important but 
unrelated kinases.98 Furthermore, neutralizing antibodies against TGF-β1 can 
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prevent the accumulation of extracellular matrix in kidneys and lungs of rodents.99-
101 Applicability of TGF-β1 inhibitor or antibodies in humans has still to be 
investigated.  
The second gene, AGT, encodes the protein angiotensinogen which is cleaved by the 
enzyme renin and angiotensin converting enzyme (ACE) to generate the 
physiologically active enzyme angiotensin II (AT-II). This renin-angiotensin-
aldosterone system (RAAS) is important in the regulation of blood pressure and 
body-fluid homeostasis, but AT-II can also influence bone remodeling. Furthermore, 
the plasma levels of angiotensin (AGT) rise during pregnancy and the RAAS is 
activated. This might explain why hearing impairment in otosclerosis often 
manifests or progresses during pregnancy. Genetic variants in AGT and ACE were 
previously found to be associated with otosclerosis, although the results were 
contradictory and could not be replicated in another study. A genetic variant of AGT 
has been associated with higher plasma AGT concentrations and a genetic variant of 
ACE with increased enzymatic activity of ACE. These variants were demonstrated to 
be over-represented in otosclerosis patients.90, 91, 95, 97, 102-104 ACE-inhibitors and AT-
II receptor inhibitors are used primarily for the treatment of hypertension and 
congestive heart failure. These drugs are interesting candidate drugs for treating 
otosclerosis as well. Further research is needed to determine the efficacy of such 
therapeutic treatments.105   
Unfortunately, DNA sequencing of the coding region of these two candidate genes in 
the OTSC10 region did not reveal a causative mutation in the present otosclerosis 
family.103 However, introns and regulatory sequences of these genes were not 
sequenced and the involvement of these genes in the present otosclerosis family 
cannot be completely excluded.  
Future perspectives and general considerations 
Hearing impairment is the most common birth defect and the most prevalent 
sensorineural disorder in developed countries. Moderate or more severe hearing 
impairment has a negative impact on speech, language and cognitive 
development.106 Therefore, universal newborn hearing screening is very important 
for early identification and management of hearing impairment in infants.107 
However, children with mild, progressive or later onset hearing impairment will be 
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missed with the newborn hearing screening.108, 109 Nevertheless, mild bilateral 
sensorineural hearing impairment might also have a negative impact on school 
performance and early intervention, and speech and language monitoring are 
recommended.110 Importantly, the underlying cause is not addressed with the 
newborn hearing screening. More than 50% of childhood sensorineural hearing 
impairment is caused by genetic factors and some of the involved genes are 
associated with mild and/or progressive hearing impairment.111 Regular 
audiometric evaluation is necessary for infants who are at risk for progressive or 
later onset hearing impairment. Long-term follow-up of these children might 
provide insight into the development of hearing impairment associated with specific 
gene mutations. Knowledge of individual genes involved in hearing impairment has 
already been used successfully in patient treatment, management and genetic 
counseling. In the future, newborn genetic screening may be helpful in identifying 
groups of children with an increased risk of developing sensorineural hearing 
impairment. However, the discussion with regard to the ethical issues and cost-
effectiveness of this type of genetic screening have to take place.112 
Unfortunately, genetic counseling is still problematic, mainly because of the large 
number of genes involved in hereditary hearing impairment. In the majority of cases 
the question on the cause of hearing impairment cannot be answered and no proper 
counseling can be given. However, with the use of whole exome sequencing by next-
generation sequencing (NGS) techniques, it is possible to obtain high-quality nucleic 
acid sequence data of whole exomes in a cost effective manner and in short period of 
time.113 NGS can identify disease causing genes in rare genetic disorders with even a 
limited number of patients samples. The sensitivity, specificity and reproducibility 
of NGS in hearing impairment is high, however, interpretation of the functional 
effect of the large amount of DNA variants is challenging. Whole exome sequencing 
by NGS can be used as a diagnostic test in hearing impairment.114, 115 However, its 
applicability in patient care is still limited. Whole exome sequencing by NGS can lead 
to the discovery of new deafness genes. Especially for these novel deafness genes, 
but also for some known deafness genes, there is insufficient phenotypic 
information available. Therefore, it is currently not always possible to provide 
satisfactory prognostic information. More phenotypic data need to be collected for 
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adequate counseling, especially because of the variation in phenotype associated 
with different defects in a specific gene or even with the same genetic defect. The 
creation of an elaborate database for the association of clinical data and the variant 
identified in the exome would be valuable. In the future, improved applications of 
NGS may help define genetic profiles of patients and contribute to personalized 
medicine.113  
In conclusion, describing large groups of patients with hereditary hearing 
impairment is, next to accurate genetic counseling of patients, also very important 
for the discovery of new deafness causing genes, for the development of routine 
DNA-diagnostics of hereditary hearing impairment and for understanding the 
(dys)function of the inner ear. In the future, novel treatment strategies like drug 
therapy, hair cell regeneration or gene therapy may be introduced in clinical 
practice. For the development of gene-specific or mutation-specific treatment 
strategies in the future, it is essential to identify the genetic defects in patients with 
hereditary hearing impairment. Moreover, for accurate evaluation of these 
treatment strategies on restoring hearing and/or preventing hearing impairment, 
elaborate genotype-phenotype correlations are necessary. At present, genotype-
phenotype correlations are mainly used for counseling of family members with 
hereditary hearing impairment. 
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Summary 
In chapter 1 of this thesis a general introduction of hereditary hearing impairment 
with special attention for otosclerosis is provided. 
Chapter 2 provides a detailed phenotypic description of three DFNA3 patients from 
two families. Mutation analyses revealed a p.Argl84Gln mutation in GJB2 in family 1 
and a p.Arg75Trp mutation in GJB2 in family 2. No mutations in GJB6 were identified. 
All three patients had severe to profound sensorineural hearing impairment. 
Vestibular function tests and computed tomographic scans yielded normal findings 
in the examined subjects. Cochlear implantation was performed in two patients, and 
their phoneme recognition scores were good.  
A thorough genotype-phenotype correlation is difficult because of the small number 
of patients and the limited available clinical data. More clinical data of DFNA3 
families need to be obtained in order to create a reliable and precise phenotype 
characterization. 
Detailed phenotypic analyses of eight DFNB8/10 families are described in chapter 3. 
The compound heterozygous variants in the TMPRSS3 gene in the present families 
included one novel variant, p.Val199Met, and four previously described pathogenic 
variants, p.Ala306Thr, p.Thr70fs, p.Ala138Glu and p.Cys107Xfs. In addition, the 
p.Ala426Thr variant, which had previously been reported as a possible benign 
polymorphism, was found in one family. All affected family members reported 
progressive bilateral hearing impairment, with variable onset ages and progression 
rates. In general, the hearing impairment affected the high frequencies first, and 
sooner or later, depending on the mutation, the low frequencies started to 
deteriorate which finally resulted in a flat audiogram configuration. The ski-slope 
audiogram configuration is suggestive for the involvement of TMPRSS3. In patients 
with progressive hearing impairment and a possible autosomal recessive mode of 
inheritance, TMPRSS3 mutations should be considered. Evaluation of performance of 
patients with a cochlear implant indicated that this is a good treatment option for 
patients with TMPRSS3 mutations as satisfactory speech reception was observed 
after implantation. 
CHAPTER 8 
244 
 
Our analyses suggest that mutations in TMPRSS3 can be classified as mild and severe 
according to their phenotypic effect. Additional studies are needed to further 
distinguish possible phenotypic differences between different TMPRSS3 mutations.  
In chapters 4.1 and 4.2, the clinical and genetic characteristics of a large Dutch 
DFNX4 family are presented. Next-generation sequencing detected one variant 
within the linkage interval, a novel c.214G>T nonsense mutation (p.Glu72X) in 
SMPX. All 25 mutation carriers exhibited hearing impairment, except one woman 
aged 25 years. The age of onset according to history was 2-10 years (mean: 3,3 
years) in men and 3-48 years (mean: 26,4 years) in women. Men showed more 
severe hearing impairment at a younger age with more pronounced progression 
during the first two decades of life, especially at the higher frequencies, while 
women demonstrated less severe hearing impairment with more gradual 
progression and a wider variation in age of onset, degree of hearing impairment and 
inter-aural asymmetry in thresholds, especially at 2-8 kHz. Longitudinal linear 
regression analysis demonstrated significant progression of at least two frequencies 
in five individuals (3 men and 2 women). Speech recognition in men and women was 
remarkably well preserved.  
The phenotype of the present family is largely similar to the phenotype of the 
previously described DFNX4 families. However, subtle differences in onset age and 
rate of progression of hearing impairment seem to exist and might be caused by the 
different mutations in SMPX. However, a thorough genotype-phenotype analysis of 
DFNX4 requires more data on DFNX4 families harbouring different SMPX mutations. 
Moreover, the phenotypic heterogeneity in females was remarkable which is 
probably related to random X-inactivation in female mutation carriers. 
The phenotype of a Dutch family with Muckle-Wells syndrome (MWS) caused by a 
novel p.Tyr859His mutation in the NLRP3 gene is described in chapter 5. Most 
affected family members reported bilateral, slowly progressive hearing impairment 
since childhood. Hearing impairment started at the high frequencies and the low- 
and mid-frequency threshold values deteriorated with advancing age. Annual 
threshold deterioration ranged from 1.3 to 1.9 dB/year with the highest values at 
the lower frequencies. Longitudinal linear regression analysis demonstrated 
significant progression for a number of frequencies in five individuals. Speech 
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recognition scores were clearly affected. However, these individuals tended to have 
higher speech recognition scores than presbycusis patients at similar PTA1,2,4 kHz 
levels. The loudness growth curves were steeper than those found in individuals 
with normal hearing, except for one family member (individual IV:6). 
Suprathreshold measurements, such as difference limen for frequency, gap detection 
and particularly speech perception in noise were within the normal range or at least 
close to data obtained in two groups of patients with a so-called conductive type of 
hearing loss, situated in the cochlea.  
Hearing impairment in MWS is variable and shows resemblance to previously 
described intra-cochlear conductive hearing impairment. The cause of hearing 
impairment in MWS is not yet understood, but the basilar membrane of the cochlea 
might be involved in the pathogenesis of hearing impairment. 
In every patient with sensorineural hearing impairment in combination with skin 
rash and musculoskeletal symptoms, MWS should be considered. However, these 
symptoms can be mild and nonspecific, as was the case in the present family. 
Therefore, the diagnosis of MWS can be easily missed. Unfortunately, an early 
diagnosis of MWS is essential to prevent irreversible damage from amyloidosis. 
Treatment with the IL-1β inhibitors has proven to be effective in reducing the 
symptoms of systemic inflammation. The effect on hearing impairment is more 
controversial, but an early start of treatment seems to be essential.  
Otosclerosis is subject of chapter 6. Detailed analysis of audiometric data from a 
Dutch otosclerosis family in which the disease is linked to OTSC10, are presented in 
chapter 6.1. The genetic analysis of this family is provided in chapter 6.2. After 
exclusion of the known loci, a genome scan was performed which localized the gene 
to chr1q41-44 with a maximum LOD score of 3.3. This locus, named OTSC10, is 
26.1Mb in size and contains 306 genes. Eleven family members were identified to be 
clinically affected and they were all carriers of the disease haplotype. Twelve 
unaffected family members carried the disease haplotype as well. Cross-sectional 
analyses of affected family members showed no significant progression of air-
conduction (AC) thresholds, bone-conduction (BC) thresholds, and air-bone gap 
(ABG) levels with increasing age. Longitudinal regression analyses in one family 
member revealed significant deterioration of AC thresholds at all frequencies. The 
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BC thresholds showed a significant increase with advancing age at 0.5 kHz, 2 kHz 
and 4 kHz. A significant progression of the ABG was seen at 8 kHz. The progressive 
conductive hearing impairment in this family member stabilized around the third 
decade with ABG levels of 50 dB, and later a progressive sensorineural component 
developed. 
The intersubject variation, in terms of age of onset, level of progression and 
audiogram configuration was remarkable, probably due to reduced penetrance and 
variable expression of the disease. Long-term audiometric data in one patient, 
however, were suitable to demonstrate progression of hearing impairment. There is 
no doubt that additional, similar studies are needed to be able to distinguish 
possible phenotypic differences between different genetic types of otosclerosis. 
Genotype-phenotype correlation studies may also help to elucidate the 
pathophysiology of otosclerosis at a molecular level and may provide possible 
targets for prevention, diagnosis and therapy of this disease. Furthermore, insight 
into the natural course of the various phenotypes of otosclerosis may provide the 
opportunity for a proper evaluation of the efficacy of current and future therapies. 
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Samenvatting 
In hoofdstuk 1 van dit proefschrift wordt een algemene inleiding over erfelijke 
slechthorendheid en otosclerose gegeven. 
Hoofdstuk 2 geeft een gedetailleerde beschrijving van het fenotype van drie DFNA3 
patiënten uit twee families. Mutatie-analyse toonde een p.Argl84Gln mutatie in GJB2 
in familie 1 en een p.Arg75Trp mutatie in GJB2 in familie 2. Mutaties in GJB6 werden 
niet geïdentificeerd. Alle drie de patiënten hadden ernstig tot zeer ernstig perceptief 
gehoorverlies. Vestibulaire functie testen en computertomografie (CT) scans gaven 
normale bevindingen in de onderzochte familieleden. Twee patiënten kregen een 
cochleair implantaat en hun foneemscores waren goed. 
Een gedetailleerde genotype-fenotype correlatie is moeilijk vast te stellen vanwege 
het kleine aantal DFNA3 patiënten en de beperkte klinische gegevens van deze 
patiënten. Meer klinische gegevens van DFNA3 families zijn nodig om een 
betrouwbare en nauwkeurige karakterisering van het fenotype te kunnen geven. 
Hoofdstuk 3 geeft gedetailleerde fenotypische beschrijvingen van acht DFNB8/10 
families. De mutaties in het TMPRSS3 gen in deze families betreffen een nieuwe 
mutatie, p.Val199Met, en vier eerder beschreven pathogene mutaties, p.Ala306Thr, 
p.Thr70fs, p.Ala138Glu en p.Cys107Xfs. Bovendien werd de p.Ala426Thr variant, die 
eerder is beschreven als een mogelijk polymorfisme, aangetoond in een familie. Alle 
aangedane familieleden hadden een bilaterale slechthorendheid met een variabele 
beginleeftijd en een variabele progressie van het gehoorverlies. In het algemeen zijn 
de gehoordrempels van de hoge frequenties als eerste toegenomen. Vroeger of later, 
afhankelijk van de mutatie, zullen ook de gehoordrempels van de lage frequenties 
verslechteren, uiteindelijk resulterend in een vlak audiogram. Het audiogram met 
een ski-hellingconfiguratie is suggestief voor betrokkenheid van TMPRSS3. Bij 
patiënten met een progressief gehoorverlies van de hoge tonen en een mogelijke 
autosomaal recessieve overerving, moeten TMPRSS3 mutaties worden overwogen 
als oorzaak. Evaluatie van de resultaten van patiënten met een cochleair implantaat 
geven aan dat dit een goede behandelingsoptie is voor patiënten met TMPRSS3 
mutaties, aangezien na implantatie een goed spraakverstaan werd waargenomen. 
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Onze analyses suggereren dat mutaties in TMPRSS3 waarschijnlijk geclassificeerd 
kunnen worden als milde of ernstige mutaties. Aanvullende studies zijn nodig om 
mogelijk kleinere verschillen in het fenotype voor verschillende TMPRSS3 mutaties 
te onderscheiden. 
In de hoofdstukken 4.1 en 4.2, zijn de klinische en genetische kenmerken van een 
grote Nederlandse DFNX4 familie gepresenteerd. Met next-generation sequencing 
van alle genen op het X-chromosoom is de c.214G>T nonsense-mutatie (p.Glu72X) in 
SMPX aangetoond. Alle 25 mutatiedragers waren slechthorend, met uitzondering 
van een 25-jarige vrouw. De subjectieve beginleeftijd van het gehoorverlies was 2-
10 jaar (gemiddeld: 3,3 jaar) voor mannen en 3-48 jaar (gemiddeld: 26,4 jaar) voor 
vrouwen. De mannen hadden al op jonge leeftijd een ernstig gehoorverlies met meer 
uitgesproken progressie van vooral de hoge frequenties tijdens de eerste twee 
decennia. Bij vrouwen daarentegen was de slechthorendheid minder ernstig met 
meer geleidelijke progressie en een grotere spreiding in beginleeftijd, in ernst van 
het gehoorverlies en in interaurale verschillen in drempels, in het bijzonder bij 2-8 
kHz. Longitudinale lineaire regressie-analyse toonde een significante progressie van 
het gehoorverlies voor tenminste twee frequenties in vijf personen (3 mannen en 2 
vrouwen). Het spraakverstaan van mannen en vrouwen was opmerkelijk goed. 
Het fenotype van de huidige familie komt grotendeels overeen met het fenotype van 
de eerder beschreven DFNX4 families. Echter, subtiele verschillen in beginleeftijd en 
progressie van het gehoorverlies bestaan en kunnen worden veroorzaakt door de 
verschillende mutaties in SMPX. Voor een uitvoerige genotype-fenotype analyse van 
DFNX4 zijn meer gegevens van DFNX4 families met verschillende SMPX mutaties 
nodig. Bovendien is de heterogeniteit van het fenotype bij vrouwen opmerkelijk. Dit 
wordt waarschijnlijk veroorzaakt door X-inactivatie in vrouwelijke mutatiedragers. 
Het fenotype van een Nederlandse familie met het Muckle-Wells syndroom (MWS), 
veroorzaakt door een nieuwe p.Tyr859His mutatie in het NLRP3 gen, is beschreven 
in hoofdstuk 5. De meeste aangedane familieleden vermelden bilaterale, langzaam 
progressieve slechthorendheid sinds kinderleeftijd. Het gehoorverlies begon bij de 
hoge frequenties en met het toenemen van de leeftijd verslechterden ook de 
gehoordrempels van de lage en midden frequenties. Het gehoorverlies nam toe met 
1,3 tot 1,9 dB per jaar, met de grootste achteruitgang voor de lage frequenties. 
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Longitudinale lineaire regressie-analyse toonde een significante progressie van het 
gehoorverlies voor een aantal frequenties in vijf personen. Spraakverstaanscores 
van de aangedane familieleden waren duidelijk verminderd. Echter, de familieleden 
hadden hogere spraakverstaanscores dan presbyacusispatiënten bij vergelijkbare 
PTA1,2,4 kHz waarden. De luidheidsgroeicurven van de aangedane familieleden waren 
steiler dan de curven van personen met een normaal gehoor, met uitzondering van 
één familielid (individu IV: 6). Bovendrempelige metingen, zoals detectie van het 
verschil in frequentie, detectie van pauze of stilte tussen twee tonen en in het 
bijzonder spraakverstaan-in-ruis waren binnen het normale bereik en vergelijkbaar 
met de resultaten van twee groepen patiënten met een zogenaamd geleidingsverlies 
gelegen in de cochlea. 
Het gehoorverlies in MWS is variabel en toont gelijkenis met het eerder beschreven 
intracochleair conductief gehoorverlies. De oorzaak van het gehoorverlies in MWS is 
nog niet duidelijk, maar het basilair membraan in de cochlea is mogelijk betrokken 
bij de pathogenese van slechthorendheid. 
In elke patiënt met perceptief gehoorverlies in combinatie met huiduitslag en spier- 
en gewrichtsklachten moet MWS worden overwogen. Echter, deze symptomen 
kunnen mild en aspecifiek zijn, zoals het geval was in deze MWS familie. Derhalve 
kan de diagnose MWS gemakkelijk gemist worden, terwijl een vroege diagnose 
essentieel is voor het voorkomen van irreversibele schade ten gevolg van 
amyloïdose. Behandeling met IL-1β remmers is bewezen effectief voor het 
verminderen van de symptomen van ontsteking. Het effect op de slechthorendheid 
is meer controversieel, maar een vroege start van de behandeling lijkt van essentieel 
belang. 
Otosclerose is het onderwerp van hoofdstuk 6. Een uitgebreide analyse van de 
audiometrische gegevens van een Nederlandse otosclerose familie, met genetische 
koppeling met het OTSC10 locus, is gepresenteerd in hoofdstuk 6.1. De genetische 
analyse van deze familie is beschreven in hoofdstuk 6.2. Na het uitsluiten van 
koppeling met bekende loci, werd een genoomscan uitgevoerd, waarbij het gen voor 
deze familie gelokaliseerd werd op chr1q41-44 met een maximale LOD score van 
3.3. Dit locus, genaamd OTSC10, is 26.1Mb groot en bevat 306 genen. Elf 
familieleden werden geïdentificeerd als klinisch aangedaan en deze familieleden 
CHAPTER 8 
250 
 
waren allemaal drager van het otosclerose veroorzakende haplotype. Twaalf niet 
aangedane familieleden waren eveneens drager van het haplotype dat otosclerose 
kan veroorzaken. Cross-sectionele analyses van de audiometrische gegevens van de 
aangedane familieleden toonden geen significante progressie van de 
luchtgeleidingsdrempels, beengeleidingsdrempels en air-bone gap (ABG) met 
toenemende leeftijd. Longitudinale regressie-analyses van de audiometrische 
gegevens van één aangedaan familielid gaf wel een significante progressie van de 
luchtgeleidingsdrempels over alle frequenties. De beengeleidingsdrempels toonden 
een significante toename met de leeftijd bij 0,5 kHz, 2 kHz en 4 kHz. Een significante 
progressie van de ABG werd vastgesteld bij 8 kHz. Het progressieve conductieve 
gehoorverlies stabiliseerde rond het derde decennium met een ABG van 50 dB en 
later ontwikkelde zich een progressieve perceptieve component. 
De interindividuele variatie wat betreft de beginleeftijd, de mate van progressie en 
de audiogramconfiguratie was opmerkelijk. Waarschijnlijk wordt deze variatie 
veroorzaakt door de verminderde penetrantie en de variabele expressie van de 
ziekte. Longitudinale audiometrische gegevens van een patiënt zijn bruikbaar om de 
progressie van het gehoorverlies te bepalen. Er is geen twijfel mogelijk dat 
aanvullende, soortgelijke, studies nodig zijn om mogelijke fenotypische variaties 
tussen de verschillende genetische typen van otosclerose te kunnen onderscheiden. 
Genotype-fenotype studies kunnen ook bijdragen aan de ontrafeling van de 
pathofysiologie van otosclerose op moleculair niveau en kunnen mogelijke 
aanknopingspunten voor preventie, diagnose en therapie van deze ziekte aan het 
licht brengen. Bovendien kan inzicht in het natuurlijke beloop van de verschillende 
fenotypen de mogelijkheid bieden tot het verrichten van een goede evaluatie van de 
effectiviteit van huidige en toekomstige therapieën. 
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List of abbreviations 
ABG  air-bone gap 
AC  air-conduction 
ACE  angiotensin converting enzyme 
AGT  angiotensin 
ARHI  age-related hearing impairment 
ARMS  amplification refractory mutation system 
arNSHI  autosomal recessive nonsyndromic hearing impairment 
ARTA  age-related typical audiogram 
AT-II  angiotensin II 
ATD  annual threshold deterioration 
ATP  adenosine triphosphate 
AUNA  auditory neuropathy 
BAHA  bone-anchored hearing aid 
BC  bone-conduction 
BERA  brainstem evoked response audiometry 
BMI  body mass index 
BMP  bone morphogenetic protein 
BOR  branchio-otorenal syndrome 
BPPV  benign paroxysmal positional vertigo 
CAPS  cryopyrin-associated periodic fever syndromes 
CED  Camurati-Engelmann disease 
CHI  conductive hearing impairment 
CI  cochlear implant 
CINCA  chronic infantile neurologic cutaneous and articular 
CNV  copy number variant 
CT  computed tomography 
Cx26  connexin 26 
Cx30  connexin 30 
dB  decibel 
DDST  diastrophic dysplasia sulfate transporter 
DFN  deafness 
DFNA  autosomal dominant nonsyndromic hearing impairment 
DFNB  autosomal recessive nonsyndromic hearing impairment 
DFNM  modifier gene locus for nonsyndromic hearing impairment 
DFNX  X-linked nonsyndromic hearing impairment 
DFNY  Y-linked nonsyndromic hearing impairment 
DLf  difference limen for frequency 
DNA  deoxyribonucleic acid 
EAS  electric acoustic system 
EGF  epidermal growth factor 
FCAS  familial cold autoinflammatory syndrome 
FLAIR  fluid attenuated inversion recovery 
GAG  glycosaminoglycan 
GJB2  gap junction protein beta 2 
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GJB6  gap junction protein beta 6 
HI  hearing impairment 
HL  hearing level 
HLA  human leukocyte antigen 
I-A  inter-aural 
IGF-1  insulin-like growth factor-1 
IL  interleukin 
LOD  limit of detection 
LRR  leucin-rich repeats 
MAGUK membrane-associated guanylate kinase 
MHC  major histocompatibility complex 
MHI  mixed hearing impairment 
MRI  magnetic resonance imaging 
MWS  Muckle-Wells syndrome 
NBS  nucleotide binding site 
NGS  next generation sequencing 
NSHI  nonsyndromic hearing impairment 
OAE  otoacoustic emissions 
OPG-Fc  short-term recombinant osteoprotegerin 
OTSC  otosclerosis 
PCR  polymerase chain reaction 
PEST  proline glutamic acid, serine and threonine-rich 
PTA  pure tone average 
RAAS  rennin-angiotensin-aldosterone-system 
RANK  receptor activator of nuclear factor κ B 
RANKL  receptor activator of nuclear factor κ B ligand 
RNA  ribonucleic acid 
S  significant 
SD  standard deviation 
SNHI  sensorineural hearing impairment 
SNP  single nucleotide polymorphism 
SPL  sound pressure level 
SRCR  scavenger receptor cysteine-rich 
SRT  speech reception threshold 
TCR  T-cell receptor 
TGF  transforming growth factor 
TMPRSS3 transmembrane protease serine 3 
TORCH  toxoplasmosis, other infections (e.g. syphilis), rubella, cytomegalovirus, 
herpes 
TRB  T-cell receptor beta locus 
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Dankwoord 
En dan nu het meest gelezen hoofdstuk van dit proefschrift! Promoveren doe je 
zeker niet alleen. Zonder hulp van vele anderen was dit proefschrift nooit tot stand 
gekomen. Graag wil ik afsluiten met mijn woorden van dank aan de vele mensen die 
hebben bijgedragen aan dit proefschrift. 
Ten eerste wil ik alle familieleden, die vrijwillig hebben meegewerkt aan dit 
onderzoek, bedanken voor hun enthousiaste deelname. Hartelijk dank voor jullie 
hulp bij het opstellen van de uitgebreide familiestambomen. Velen van jullie hebben 
ontelbare kilometers afgelegd om in Nijmegen ‘de familiedag’ bij te wonen. Zonder 
jullie had ik dit proefschrift niet kunnen schrijven.   
Dr. H.P.M. Kunst, beste Dirk, dank voor jouw enorme vertrouwen in mij en alle 
kansen die je mij hebt gegeven! Jij gaf mij de mogelijkheid om een wetenschappelijke 
stage over erfelijke slechthorendheid te volbrengen en dankzij jou heb ik het 
onderzoek kunnen voortzetten in een promotietraject. De manier waarop jij mij de 
afgelopen jaren hebt begeleid, heb ik vanaf het begin als zeer prettig ervaren. Altijd 
kon ik met jou overleggen. Ik begrijp nog steeds niet waar je de tijd vandaan haalde! 
Jouw commentaren en adviezen waren verhelderd en aanmoedigend. Maar ik kon 
ook bij jou terecht met mijn frustraties als ik het even niet meer zag zitten. Vooral 
jouw opportunisme en loyaliteit zijn bewonderenswaardig. Ik wil je hartelijk danken 
voor jouw steun en inspanningen, niet alleen met betrekking tot dit proefschrift! 
Prof. dr. J.M.J. Kremer, beste Hannie, jij bent een grote steun voor mij geweest. Jij 
hebt mij geïntroduceerd in de wondere wereld van de genetica. Jouw kritische 
commentaren hebben een belangrijke bijdrage geleverd aan de inhoud van dit 
proefschrift. Jij wist mij te inspireren en te stimuleren met jouw opbouwende 
kritieken. Enorm bedankt voor je hulp, begeleiding en vriendschap! Ik vind het een 
eer om jouw promovendus te zijn. 
Prof. dr. C.W.R.J. Cremers, beste professor, ons eerste gesprek over een familie met 
erfelijke slechthorendheid kan ik mij nog goed herinneren. Dit gesprek bevestigde 
mijn enthousiasme voor de KNO. Ik heb bewondering voor uw visie, inzet en 
begeleiding. Uw uitgebreide ervaring als promotor heeft mij zeer geholpen bij de 
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succesvolle afronding van dit proefschrift. Ook tijdens de familiedagen was u altijd 
bereid om mee te helpen. U wist mij elke keer weer te verbazen met de snelle 
correctie van de stukken. Veel dank voor alles!  
Dr. P.L.M. Huygen, beste Patrick, jouw wetenschappelijke kennis heeft een essentiële 
bijdrage geleverd aan deze promotie. Het was mij een genoegen om samen te 
brainstormen over de statistische analyses. Dankzij jou is mijn statistische kennis 
significant toegenomen! Geweldig dat jouw deur altijd open stond en ik altijd even 
binnen kon lopen. Ik hoop dat nog velen van jouw unieke kwaliteiten en creativiteit 
mogen genieten. Hartelijk bedankt voor jouw betrokkenheid en fijne gezelschap! 
Dr. R.J.E. Pennings en dr. R.J.C. Admiraal, beste Ronald en Ronald, dankbaar heb ik de 
afgelopen jaren gebruik gemaakt van jullie otogenetische kennis en ervaring. 
Bedankt voor jullie begeleiding, maar vooral voor de plezierige samenwerking! Ik 
waardeer jullie oprechte interesse en belangstelling enorm. Geweldig dat ik altijd op 
jullie steun kon rekenen! 
Prof. dr. G. van Camp en dr. I. Schrauwen, beste Guy en Isabelle, hartelijk dank voor 
de fijne samenwerking die heeft geleid tot de hoofdstukken 6.1 en 6.2. In zekere zin 
waren wij afhankelijk van elkaars data. Bedankt voor de onmisbare genetische 
inbreng. Ik bewonder de onderzoeksresultaten die jullie hebben bereikt en ik ben 
trots dat ik daaraan heb mogen bijdragen. Bedankt voor jullie hulp! Ik wens jullie 
beiden enorm veel succes met jullie verdere carrières. 
Beste medewerkers van de afdeling antropogenetica, Margit Schraders, Jaap Oostrik, 
Lies Hoefsloot en Saskia ver der Velde, bedankt voor alle analyses van de genetische 
data. Ik heb onze samenwerking altijd als zeer prettig ervaren. Beste Margit, in het 
bijzonder bedankt voor de uiterst aangename besprekingen van de vele families en 
het goede overleg tijdens het schrijven van de artikelen. Jouw continue inzet en ijver 
werkten aanstekelijk. Beste Saskia van der Velde, ik wil je in het bijzonder bedanken 
voor de goede logistieke organisatie van de bloedmonsters. We vormden een goed 
team!   
Beste medewerkers van het audiologisch centrum, bedankt voor jullie bereidheid 
om op zaterdagen de audiologische onderzoeken te verrichten. De vele uitgebreide 
meting bij patiënten waren essentieel voor dit proefschrift. Tijdens de familiedagen 
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kon ik altijd op jullie rekenen. Dank voor jullie inzet! Beste Ad Snik en Joop 
Leijendeckers, bijzonder dank voor jullie bijdrage aan de psychofysica testen. 
Ondanks de drukke agenda’s wisten jullie altijd op korte termijn nog tijd vrij te 
maken voor overleg. Jullie inbreng was zeer waardevol. Bedankt voor de vele nuttige 
adviezen en de prettige samenwerking!  
Beste medewerkers van het vestibulair onderzoek, Andy Beynon en Karin 
Krommenhoek, dank voor jullie bijdrage. Het spreekt voor zich dat de vestibulaire 
resultaten een meerwaarde aan de artikelen geven. Bedankt voor jullie inzet en 
medewerking! Andy, bedankt voor jouw enthousiaste uitleg en de fijne gesprekken 
over het vak!  
Dr. A. Simon, beste Anna, bedankt voor je inbreng aan hoofdstuk 5. Jouw resultaten 
waren niet alleen een interessante toevoeging aan het artikel, maar nog veel meer 
van belang voor de patiënten van deze familie. Bedankt voor jouw betrokkenheid en 
fijne samenwerking! 
Beste KNO poli verpleegkundigen, dank voor jullie hulp tijdens de familiedagen. 
Dankzij jullie verliep de bloedafname bij patiënten probleemloos. Bedankt voor de 
inzet en gezelligheid tijdens de familiedagen! 
Beste medewerkers van het KNO stafsecretariaat en de KNO poli administratie, 
hartelijk dank voor alle ondersteunde werkzaamheden! Veel patiënten betekent ook 
veel papierwerk en een strakke organisatie. Bedankt voor jullie hulp, interesse en de 
prettige gesprekken! 
Beste leden van de manuscriptcommissie, prof. dr. F.P.M. Cremers, prof. dr. C.B. 
Hoyng en prof. dr. I.J.M. Dhooge, hartelijk dank dat u het manuscript heeft willen 
beoordelen.  
Beste arts-assistenten KNO, dank voor de collegialiteit en plezierige samenwerking. 
Beste Robbert-Jan Miserus, dank voor jouw steun tijdens de vele kopjes koffie. Jij 
was altijd bereid mee te denken en te discussiëren. Ik denk met veel genoegen terug 
aan deze tijd. Bedankt voor je betrokkenheid! Heel veel succes met jouw opleiding 
tot audioloog. 
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Beste collega’s van de Allergologie Praktijk Arnhem, dank voor het welkome 
ontvangst, de prettige samenwerking en de fijne sfeer. Ik heb ontzettend veel 
geleerd over verscheidene aspecten van de medische wereld. Ik had deze gezellige 
en leerzame tijd voor geen goud willen missen! Beste Ad Jansen, jij stond altijd voor 
mij klaar met opbouwende kritiek. Er was altijd ruimte voor discussie. Maar wat mij 
het meest is bijgebleven is jouw vermogen om te relativeren en alles weer in de 
juiste context te plaatsen. Fijn om altijd op jouw steun te kunnen vertrouwen!  
Beste staf van de Neus-, Keel- en Oorheelkunde van het Universitair Ziekenhuis te 
Gent, bedankt voor het in mij gestelde vertrouwen en voor de kans die jullie mij 
hebben gegeven om mijn opleiding tot Neus-, Keel- en Oorarts in Gent te volgen. 
Beste arts-assistenten NKO, bedankt voor jullie steun, gezelligheid en collegialiteit. 
Door jullie warme onthaal voel ik mij helemaal thuis in Gent! Dank voor alle leuke 
dingen die we samen hebben beleefd. 
Lieve vrienden, dank voor alle leuke momenten. Velen van jullie heb ik de afgelopen 
maanden minder frequent gezien, maar ik hoop dat we nog lang van het leven 
mogen genieten. Het is fantastisch om jullie om me heen te hebben en gezellig te 
kletsen over niet-medische zaken. Bedankt voor alles wat jullie voor mij betekenen!  
Lieve schoonfamilie, Leo en Ria, Michel en Marie-Louise, Dorien en Daniel, dank voor 
jullie getoonde interesse. Het is wellicht niet altijd duidelijk geweest waar ik nou 
eigenlijk mee bezig was, maar jullie belangstelling is altijd gebleven. Bij jullie vind ik 
altijd een warm thuis en ik ben blij dat Joy en ik regelmatig gebruik mogen maken 
van jullie gastvrijheid. Ik weet dat ik altijd op jullie kan rekenen. Dorien, de omslag is 
echt fantastisch! In het bijzonder bedankt voor het geweldige ontwerp. 
Lieve Denise en Derk Jan, dank voor jullie oprechte meeleven de afgelopen jaren. 
Jullie betekenen ontzettend veel voor mij! Denise, bedankt voor je correcties van de 
Nederlandse teksten. Ik ben trost op je en blij om je zus te zijn! Bedankt voor alles! 
Lieve papa en mama, het valt niet in woorden uit te drukken hoe waardevol ik jullie 
onvoorwaardelijke liefde, steun en vertrouwen vind. Ik ben ontzettend dankbaar 
voor alle kansen die jullie mij hebben gegeven. Jullie hebben mij altijd gestimuleerd 
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mijn mogelijkheden ten volle te benutten. Zonder jullie was ik niet wie en waar ik nu 
ben! Met trots draag ik dit boekje aan jullie op. 
Lieve Joy, de laatste woorden in dit boekje zijn voor jou. Als er iemand is die mij het 
meest heeft gesteund dan ben jij dat wel! Onbeschrijfelijk lief dat je er altijd voor mij 
bent. In dit proefschrift zitten heel wat kostbare uurtjes die eigenlijk voor jou 
bestemd waren… Bedankt voor je geduld en begrip! Jouw steun en liefde waren 
essentieel voor de succesvolle afronding van dit proefschrift. Ik hoop dat we nog 
vele jaren samen kunnen doorbrengen en ik kijk enorm uit naar de toekomst samen 
met jou! 
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Nicole Weegerink werd op 21 november 1983 geboren te Enschede. Aan het Assink 
Lyceum te Haaksbergen haalde zij in 2001 haar HAVO eindexamen en in 2003 haar 
VWO eindexamen. In datzelfde jaar begon zij met de studie Geneeskunde aan de 
Radboud Universiteit te Nijmegen. Tijdens haar coschappen in the UMC St Radboud 
groeide haar enthousiasme voor de Keel-, Neus- en Oorheelkunde. In 2009 volgde 
een onderzoeksstage naar erfelijke slechthorendheid op de afdeling KNO in het UMC 
St Radboud onder leiding van dr. H.P.M. Kunst. Deze stage resulteerde in een 
aanstelling als arts-onderzoeker op de KNO afdeling. Onder leiding van dr. H.P.M. 
Kunst, prof. dr. H. Kremer en prof. dr. C.W.R.J. Cremers werd het onderzoek naar 
erfelijke slechthorendheid voortgezet, wat uiteindelijk heeft geleid tot het tot stand 
komen van dit proefschrift. Tijdens de afronding van haar proefschrift werkte zij als 
arts-assistent op de Allergologie Praktijk Arnhem. In oktober 2012 is zij gestart met 
de opleiding tot Keel-, Neus- en Oorarts in het Universitair Ziekenhuis te Gent. 
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